

AUTHOR INDEX

Arthritis and Rheumatism, Volume 33, Numbers 1 through 12, 1990

A

Abeles M, 160
Abrams J, 885
Accavitti MA, 187, 1347
Adelsberg BR, 1598
Adkins B, 702
Agnello V, 1710
Ahlstrom H, 1763
Ahmed M, 859
Al-Janadi MA, 1864
Alarcon GS, 9, 37, 303,
1156, 1599, 1601
Alavi-Sadrieh A, 1655
Albani S, 1836
Albrecht ME, 1406
Alegre J, 1594
Alexander SS, 774
Allard SA, 1170
Alms W, 842
Alper CA, 985, 1542
Alsalameh S, 1477
Altman RD, 1601
Alvarez B, 1594
Alvarez-Ruiz S, 1052
Anderson JJ, 140, 525, 1449
Anderson L, 330
Andrews HJ, 1733
Andrews JL, 1384
Ansell BM, 615
Appelboom T, 268
Appelrouth D, 1601
Arasa J, 1753
Arend WP, 305, 1065, 1068,
1088, 1094, 1101, 1108,
1114, 1122, 1129, 1135
Arimori S, 1674
Ariza CR, 301
Arnaiz-Villena A, 1598
Arnett FC, 1240, 1682
Arora Y, 199
Aspar DG, 253
Astaldi-Ricotti GCB, 180
Atkinson J, 49
Austen KF, 1149
Austin JV, 9
Awdeh Z, 985
Axford JS, 1655
Aymard B, 602
Azoulay E, 602

B

Baboonian C, 1749
Bacon PA, 1596
Baer AN, 107, 151
Baerwald C, 733
Baethge BA, 1007

Baggott JE, 9
Baker MS, 454
Balow JE, 49, 578
Banchereau J, 1180
Bankhurst AD, 827
Bannwarth B, 451
Bar-Tana R, 1554
Barbasan C, 1753
Bardin T, 301, 1567
Barez S, 49
Bariety J, 1444
Barile L, 301
Barnes JL, 1710
Baron M, 790
Barron KS, 1371
Barth WF, 1438
Bartholomew LE, 810
Bartolucci AA, 37, 1156,
1599
Bataille R, 398
Bautz FA, 1378
Bayliss MT, 1170
Bednar J, 1753
Bell MJ, 591
Bellamy N, 739
Ben-Chetrit E, 349
Ben-Yehuda A, 1554
Benedict RS, 73, 80
Benincaso AI, 1149
Bennett RM, 160
Bentin J, 268
Berdin JHM, 970
Berger RG, 1284
Bernstein B, 199
Bertheau JM, 602
Bestagno M, 180
Bhown AS, 187
Birchmore DA, 91
Biundo J, 330
Bjork J, 452
Bjurholm A, 859
Blackburn WD, Jr., 228,
303, 1333
Blair C, 1249
Blancuzzi V, 1023
Bloch DA, 121, 1065, 1068,
1088, 1094, 1101, 1108,
1114, 1122, 1129, 1135,
1601
Block S, 330
Blumenthal DR, 757, 910
Boerbooms AMTh, 759
Boers M, 95
Bohm L, 1836
Boissier M-C, 1

Bombardier C, 160, 591,
1751
Bona CA, 711
Borenstein D, 1601
Boughman JA, 569
Boumpas DT, 49, 578
Bouthillier Y, 1716
Bouvet J-P, 1716
Brandt KD, 412, 1406,
1601, 1626
Brandt R, 790
Braunstein EM, 412, 456
Breedveld FC, 95, 1646,
1865
Bremell T, 1739
Breton J, 261
Brewer EJ, Jr., 466
Briancon S, 1001
Brick JE, 1037
Brik R, 199
Brocq O, 1063
Brooks PJ, 91
Broom ND, 1512
Brower AC, 316
Brown C, 1601
Brown M, 299
Brown MS, 827
Buchanan WW, 739
Buckelew SP, 1279
Buckland-Wright JC, 57
Bulpitt KJ, 918
Bunning RAD, 1733
Burdin P, 911
Burger EH, 66
Burmester GR, 1477
Burrows-Mezu A, 650
Buyon JP, 563, 609
Buzas E, 866

C

Calabrese LH, 1065, 1068,
1088, 1094, 1101, 1108,
1114, 1122, 1129, 1135
Calin A, 1600
Callahan LF, 281, 407, 1317
Callen JP, 1852
Campbell IK, 542
Campbell J, 739
Campbell SM, 160
Camps JAJ, 95
Capelli HA, 574
Capello W, 1626
Caporali R, 180
Carlson PL, 29
Carlsten H, 1739
Carson DA, 909, 1347

Carter JR, 674
Castenada S, 455
Cats A, 95, 173, 1462, 1770
Cawston TE, 1733
Cedel SL, 1487
Cerino A, 180
Chang PC, 95
Chang RW, 947
Chang WL, 1037
Chaptal PA, 398
Chatham WW, 228, 1333
Chen PP, 1188
Cheung HS, 235
Chin JE, 1776
Chin NW, 910
Chiocchia G, 1
Chiu B, 87
Choi J, 650, 842
Christian C, 299
Claman HN, 1702
Clark B, 57
Clark IM, 1733
Clark P, 160
Clements PJ, 918, 1256
Cleveland DW, 1501
Cobianchi F, 180
Coblyn JS, 330, 1149
Coe MD, 1438
Cohen Tervaert JW, 1264
Cohen AS, 302
Cohen DL, 569
Cohen IR, 1554
Cohen PR, 903
Colaco B, 299
Colditz GA, 947
Coloma MJ, 1188
Combe B, 485
Conant MA, 1574
Connor JR, 261
Cooke TD, 1601
Cooper SM, 607
Cooperstein LA, 1640
Cordero-Sanchez M, 1052
Cote T, 930
Couderc J, 1716
Cowchock S, 607
Craft J, 1431
Cremer MA, 1287
Curd JG, 1590
Cush JJ, 19, 623
Cywiner-Golenzer C, 301
Czarnecki M, 375

D

D'Arpa P, 1501
Daha MR, 1646

Dalal N, 1340
 Dalton BJ, 261
 Dang H, 774
 Daniel W, 1601
 Daniels L, 724
 Danon F, 877
 Dauphinee MJ, 774
 Dayer E, 1394
 Dayer J-M, 305, 1807
 de Gennaro F, 180
 de Jong M, 66
 de Vernejoul MC, 1444
 de Vries RRP, 173, 1770
 Debbas ME, 1836
 Degiannis D, 375
 del Pozo E, 247
 DeLeo VA, 903
 Delmonico RL, 1279
 Delons S, 1567
 Delves PJ, 299, 1655
 DeMarco D, 1526
 Deutscher SL, 102
 Diamond J, 909
 Dickey WD, 102
 DiGiacomo R, 810
 Dijkmans BAC, 95, 173, 1462, 1770
 DiLiberti MA, 711
 Dougherty S, 1310
 Draganich LF, 853
 Drogou A, 339
 Drosos AA, 1579
 Druke T, 1567
 Dryll A, 301
 Ducailar A, 1716
 Dugowson CE, 1042
 Duku E, 739
 Dunn CJ, 253
 Dupuy d'Angeac A, 1180
 Duston MA, 302
 Duvic M, 1240, 1574

E

Earnshaw WC, 724, 1501
 Ebling FM, 978
 Edmonds-Alt X, 1688
 Edworthy SM, 1068, 1094, 1108, 1114, 1122, 1129
 Egger MF, 477
 Egidio J, 685
 Eleftheriades EG, 49
 Elema JD, 1264
 Elford P, 247
 Elhamiani M, 1688
 Ellman MH, 1060
 Engle EW, 281
 Engleman EG, 205
 Enzenauer RJ, 1582
 Epstein WV, 746
 Esdaile JM, 403
 Espinoza LR, 1296

Euller-Ziegler L, 1063

F

Fam AG, 160
 Farah MJ, 1287
 Farber SJ, 160
 Farge D, 1444
 Farinas MC, 553, 702
 Fasy TM, 1836
 Fauci AS, 1065, 1068, 1094, 1101, 1108, 1114, 1122, 1129, 1135
 Faure M-P, 1466
 Favard L, 911
 Favier F, 485
 Felson DT, 140, 525, 1449, 1724
 Feltelius N, 1763
 Felts WR, 750
 Fener P, 451
 Feremans W, 268
 Fernandez-Vina MA, 1787
 Fernsten P, 1226
 Ferreira JL, 1753
 Fibbe WE, 1865
 Fidanza V, 711
 Fiechtner JJ, 160
 Fienhold M, 1029
 Fink CW, 1787
 Firestein GS, 768
 Fischer HD, 563
 Fitzcharles M-A, 403
 Fok F, 1047
 Fontana JA, 650
 Fort JG, 607
 Foto F, 1297
 Fouquet B, 911
 Fournie A, 877
 Fournie B, 877
 Fournier C, 1
 Fox RI, 349
 Franc B, 1716
 Frangione B, 880, 1710
 Franklin CM, 160
 Franz KA, 253
 Frati A, 301
 Frayssinoux F, 485
 Freundlich B, 1863
 Fries JF, 121, 605, 1065, 1068, 1101, 1108, 1135, 1611
 Fritzler MJ, 274
 Fronek Z, 978, 1542
 Fujii K, 1493
 Fujisaku A, 102
 Furst DE, 898, 1256, 1611

G

Gabriel CA, 587
 Galinet LA, 253
 Gall E, 330

Gallo GR, 880
 Geo X, 939
 Garcia C, 1294
 Garcia R, 301
 Garcia-Talavera JR, 1052
 Garry RF, 774
 Gaston JSH, 1596
 Gatter RA, 160
 Gaucher A, 451, 602, 1001
 Gavilondo-Cowley JV, 1188
 Gayer K, 842
 Geiger A, 381
 Gelfand E, 1015
 Genant HK, 441
 Genetet B, 339
 Genetzky P, 657
 Genth E, 657
 Georgiakodis F, 1634
 Germain BF, 330
 Gharavi AE, 501
 Ghosh P, 1384
 Giannini EH, 466, 1371
 Gibbons WE, 1420
 Gigli I, 888
 Gilkeson GS, 153
 Gillet P, 451
 Ginsberg D, 1060
 Ginsburg WW, 1442
 Giorno RC, 1702
 Giovannoni J-L, 1752
 Glant TT, 866, 1394
 Glickstein SL, 298
 Goebel K-M, 733
 Goldenberg DL, 160, 381
 Goldfarb RA, 885
 Goldschmeding R, 1264
 Goldsmith CH, 739, 1751
 Goldstein R, 1240
 Gomez-Reino J, 1598
 Goni F, 1710
 Gonzalez T, 1294
 Gonzalez-Anton R, 1294
 Gonzalez-Cabrero J, 685
 Goodwin JS, 1448
 Gordon DS, 1233
 Goronzy JJ, 511
 Goto M, 1493
 Goupille P, 911
 Graeber M, 247
 Grandjean C, 1029
 Gratwick GM, 450
 Gray R, 1601
 Green FA, 107
 Green SP, 454
 Greenberg M, 418
 Greenwald M, 1015
 Greenwald RA, 453, 1601
 Griffey RH, 827
 Grignon B, 602
 Grondahl K, 1739
 Gross L, 1665

Grudier JP, 153
 Guillemin F, 1001
 Guillemin L, 1871
 Gumpel JM, 615
 Gustafsson R, 1534

H

Habets WJ, 834
 Hadler NM, 436
 Hahn BH, 978, 1542
 Hain N, 1477
 Hall S, 1487
 Halla JT, 325
 Hallgren R, 1534, 1763
 Hamakubo T, 728
 Hamamoto T, 728
 Hamaty D, 160
 Hamer DH, 1438
 Hamilton JA, 542
 Hammer M, 1795
 Hamuryudan V, 1586
 Hanash S, 1665
 Hannan MT, 525
 Hanson V, 199
 Hardin JG, Jr., 325
 Hardin JA, 1431
 Harley JB, 102
 Harmand M-F, 219
 Harpster E, 888
 Hart DJ, 774
 Hart DA, 274
 Hartl PW, 657
 Hashida S, 893
 Hasty KA, 388
 Hauzeur J-P, 268
 Hawkins CC, 757
 Hazes JMW, 173, 1462, 1770
 Healey LA, 1872
 Heck LW, Jr., 212, 228, 1333
 Heesemann J, 1795
 Helenon O, 1567
 Helewa A, 1751
 Helfgott SM, 604
 Helle M, 1695
 Hellmann DB, 277
 Henderson B, 241
 Hene RJ, 1264
 Hennekens CH, 947
 Henzen-Logmans SC, 970
 Herbage D, 1
 Hernandez-Avila M, 947
 Herrero-Baumont G, 455, 685
 Herzenberg LA, 553
 Hesp R, 615
 Hess EV, 1295
 Hewett JE, 666, 1279
 Heyermann H, 1710
 Heymanns J, 733

Hilario MO, 1371
 Hildebrandt S, 724
 Hirata M, 1801
 Hirn M, 1688
 Hirohata S, 644
 Hitchman E, 1273
 Hochberg MC, 131, 277,
 281, 930, 1323, 1601
 Hoet MH, 834
 Hoffman J, 898
 Hoffman RW, 666
 Hoffman WL, 1196
 Holick M, 1724
 Holman RT, 1526
 Holmdahl R, 693
 Horst G, 634
 Horwitz DA, 1216
 Hou S, 1060
 Howard EJ, 1297
 Howard RF, 1233
 Howell D, 1601
 Huber-Bruning O, 1695
 Hubert HB, 121
 Huckins D, 1724
 Huerter CJ, 1047
 Hughes RA, 758
 Huitema MG, 1264
 Hummel EJ, 634
 Hunder GG, 1065, 1068,
 1088, 1094, 1101, 1108,
 1114, 1122, 1129, 1135
 Hunter JA, 574
 Hurley JA, 1047

I

Ichikawa Y, 1674
 Ike R, 1601
 Ikebe T, 1801
 Imura H, 893
 Inman RD, 87
 Irby R, 330
 Iribe H, 1801
 Irvin WS, 1279
 Isenberg DA, 339
 Ishikawa E, 893
 Itoh K, 505
 Itoh Y, 1815

J

Jaffe ES, 578
 Jaffe IA, 1064
 James JA, 102
 Jarjour W, 1226
 Jasin HE, 623
 Jeng AY, 1023
 Jennische E, 1739
 Jimenez SA, 1829
 Johnson AE, 1361
 Johnson M, 1665
 Johnson R, 623
 Johnson WJ, 261

Joseph AK, 1371
 Jouquan J, 339
 Jourdan M, 398
 Jubiz W, 810
 Juji T, 1867
 Jump AA, 1196

K

Kahari L, 1829
 Kahl LE, 1249, 1842
 Kalden JR, 1477
 Kallenberg CGM, 634, 1264
 Kallman DA, 1323
 Kalunian KC, 978, 1542
 Kang AH, 388
 Kangro HO, 1749
 Kannel WB, 525
 Kano S, 505
 Kapila P, 1601
 Kaplan D, 450, 1601
 Kaplan H, 330
 Katayama K, 1493
 Katsikis P, 339
 Katz D, 615
 Katz PP, 1205
 Katzenstein PL, 674
 Kaufmann S, 657
 Kawamura H, 505
 Kay DR, 1279
 Keat ACS, 758
 Keene JD, 102
 Keil JE, 1062
 Kengen RA, 1728
 Kenik JG, 1047
 Kenny TP, 1188
 Kerr LD, 1598
 Kessler M, 602
 Khan MM, 205
 Kidd VJ, 1655
 Kipnis RJ, 1431
 Kitada H, 287
 Klareskog L, 693, 1534
 Klein B, 398
 Klein-Nulend J, 66
 Kleinau S, 693
 Klimsa S, 1795
 Klippel JH, 578, 1310
 Kobayashi S, 1493
 Koehnke R, 898
 Koepsell TD, 1042
 Koga T, 1801
 Komaroff AL, 381
 Konda S, 287
 Koolen MI, 1264
 Koopman WJ, 19, 187, 366,
 1156, 1347, 1601
 Koplon S, 212
 Kosuge E, 1867
 Kotowicz MA, 1487
 Kratz LE, 569
 Krause A, 733

Kreicbergs A, 859
 Kremer JM, 810
 Krieg T, 657
 Kriet JD, 1815
 Krumdieck CL, 9
 Krzesicki RF, 1776
 Kujala GA, 1037
 Kulp-Shorten CL, 1852
 Kumagai S, 893
 Kumar A, 1445
 Kuntz D, 301
 Kurup I, 235
 Kuzmina N, 466
 Kyriakidis M, 1634

L

Lachenbruch PA, 1256
 Lahita RG, 1857
 Lamour A, 339
 Landau A, 910
 Lang BA, 418
 Lange S, 1739
 Laposata M, 1526
 Larkin JK, 1149
 Larrick JW, 1188
 Larsson P, 693
 Lassoued K, 877
 Lassoued S, 877
 Lawrence DA, 810
 Laxer RM, 418, 1015
 le Goff P, 339
 Leavitt RY, 1065, 1068,
 1088, 1094, 1101, 1108,
 1114, 1122, 1129, 1135
 Lehman TJA, 199
 Lem D, 1526
 Lemmo A, 800
 Lenert L, 1611
 Leroy JP, 1579
 Lessard J, 160
 Leventhal LJ, 1526, 1863
 Levin ML, 930
 Levinson AI, 1340
 Levinson JE, 587
 Levy CS, 1438
 Levy EN, 1842
 Levy RA, 501
 Liang MH, 947
 Lichtbroun AS, 160
 Lidsky MD, 885
 Lie JT, 1065, 1068, 1074,
 1088, 1094, 1101, 1108,
 1114, 1122, 1129
 Lieberman JD, 1233
 Life PF, 1596
 Lightfoot RW, Jr., 1065,
 1068, 1088, 1094, 1101,
 1108, 1114, 1122, 1129,
 1135
 Limburg PC, 634, 1264,
 1416

Lindner H, 1273
 Lindsley HB, 1162
 Linker-Israeli M, 1216
 Liote F, 301
 Lippiello L, 1029
 Lipsky PE, 19, 623
 Littman BH, 29
 Lockitch G, 1560
 Lockshin MD, 501, 606
 Longley S, 1601
 Loose LD, 29
 Lopez-Beltran A, 150
 Lopez-Ochoa J, 1052
 Losman JA, 1836
 Louie JS, 978
 Lowther DA, 454
 Luger AM, 666
 Lund T, 1655
 Lydyard PM, 299, 339, 431,
 1655
 Lynch JA, 57
 Lyon MG, 1279

M

Macfarlane DG, 57
 Mackenzie L, 339, 1655
 Mackinnon M, 1560
 Madaio MP, 1554
 Madhok R, 574
 Mahy M, 1560
 Maier WP, 1233
 Maini RN, 1170, 1749
 Maisiak R, 212
 Malaviya A, 1445
 Malemud CJ, 674
 Malleson PN, 821, 1560
 Mann KG, 1487
 Marcus-Bagley D, 985
 Maricq HR, 1062
 Markusse HM, 1865
 Marshall KW, 87
 Martel-Pelletier J, 1466
 Martinez-Montero JC, 685
 Martini A, 1836
 Masi AT, 160, 1065, 1068,
 1088, 1094, 1101, 1108,
 1114, 1122, 1129
 Massa M, 1836
 Massie JD, 1287
 Mathai L, 1394
 Matsuta K, 1867
 Maul GG, 960
 Mayer R, 711
 McCain GA, 160
 McCarty DJ, 235
 McCurdy DK, 199
 McDevitt HO, 978, 1542

McGopwan JF, 1279
McGrath H, Jr., 302
McMenemy AM, 1240
McShane DJ, 1065, 1068,
1088, 1094, 1101, 1108,
1114, 1122, 1129, 1135,
1601
Medsgar TA, Jr., 1601,
1640, 1822
Meenan RF, 140, 302, 439,
1449
Mehlhoff MA, 293
Mehra N, 1445
Melmon KL, 205
Melnik VO, 493
Mentions B, 1751
Menoyo V, 1444 z
Menu R, 268
Merdrignac G, 339
Merriman RC, 330
Meryhew NL, 356
Messner RP, 356
Meunier PC, 261
Meurer M, 657
Meyer AA, 1279
Meyer FA, 1518, 1807
Michel BA, 1065, 1068,
1088, 1094, 1101, 1108,
1114, 1122, 1129, 1135
Michels H, 1378
Mierau R, 657
Mikdashi J, 1620
Mikecz K, 866, 1394
Miller A, 1447
Miller EB, 1870
Miller FW, 1361
Miller JJ, III, 520
Miller SB, 1233
Mills JA, 756, 1065, 1068,
1088, 1094, 1101, 1108,
1114, 1122, 1129
Milner MR, 1438
Mimura T, 1226
Mineau F, 1466
Miossec P, 485, 1180, 1688
Mitchell R, 615
Miyamoto T, 644, 1867
Miyasaka N, 1493
Miyatsu M, 1493
Mooser PJ, 151
Molina R, 49
Mollenhauer J, 1477
Monestier M, 1836
Mongan ES, 451
Montalvo JF, 1371
Montecucco C, 180
Moore TL, 954
Mooyaart EL, 1728
Moreau J-F, 1567
Morgan RK, 1279
Morgan SL, 9, 1447

Moses LE, 1137
Moskowitz RW, 674
Mouton D, 1716
Moutsopoulos HM, 339,
1579
Muirden KD, 542
Muller S, 339
Murakami M, 893
Murphy G, 241
Murphy W, 1601
Muskiet FAJ, 1416
Myers SL, 1406

N

Nagai Y, 1493
Nagy G, 453
Nades SJ, 1297
Naimark A, 525
Nakagawa Y, 728
Nakaizumi H, 287
Nakano K, 1867
Nam MH, 1438
Naparstek Y, 1554
Naviliat M, 1180
Needleman BW, 569, 650,
842, 1847
Neeman Z, 1554
Negri C, 180
Nelson JL, 1042
Nesbitt, LT, Jr., 302
Nesher G, 954
Netter P, 451, 602
Neuer G, 1378
Newkirk MM, 800
Newman-Tarr T, 261
Ng SC, 1256
Nietfeld JJ, 1695
Nishioka K, 1493
Nobunaga M, 1868
Noell S, 724
Nossent HC, 970
Neurnberg B, 898
Nur MA, 1864
Nyman R, 1763
Nyman U, 666

O

O'Brien CA, 102
O'Byrne EM, 1023
O'Connor BL, 1406
O'Connor CR, 1753
Oddis CV, 1640
Ogea JL, 150
Okano Y, 1822
Oksman F, 877, 1871
Older SA, 49
Olds LC, 520
Olsen NJ, 939
Ordonez JV, 842
Orson FM, 1371
Ortega C, 150

Osial T, 1601
Osman HK, 1749
Osteaux M, 1426
Ott H, 1752
Otter WD, 1695

P

Palmieri GMA, 1287
Panayi GS, 1599
Panosian-Sahakian N, 978
Papazoglou S, 1634
Paquin J, 790
Parish RC, 91
Parke AL, 605
Parker JC, 1279
Pasteels J-L, 268
Pathria MN, 674
Paulus HE, 113, 477, 918,
1056
Pauwels EKJ, 95
Payne T, 247
Pelletier J-P, 1466
Peltonen J, 1829
Pena J, 150
Penner E, 1273
Peterlin BM, 1542
Petersen J, 993
Peterson H, 1852
Peterson M, 605
Petit E, 1063
Petri M, 277
Pettersson I, 666
Pettipher ER, 241
Petty RE, 821, 1560
Phillips FM, 853
Piccoli DS, 542
Piccolo F, 790
Picken MM, 880
Pillemer S, 1310
Pinals RS, 1287
Pincus T, 281, 407, 569,
939, 1317
Pisetsky DS, 153
Pizov G, 1554
Plumpton TA, 1733
Poignet JL, 1444
Polisson R, 330
Pollack MS, 1240
Pollmann H-J, 657
Poole AR, 790, 866, 1394
Pope RM, 1597
Portier M, 485
Postlethwaite AE, 19
Pottenger LA, 853
Pourel J, 1001
Pourrat J, 1871
Pruzanski W, 880
Pullman-Moore S, 1526

Q

Qamar T, 501
Quiros J, 685
Quismorio FP, Jr., 1216

R

Ramsey-Goldman R, 1249,
1601, 1842
Rapini RP, 1682
Raska K, Jr., 375
Raskova J, 375
Ratain JS, 131, 277
Rauch J, 800
Raziuddin S, 1864
Redecha P, 299
Reese DJ, 910
Reeve J, 615
Reginato AJ, 1753
Reichlin M, 1240, 1815
Reife RA, 388
Reme T, 485
Remy Ph, 1444
Rene J, 1870
Renner JB, 426
Rettenmaier LJ, 666
Reveille JD, 37, 1240, 1574
Reynolds WJ, 160
Rhodes G, 993
Rhodes RH, 1852
Rich SA, 1420
Richard KA, 253
Richardson B, 1665
Rigby AS, 1751
Riggs BL, 1487
Rivera J, 150
Robbins DL, 1188
Roberts DE, 1590
Roberts MJ, 542
Roberts N, 790
Rodriguez C, 1294
Roifman CM, 1015
Roman E, 782
Roman S, 1340
Romano TJ, 160
Ronziere M-C, 1
Rook G, 431
Rosenbaum JT, 493
Rosner B, 947
Rothfield NF, 605, 724,
1501
Rothschild B, 1601
Roubenoff R, 930
Roudier J, 993
Rousselin B, 1567
Rubin RA, 885, 1145
Rubin RL, 1582
Rusin LH, 298
Russell AS, 605
Russell LJ, 160

Russell RGG, 1733
Ryan LM, 235
Rynes R, 810

S

Saadeh C, 1371
Sagara M, 1493
Saleh MN, 1233
Sambrook PN, 615
Samaritano L, 501
Sanders KM, 29
Sanders ME, 1776
Santamaria M, 150
Sany J, 485, 1180, 1688
Sauermaun G, 1273
Sawada M, 287
Saway A, 19
Schaefer S, 1620
Scharosch LL, 1297
Scheinbart L, 1665
Scheynius A, 1534
Schrohenloher RE, 19, 187, 1156, 1347
Schuger L, 1554
Schultzberg M, 859
Schur PH, 985
Schurman DJ, 533
Schwartz BD, 457
Scopelitis E, 302
Scott WW, Jr., 1323
Sebes JJ, 1287
Seckinger P, 1807
Segal R, 1745
Seguin J, 398
Segurado OG, 1598
Seibold JR, 375, 1702
Senecal J-L, 724
Sfikakis P, 1634
Sfikakis PP, 1634
Shah F, 1682
Shahabpour M, 1426
Shaham B, 199
Shaikov A, 466
Shamma'a JM, 1037
Sharp GC, 666
Shaw M, 1226
Shawe D, 615
Sheon RP, 160, 674
Sherman L, 493
Sherman M, 810
Shimizu H, 1674
Shimizu K, 728
Shimizu S, 287
Shimozuru Y, 1493
Shiokawa S, 1868
Shipley GD, 493
Shore A, 1015
Shulman LE, 913
Sibbitt RR, 827
Sibbitt WL, Jr., 827
Siegert CEH, 1646

Silman AJ, 782, 1062
Silverman ED, 205, 418, 1015
Silverman GJ, 1347
Silyn-Roberts H, 1512
Simkin PA, 73, 80
Simmons M, 1256
Simms RW, 381
Singh G, 121, 1611
Singh RR, 1445
Singh YN, 1445
Skinner M, 302
Sledge CB, 293
Slowman-Kovacs SD, 412
Small R, 330
Smarr KL, 1279
Smedegard G, 452
Smiley JD, 1196
Smith CA, 1682
Smith DD, 1162
Smith GN, Jr., 1626
Smith HR, 1061
Smith LR, 583
Smith MD, 1655
Smith RL, 533
Smythe HA, 160, 1751
Soler J, 1753
Solinger AM, 1295
Solomon SD, 330
Solovera JJ, 553
Solsky M, 898
Somma C, 205
Soto-Gil RW, 1188
Sparling M, 821
Spector TD, 782
Speizer FE, 947
Spence RJ, 1620
Sperling RI, 1149
Spiera H, 1598
Spitz PW, 121
Sprenger HG, 1728
Spruill WJ, 91
Staite ND, 253
Stall AM, 553, 702
Stampfer MJ, 947
Stanford J, 431
Stanosheck JF, 1047
Stark K, 1601
Starz T, 1870
Stastny P, 939, 1787
Steen VD, 1249
Stein LD, 1015
Steinberg AD, 578
Stern AC, 1865
Sternfeld MD, 493
Sterz M, 1256
Stevens MB, 1065, 1068, 1088, 1094, 1101, 1108, 1114, 1122, 1129, 1135
Stobo JD, 1059
Stock K-P, 1477

Stoller DW, 441
Strahler J, 1665
Strickland SR, 298
Strober S, 553, 702
Stuart JM, 388
Suarez SM, 903
Sugai S, 287
Suginoshita T, 893
Suranyi P, 453
Suzuki K, 728
Svensson L, 1739
Swaak AJG, 1695
Swaak TJG, 970
Symmons D, 1062
Szegedi G, 453

T

Tachibana J, 287
Takeda Y, 666
Takemitsu Y, 1493
Takeuchi F, 1867
Talal N, 774
Tamsma JT, 1728
Tan EM, 349
Tanaka K, 893
Taneja V, 1445
Taniguchi N, 505
Taramelli D, 842
Targoff IN, 1240, 1361
Tarkowski A, 1739
Tarlinton DM, 553
Tartakovsky B, 1745
Tausk F, 888
ter Borg EJ, 634
Teran J, 1594
Terato K, 1493
The TH, 1264
Theofilopoulos AN, 583
Thomas TJ, 356
Thorner P, 418
Timmerman LA, 1542
Tobin JD, 1323
Tokunaga K, 1867
Torley HI, 574
Tornero J, 455
Torretti D, 330
Toutouzas P, 1634
Treseler PA, 604
Truckenbrodt H, 1378
Tsokos GC, 49
Tsukada S, 287
Tuallon N, 339
Tugwell P, 160, 591
Tulleken JE, 1416
Tuzuner N, 1586

U

Uitto J, 1829
Umehara H, 893
Uveges JM, 1279

V

Valat J-P, 911
van Brummelen P, 95
van de Putte LBA, 759
van der Giessen M, 1264
van der Hem GK, 1264
VAN DER Voort EAM, 1646
Van Linthoudt D, 1752
van Rijswijk MH, 1416
van Roy JLAM, 1695
van Roy P, 1426
van Strien ME, 66
van Venrooij WJ, 834
van Zeben D, 1462
Vandenbroucke JP, 173, 1462, 1770
Vaughan JH, 993
Vaughn WH, 9
Veldhuijzen JP, 66
Venables PJW, 1749
Verbruggen LA, 1426
Vergos C, 1634
Verity MA, 918
Vidal J, 455
Viejo JL, 1594
Vilamitjana-Amedee J, 219
Villanueva JL, 150
Viner NJ, 1596
Visco DM, 1406
Visser H, 1871
Vivino FB, 960
von dem Borne AEGKr., 1264
von Muhlen CA, 657
von Wilmowsky H, 657
Vroom TM, 970
Vuturo GJ, 450

W

Wahl S, 1310
Walker SM, 199
Wall B, 330
Wallace SL, 1065, 1068, 1088, 1094, 1101, 1108, 1114, 1122, 1129, 1135
Ward JR, 477, 1156
Waring R, 574
Warner NB, 1240, 1682
Watson R, 930
Weinblatt ME, 330, 1149
Weiner E, 724
Weinrich MC, 1062
Weissman I, 702
Weits J, 1728
Wesierska-Gadek J, 1273
West SG, 1582
Westgeest AAA, 759

Weyand CM, 511
Wheby MS, 578
White-Cooper H, 1501
Wietting H, 199
Wigley FM, 1323, 1620
Wilbrink B, 1695
Wilder RL, 1310
Willett WC, 947
Williams CA, 121
Williams HJ, 477, 1156
Williams RJ, III, 533
Wilson DE, 1023
Winchester R, 609
Winfield JB, 1226
Winkelstein A, 1870
Winterrowd GE, 1776
Wise RA, 1620

Wittmann B, 1378
Witter J, 790
Wohlgethan JR, 1061
Wolf RF, 1728
Wolf RE, 1007
Wolfe F, 160, 330, 1601,
1863
Wong M, 1023
Wood B, 821
Woodlee PM, 1233

Y

Yamamuro T, 728
Yamashita I, 1493
Yanaga F, 1801
Yaron I, 1518, 1807
Yaron M, 1518, 1745, 1807

Yasuda M, 1868
Yasuda Y, 287
Yazici H, 1586
Yee AMF, 563
Yelin EH, 750, 1205
Yiannopoulos DI, 1579
Yip YK, 563
Yocum DE, 1310
Yoshida M, 1674
Youinou P, 339, 1579
Young PK, 9
Yount WJ, 1284
Yu LP, Jr., 1626
Yunis EJ, 985
Yunus MB, 160
Yurdakul I, 1586
Yurdakul S, 1586

Z

Zacharias W, 366
Zaghouni H, 711
Zanelli JM, 615
Zehner M, 453
Zeidler H, 1795
Zhang XG, 398
Ziegler G, 1063
Ziff M, 761
Zingraff J, 1567
Zoma A, 574
Zucker JR, 757
Zurier RB, 1526
Zvaifler NJ, 768, 1065,
1068, 1088, 1094, 1101,
1108, 1114, 1122, 1129,
1135

SUBJECT INDEX

Arthritis and Rheumatism, Volume 33, Numbers 1 through 12, 1990

A

- Abdominal fat aspiration, in amyloidosis, 301
- Abdominal pain
 - acute, in Henoch-Schönlein purpura, 1114
 - in *Yersinia* reactive arthritis and HIV infection, 758
 - in polymyalgia rheumatica, 403
- Abortion, IgG antiphospholipid antibody in SLE and, 501
- Aching, classification of OA of hand and, 1601
- Acid lability, α -IFN and, in SLE, 563
- Acquired immunodeficiency syndrome (AIDS)
 - acute myositis in, 298
 - arthritis associated with, 268
 - Mycobacterium avium* septic arthritis and osteomyelitis, 757
 - nontropical pyomyositis and myalgia in, 1728
 - RA and, 1064
 - retroviral antibodies in Sjögren's syndrome and, 774
- Acromegalic arthropathy, radiographic abnormalities in, 455
- Activities of daily living
 - health status and, in elderly with arthritis, 1205
 - impact of musculoskeletal conditions and, 750
 - in rheumatic disease assessment, 1317
- Acute-phase reactants, NSAID in RA and, 623
- Adenosine diphosphate and adenosine triphosphate, in neuropsychiatric SLE, 827
- Adhesion molecule
 - cytokines in inflammatory synovitis and, 1776
 - 1, on fibroblasts in scleroderma, 1847
- Adjuvant arthritis, in rats after cyclosporin A, bone and cartilage loss in, 247
- Adrenal insufficiency, anticardiolipin antibodies and, 1842
- Adverse reactions
 - diarrhea after auranofin in JRA, 466, 587
 - in RA
 - of low-dose methotrexate and auranofin, 330
 - rash after NSAID in, 623
 - to ciamexon, 733
 - to second-line drugs, 1449
 - sulfoxidation status of penicillamine and, 574
 - toxicity index for, of drugs, 121
- Affinity chromatography, to study IgM antilymphocyte autoantibodies in SLE, 1226
- Age
 - ACR 1990 criteria for classification of fibromyalgia and, 160
 - arthritis information service user behavior and, 212
 - glucocorticoid drugs, Gla-protein and, in rheumatic disease, 1487
 - in OA, 525, 1323
 - outcome measures in AS and, 1001
 - in RA, 95, 325, 810, 947, 1611
 - in SLE, 407, 970, 978
 - soluble IL-2 receptors in SSc and, 375, 1145
- Age at onset
 - of first pregnancy, risk of RA and, 1770
- Age at onset (*cont'd*)
 - in giant cell arteritis, 1122
 - in Henoch-Schönlein purpura, 1114
 - in hypersensitivity vasculitis, 1108
 - prognosis in SLE and, 37
 - in Takayasu arteritis, 1129
- Agglutinators, pepsin, IgG idiotype in RA and, 1196
- Agglutinin, solid-phase wheat germ, in study of IgM antilymphocyte autoantibodies in SLE, 1226
- Alanine
 - aminotransferase, in polyarteritis nodosa, 1088
 - EBNA-1 and, in RA and SLE, 993
- Albumin
 - hepatitis, fibrosis, methotrexate and, in RA, 1037
 - intravenous gamma globulin in systemic JRA and, 1015
 - kinetics, in normal canine wrists and knees, 73
 - serum, IL-6 in CSF in SLE and, 644
- Alleles
 - HLA antigens in juvenile arthritis and, 1787
 - major histocompatibility complex markers, ethnicity and, in SLE, 985
 - restriction fragment length polymorphism in scleroderma and, 569
- Allergic granulomatosis, 1990 criteria for classification of, 1094
- Allergy, in Churg-Strauss syndrome, 1094
- Allotypes
 - complement, ethnicity, major histocompatibility complex markers and, in SLE, 985
 - HLA, ANA and, in scleroderma, 657
 - α gene, T cells, restriction fragment length polymorphism and, in scleroderma, 569
- Alpha-IFN, acid lability to, in SLE, 563
- α -tocopherol, vitamin E, dietary fish oil and, in RA, 1416
- American College of Rheumatology (ACR)
 - Audiovisual Aids Subcommittee, 1442
 - Diagnostic and Therapeutic Criteria Committee, 1065, 1068, 1074, 1088 1094, 1101, 1108, 1114, 1122, 1129, 1135
 - FDA approval of over-the-counter NSAID and, 1056
 - goals of, 450
 - marketing of, 436, 439
 - 1990 criteria for classification of fibromyalgia, 160, 1863
 - 1990 criteria for classification of vasculitis, 1065, 1068, 1074, 1088 1094, 1101, 1108, 1114, 1122, 1129, 1135
 - slide competition and collection, 1442
 - Vasculitis Study Registry, 1074
- American Rheumatism Association (ARA) 1987 revised criteria for RA, 1042
- Amino acids
 - eosinophilia-myalgia syndrome after oral L-tryptophan and, 913, 918, 930
 - in HIV-associated psoriasis, 1574
 - HLA-D, anti-Jo-1 and, in myositis, 1240
 - human RF cross-idiotype and, 1710
 - I-E genes in autoimmune NZW mice and, 583
 - in RA, 939, 993

Amino acids (*cont'd*)

- rheumatoid synovial cell-derived monoclonal RF and, 1188
 - serine proteinase inhibitors of articular cartilage and, 1384
 - in SLE, 993, 1542
- Aminoacyl-tRNA synthetase, anti-signal recognition particle in PM and, 1361

Aminotransferase, in polyarteritis nodosa, 1088

Amputation, in Raynaud's phenomenon and SSc, 274

Amyloid

- biochemical characterization of, 880
- in hemodialysis, 602, 1567

Amyloidosis

- abdominal fat aspiration in diagnosis of, 301
- in Behçet's syndrome, 1586
- cranio-cervical pseudotumor during hemodialysis and, 1567
- κ light chain subgroup III and, 880

Anatomy

- of atrial myxoma, 1442
- phosphates in CNS in neuropsychiatric SLE, 827

Anemia

- in eosinophilia-myalgia syndrome after L-tryptophan ingestion, 913, 918, 930
 - intravenous gamma globulin in systemic JRA and, 1015
- Aneurysms, coronary artery, soluble IL-2R in childhood Kawasaki syndrome and, 1371

Angiitis, 1990 criteria for classification of, in Churg-Strauss syndrome, 1094

Angiographic abnormalities, in polyarteritis nodosa, 1088

Angioimmunoblastic lymphadenopathy, synovitis in, simulating RA, 578

Animal studies. *See also* Canine; Chicken; Guinea pig; Mouse; Rat; Rabbit

gamma-linolenic acid in RA and, 1526

Ankle

- Charcot arthropathy after joint trauma in diabetic neuropathy and, 412
- in collagen arthritis in rats, 693

Ankylosing spondylitis (AS)

- in Canary Island aborigines (guanches), 1294
- cricoarytenoid synovitis in, 604
- long-term disability and sick leave as outcome measures in, 1001

Antagonists, cytokine, in RA, 305

Anterior cruciate ligament

- sectioning of, metalloproteinase in canine OA and, 1466
- transection of, 412, 1406

Anti-A1 antibodies, nRNP core protein and, in RA and SLE, 180

Anti-aminoacyl-tRNA synthetase, anti-signal recognition particle in PM and, 1361

Anti-B cell antibodies, in proteoglycan-induced polyarthritis and spondylitis in BALB/c mice, 866

Antibiotics, gonococcal pericarditis with tamponade in SLE and, 1438

Antibodies

- anti-B cell, 866
- anticardiolipin, 607, 1249, 1842
- anticentromere, 657
- anticytoplasmic, 1361

Antibodies (*cont'd*)

- anti-DNA, 153, 287, 356, 553, 1216, 1554, 1716
 - anti-dsDNA, 634
 - anti-EBNA-1, 993
 - anti-erythrocyte, 711
 - anti-histone H1, 1273, 1836
 - anti-HLA-DR β 1, 1867
 - anti-HMG-1, 1378
 - anti-human herpesvirus 6, 1740
 - antiidiotypic, 1196, 1347
 - anti-Jo-1, 1240, 1640
 - antikeratin, 180
 - antilamin, 877
 - antineutrophil cytoplasmic, 1264, 1871
 - anti-NOR, 90, 1431
 - antinuclear, 366, 578, 657, 1378, 1582, 1682, 1716
 - antinucleoprotein, 1216
 - anti-parvovirus B19 IgM, 1297
 - antiphospholipid, 501
 - anti-recombinant human IL-6, 1695
 - anti-RNP, 834
 - anti-T cell, 866
 - anti-Th RNP, 1431, 1822
 - anti-transforming growth factor β , 1180
 - anti-type II collagen, 1493, 1716
 - arthritogenicity of minor collagens in mice and, 1
 - autoimmune, 366
 - autoreactive, 866
 - binding of, recombinant Ro (SS-A) fusion protein and, 102
 - calpains, calpastatin and, in OA, 728
 - cartilage proteoglycan-induced arthritis in BALB/c mice and, 1394
 - CD5-expressing B cells in RA and, 339
 - congenital complete heart block and, 609
 - cross-reactive idiotypes of human RF and, 1347
 - HMG-2, 1378
 - IgA, 1646
 - IgG, 520, 1196, 1378, 1646
 - IgM, 520, 1340
 - intravenous gamma globulin in systemic JRA and, 1015
 - LC1, 1347
 - monoclonal, 187, 205, 219, 485, 711, 1170, 1216, 1347, 1394, 1534
 - monospecific rabbit, 1795
 - nephritogenic, 978
 - nRNP core protein and, in RA and SLE, 180
 - in NZB mice, 711
 - in RA, 993
 - retroviral serum, 774
 - Ro, 1682
 - in SLE, 993
 - SS-A, 302
 - SS-A (Ro) polypeptides in SLE and Sjögren's syndrome and, 349
 - stromelysin, 388
 - synoviocyte synthesis of fibroblast growth factor and, 493
- Anticardiolipin antibodies
- adrenal insufficiency and, 1842
 - interpretation of tests for, 607
 - pregnancy and, in Raynaud's phenomenon, 1249

- Anticentromere**
 antibodies, immunogenetics of, 657
 autoantibodies, immunoglobulin isotypes, anti-topo I and, 724
- Anticoagulant activity, of IgG antiphospholipid antibody in SLE, fetal death and, 501**
- Anticollagen**
 arthritogenicity of minor collagens in mice and, 1
 autoantibodies, in collagen arthritis in rats, 693
- Anticytoplasmic antibodies, anti-signal recognition particle in PM and, 1361**
- Anti-DNA**
 antibodies, 153, 287, 356, 553, 1554, 1716
 immunoglobulin idiotypes in SLE and, 978
- Anti-DNA-topoisomerase I, immunogenetics of, 657**
- Anti-dsDNA antibodies, 634, 1216**
- Anti-EBNA-1, in RA and SLE, 993**
- Anti-gag reactivity, retroviral antibodies in Sjögren's syndrome and, 774**
- Antigen-induced arthritis, metalloproteinase and cartilage proteoglycan depletion in, 241**
- Antigenicity, of a recombinant Ro (SS-A) fusion protein, 102**
- Antigens**
 antiperinuclear factor, 960
 anti-RNP antibodies in rheumatic diseases and, 834
 congenital complete heart block and, 609
 cross-reactive, 431
 cytoplasmic, 960
 histone H1 autoantibodies in SLE and, 1273
 HLA. *See* HLA antigens
 Ia, 261
 immune response toward articular chondrocytes and, 1477
 infectious agents, immunity, rheumatic diseases and, 457
 Leu-8, 1674
 lupus-inducing drugs, circular DNA and, 366
 major histocompatibility complex, 1542, 1776
 in mice, 1, 253, 583, 711, 866, 1394
 nuclear, 993, 1431
 nucleolar, 1431
 OA-related changes in human articular cartilage and, 219
 recombinant Ro (SS-A), 102
 restriction fragment length polymorphism in scleroderma and, 569
 Ro (SS-A), 1815
 in SLE, 153, 1273, 1542
 soluble recall, cyclosporin A in RA and, 1310
 synovium-cartilage junction of human knee and, 1170
- Antihistone antibodies**
 in ANA-positive juvenile arthritis, 1836
 histone H1 autoantibodies in SLE and, 1273
- Anti-HLA-DR monoclonal antibody, IgG, autoantibody synthesis and, in SLE, 1216**
- Anti-HMG-1, anti-HMG-2, in JRA, 1378**
- Antidiotypic antibodies**
 human V_H4 gene RF and, 1347
 IgG idiotypes in RA and, 1196
- Anti-Jo-1**
 antibody, subluxing arthropathy and, in PM/DM, 1640
 signal recognition particle in PM and, 1361
- Antikeratin antibodies, nRNP core protein and, in RA and SLE, 180**
- Anti-KJ, HLA-D, anti-Jo-1 and, in myositis, 1240**
- Antilamin antibodies, in RA, 877**
- Anti-La (SS-B)**
 congenital complete heart block and, 609
 retroviral antibodies in Sjögren's syndrome and, 774
- Anti-lipid A, C3 activation and, in pauciarticular JRA, 520**
- Antilymphocyte autoantibodies, IgM, in SLE, 1226**
- Antilymphocyte globulin, T cell depletion in SSc and, 511**
- Antimalarial drugs, in RA, 113, 1449**
- Antineutrophil cytoplasmic autoantibodies**
 in polyarteritis nodosa, 1871
 in vasculitis, 1264
- Anti-NOR 90 antibodies, in scleroderma, 1431**
- Antinuclear antibodies (ANA)**
 anti-HMG proteins in JRA and, 1378
 in collagen arthritis, 1716
 in connective tissue diseases, 1682
 fluorescent, in synovitis in lymphadenopathy, 578
 lupus-inducing drugs, circular DNA and, 366
 penicillamine-induced LE and, 1582
 in SSc, 657, 1822
- Antinuclear autoantibodies, in scleroderma, 1431**
- Antinucleolar autoantibodies, in scleroderma, 1431**
- Antinucleoprotein antibodies, IgG, autoantibody synthesis and, in SLE, 1216**
- Anti-parvovirus B19 IgM antibody, rheumatologic manifestations of B19 infection and, 1297**
- Antiperinuclear factor**
 antigen, characterization of, 960
 in RA, 759
- Antiphospholipid antibodies, IgG, fetal death in SLE and, 501**
- Anti-PL-7, anti-PL-12, HLA, anti-Jo-1 and, in myositis, 1240**
- Anti-PM-Scl, immunogenetics of, 657**
- Anti-rat type II collagen autoantibody, in collagen arthritis in rats, 693**
- Anti-recombinant heterogenous nRNP core protein, in RA and SLE, 180**
- Anti-retroviral drugs, in AIDS-associated arthritis, 268**
- Antirheumatic drugs, in RA, 1611**
- Anti-RNP, antibodies, in rheumatic diseases, 834**
- Anti-Ro (SS-A)**
 antigen, 102, 1815
 congenital complete heart block and, 609
 retroviral antibodies in Sjögren's syndrome and, 774
- Anti-signal recognition particle, in PM, 1361**
- Anti-Sm, in rheumatic diseases, 834**
- Anti-snRNP, in rheumatic diseases, 834**
- Anti-SRP, HLA-D, anti-Jo-1 and, in myositis, 1240**
- Anti-T cell**
 antibodies, in proteoglycan-induced polyarthritis and spondylitis in BALB/c mice, 866
 autoantibodies, IgM, in SLE, 1226
 autoimmunity, in collagen arthritis, 1716
- Anti-Th RNP antibodies, autoantibodies in SSc and, 1431, 1822**
- Anti-topoisomerase I (anti-topo I)**
 immunogenetics of, 657
 immunoglobulin isotypes, anticentromere autoantibodies and, 724

- Anti-topoisomerase I (cont'd)**
 molecular characterization of topo I in scleroderma and, 1501
- Anti-transforming growth factor β antibodies, IL-4 and, in rheumatoid synovitis, 1180**
- Anti-type II collagen**
 in collagen arthritis, 1716
 in RA, 1493
- Anti-(U1) RNP, in rheumatic diseases, 834**
- Anti-(U1) snRNP A protein, antibodies, in rheumatic diseases, 834**
- Anti-(U1,U2) RNP, in rheumatic diseases, 834**
- Aorta, in Takayasu arteritis, 1074, 1129**
- Apatite deposition disease, foreign body synovitis and, 1753**
- Arachidonic acid**
 dietary omega-3 fatty acids, articular cartilage in rats and, 1029
 in RA, 1149, 1526
- Arginine, I-E genes in autoimmune NZW mice and, 583**
- Arm**
 diltiazem in calcinosis in CREST syndrome and, 1287
 in eosinophilia-myalgia syndrome after oral L-tryptophan, 913
 in Takayasu arteritis, 1129
- Arteries**
 in giant cell arteritis, 1122
 in polyarteritis nodosa, 1088
 in Takayasu arteritis, 1129
- Arteriography, in Takayasu arteritis, 1129**
- Arterioles**
 in hypersensitivity vasculitis, 1108
 small, in Henoch-Schönlein purpura, 1114
- Arteritis**
 giant cell, 1990 criteria for, 1068, 1074, 1122
 necrotizing, in giant cell arteritis, 1122
 systemic, Henoch-Schönlein purpura and, 1114
 Takayasu, 1990 criteria for, 1068, 1074, 1129
 temporal, 1990 criteria for, 1068, 1074, 1122
- Arthralgia**
 anti-Th in SSc and, 1822
 NSAID-enhanced PGE₂ secretion by synoviocytes and, 1162
- Arthritis**
 adjuvant, 247
 AIDS-associated, 268
 antigen-induced, 241
 anti-signal recognition particle in PM and, 1361
 anti-Th in SSc and, 1822
 bacterial, 1739
 cartilage proteoglycan, 1394
 childhood, 821, 1560
 chronic, 821, 1560
 collagen, 388, 451, 693, 1716
 destructive, 1600
 economics and, 746
 erosive, 253, 1297
 experimental, 87
 in foreign body synovitis, 1753
 gonococcal, 1438
 health status in elderly with, 1205
 inflammatory, 388, 542, 1596, 1716
- Arthritis (cont'd)**
 juvenile, 821, 1787
 monarticular, 241, 253
 NSAID-enhanced PGE₂ secretion by synoviocytes and, 1162
 peripheral, 1574
 polyarthritis, 1, 268, 947
 polycation-induced, 241
 psoriatic, 1574, 1723
 reactive, 758
Salmonella-induced, 1795
 septic, 533, 757, 1442, 1753
 staphylococcal, 1739
 substance P and, 87
 traumatic, 87
Yersinia-induced, 1795
- Arthritis and Rheumatism**
 In appreciation of William J. Koopman, MD, Editor, 909
 Schur, Peter H., new Editor, 1059
- Arthritis information telephone service, user behavior, 212**
- Arthritogenicity, of minor cartilage collagens in mice, 1**
- Arthropathy**
 acromegalic, radiographic abnormalities in, 455
 Charcot, joint trauma in diabetic neuropathy and, 412
 in hemodialysis, 602, 1567
 subluxing, anti-Jo-1 antibody in PM/DM and, 1640
- Arthroplasty, hip and knee, with and without cement, 293**
- Arthroscopy, MRI in JRA and, 1426**
- Articular cartilage**
 collagen and, 1512, 1626, 1716
 degradation of, stromelysin and, in inflammatory arthritis, 388
 dietary omega-3 fatty acids and, 1029
 IL-1 and, 1695, 1807
 immune response toward chondrocytes and, 1477
 inorganic pyrophosphate, glycosaminoglycan synthesis and, 235
 in OA, 219, 674, 1406, 1626
 proteoglycan, depletion of, metalloproteinase and, in chronic arthritis, 241
 in proteoglycan-induced arthritis in BALB/c mice, 866
 serine proteinase inhibitors of, 1384
Staphylococcus aureus in septic arthritis and, 533
 substance P, IL-1, and tumor necrosis factor in, 1023
 synovium-cartilage junction of human knee and, 1170
- Articular chondrocytes**
 human, 1477, 1733
 tumor necrosis factor, cartilage degradation and, 542
- Articular destruction, MRI of, in JRA, 1426**
- Articular features of systemic JRA, as outcome measure after intravenous gamma globulin, 1015**
- Articular involvement, in early-onset primary OA and chondrodysplasia, 674**
- Articular pathology, arthritogenicity of minor collagens in mice and, 1**
- Articular swelling, bone and cartilage loss in adjuvant arthritis in rats after cyclosporin A, 247**
- Ascites, hepatitis, fibrosis, methotrexate and, in RA, 1027**
- Aspartate aminotransferase, in polyarteritis nodosa, 1088**
- Aspirin, in RA, 1611**
- Asthma, in Churg-Strauss syndrome, 1094**

Atlantoaxial facet joint, in RA, 325
 Atlas, craniocervical pseudotumor during hemodialysis and, 1567
 Atrial myxoma, 1442
 Auranofin
 in JRA, 466, 587
 in RA, methotrexate and, 330, 1449
 Autoantibodies
 anticentromere, immunoglobulin isotypes, anti-topo I and, 724
 anti-collagen, in collagen arthritis, 693, 1716
 antigenicity of recombinant Ro (SS-A) fusion protein and, 102
 anti-HMG proteins in JRA and, 1378
 antineutrophil cytoplasmic, in vasculitis, 1264
 antinucleolar, 1431
 antiperinuclear factor antigen, 960
 anti-RNP and, 834, 1822
 anti-U1-70-kd, HLA-DR4 and, in connective tissue diseases, 666
 congenital complete heart block and, 609
 HLA-D, anti-Jo-1 and, in myositis, 1240
 human V_H4 RF and, 1347
 immune response toward articular chondrocytes and, 1477
 myeloperoxidase, in vasculitis, 1264
 in New Zealand black mice, 711
 in RA, 339, 877, 1493
 in scleroderma, 1431, 1502
 in Sjögren's syndrome, 349, 774
 in SLE, 349, 1216, 1226, 1273, 1857
 Autoantigens, antiperinuclear factor antigen and, 960
 Autoimmune antibodies, Z-DNA, lupus-inducing drugs, circular DNA and, 366
 Autoimmune disease
 antiperinuclear factor antigen in, 960
 effect of TLI on Ly-1 B cells on, in (NZB × NZW)_F₁ mice, 553
 IL-6 in cardiac myxoma and, 398
 intravenous gamma globulin in systemic JRA and, 1015
 T cell DNA methylation in SLE and RA and, 1665
 Autoimmune exocrinopathy, retroviral antibodies in primary Sjögren's syndrome and, 774
 Autoimmune injury, congenital complete heart block and, 609
 Autoimmune mice
 autoantibodies in NZB mice, 711
 estrogen metabolism in (NZB × NZW)_F₁ model of SLE, 107
 New Zealand, I-E genes in, 583
 Autoimmune response
 anti-RNP antibodies in rheumatic diseases and, 834
 HLA-D, anti-Jo-1 and, in myositis, 1240
 molecular characterization of topo I in scleroderma and, 1501
 to SS-A (Ro) polypeptides in SLE and Sjögren's syndrome, 349
 Autoimmunity
 in collagen arthritis, 1716
 congenital complete heart block and, 609
 Autoreactive antibodies, in proteoglycan-induced polyarthritis and spondylitis in BALB/c mice, 866

Autosensitivity, DNA, in Japanese sisters, 287
 Avascular necrosis, triamcinolone hexacetonide in juvenile arthritis and, 821
 Azathioprine
 in JRA, 587
 neoplasia induced by, 605
 Azidothymidine (AZT), in AIDS-associated arthritis, 268

B

B cells
 autoantibodies and, in NZB mice, 711
 collagen arthritis in rats and, 693
 IL-6 in cardiac myxoma and, 398
 in primary Sjögren's syndrome, 49, 453
 in RA, 339, 623, 993, 1180
 in SLE, 978, 993, 1216
 TLI and, 553, 702
 B10.PL (H-2^u) mice, I-E genes in autoimmune NZW mice and, 583
 Bacterial arthritis, staphylococcal, osteitis and, in mice, 1739
 Bacterial cell wall, catabolic effects of muramyl dipeptide on rabbit chondrocytes and, 1801
 BALB/c mice, naive, proteoglycan-induced polyarthritis and spondylitis in, 866
 Baltimore Longitudinal Study of Aging, hand OA in men and, 1323
 Basement membrane, fibronectin in chronic nephritis in rats in, 685
 Basic fibroblast growth factor, synoviocytes and, 493
 Bb fragment, factor B in SLE and, 1598
 Behçet's syndrome
 amyloidosis in, 1586
 pediatric, myositis in, 418
 β gene, T cells, restriction fragment length polymorphism and, in scleroderma, 569
 Beta-galactosidase fusion protein (βgal-Ro), recombinant Ro (SS-A) fusion protein antigenicity and, 102
 β₂-microglobulin
 in hemodialysis, 602, 1567
 renal disease in chronic childhood arthritis and, 1560
 BF marker, ethnicity and, in SLE, 985
 Biliary tract, elimination of low-dose methotrexate by, 898
 Biochemical characterization, of amyloid from κ light chain subgroup III, 880
 Biochemical studies, calpains and calpastatin in OA synovial fluid, 728
 Biomechanics
 bone resorption and, 66
 collagen-proteoglycan interactions in cartilage and, 1512
 Biopsy
 in Churg-Strauss syndrome, 1094
 in classification of vasculitis, 1135
 in connective tissue diseases, 1682
 dermal mast cells and, in SSc, 1702
 excisional, in foreign body synovitis, 1753
 in giant cell arteritis, 1122
 in Henoch-Schönlein purpura, 1114
 in histopathologic classification for vasculitis, 1074
 in hypersensitivity vasculitis, 1108

Biopsy (cont'd)

lymph node, in synovitis with lymphadenopathy, 578
multicentric reticulohistiocytosis, melanoma, cyclophosphamide and, 1047
muscle, 418, 913, 918, 930, 1579
in pediatric Behçet's syndrome with myositis, 418
pericardial, in gonococcal pericarditis with tamponade in SLE, 1438

in polyarteritis nodosa, 1088

in RA, 1037, 1594

rectal, in amyloidosis in Behçet's syndrome, 1586

renal, in lupus nephritis, 970

skin, 418, 578, 913, 918, 930, 1534

surgical, in synovitis with lymphadenopathy, 578

synovial, 268, 578, 1406, 1795

Biosynthesis, of low molecular weight serine proteinase inhibitors of human articular cartilage, 1384

Bla RF cross-idiotype specificity, monoclonal antibody 6B6.6 idiotope on, 187

Bleeding disorders, DNA autosensitivity in Japanese sisters and, 287

Blood

cells, umbilical cord, 1340, 1420

cholesterol, fibronectin in chronic nephritis in rats and, 685

markers, cartilage metabolism in RA and, 790

mononuclear cells, human IgM-RF and, 1340

peripheral, T cells in, in Sjögren's syndrome, 1674

Blood pressure

in polyarteritis nodosa, 1088

systolic, in Takayasu arteritis, 1129

Blood urea nitrogen, in polyarteritis nodosa, 1088

Blood vessels

in Churg-Strauss syndrome, 1094

in histopathologic classification of vasculitis, 1074

metalloproteinase in canine OA and, 1466

walls of, synovial membrane nerves in Sprague-Dawley rat and, 859

Blood-brain barrier function, IL-6 in CSF in SLE and, 644

Body mass index, estrogen and, in knee OA in women, 525

Bone

changes in, microfocal radiography of hand OA and, 57
cysts, craniocervical pseudotumor during hemodialysis and, 1567

Gla-protein, glucocorticoid drugs and, in rheumatic disease, 1487

loss of, 247, 615

marrow of, 66, 398, 1763

MRI of sacroiliac joint inflammation and, 1763

in RA, 325, 615

resorption of, 66, 247, 615

scans of, 426, 1287

sclerosis of, osteonecrosis and, after renal transplantation, 1444

subchondral, IL-1 and, in methylated bovine serum albumin-induced arthritis in mice, 253

synovium-cartilage junction in human knee and, 1170

triamcinolone hexacetonide in juvenile arthritis and, 821

tumor, foreign body synovitis and, 1753

Book Reviews

Antiinflammatory Steroid Action: Basic and Clinical Aspects (Schleimer, Claman, and Oronsky, eds), 1448

Proceedings: Early Decisions in DMARD Development (Johnson and Strand, eds), 1872

Borage seed oil, in RA, 1526

Bovine studies

acute erosive monarticular arthritis in mice and, 253

antihistone antibodies in ANA-positive juvenile arthritis and, 1836

anti-type II collagen in RA, 1493

arthritogenicity of minor collagens in mice and, 1

congenital complete heart block and, 609

septic arthritis, 533

Bowel, small, anti-Th in SSc and, 1822

Brachial artery, in Takayasu arteritis, 1129

Brain, tissue, phosphates in, in SLE, 827

Bridging fibrosis, hepatitis, methotrexate and, in RA, 1037

Brucellosis, lumbosacral pain in, 1052

Bruit, subclavian artery, in Takayasu arteritis, 1129

Buccal mucosa, antiperinuclear factor antigen and, 960

Bullous photosensitivity, to naproxen, 903

Bursa

in foreign body synovitis, 1753

suprapatellar, knee, *Streptococcus pneumonia* infection in, 1063

C

CII autoantibodies, in collagen arthritis, 1716

C3d:C3 ratio, C3 activation, anti-lipid A and, in juvenile arthritis, 520

C4 null alleles, ethnicity in SLE and, 985

C4A protein, major histocompatibility complex genes in SLE and, 1542

C4AQ0, ethnicity and, in SLE, 985

Calcifications, periarticular, triamcinolone hexacetonide in JA and, 821

Calcinosis

autoantibodies in scleroderma and, 1431

diltiazem in, in CREST syndrome, 1287

subluxing arthropathy, anti-Jo-1 antibody and, in PM/DM, 1640

Calcitonin gene-related peptide, synovial membrane nerves in Sprague-Dawley rat and, 859

Calcitriol, periarticular bone loss in RA and, 615

Calcium

calpains and calpastatin in OA, 728

diltiazem in calcinosis in CREST syndrome and, 1287

inhibition of bone resorption in mouse fetus and, 57

ionophore, 261, 1149

Calcium pyrophosphate dihydrate (CPPD) crystals

cartilage inorganic pyrophosphate, glycosaminoglycan synthesis and, 235

in pseudogout and staphylococcal septic arthritis, 1442

Calpains and calpastatin, in OA synovial fluid, 728

cAMP, T cells in JRA and, 205

Canine studies

anti-signal recognition particle in PM, 1361

Charcot arthropathy after joint trauma in diabetic neuropathy, 412

Canine studies (*cont'd*)

- effect of hemostasis on anterior cruciate ligament transection-induced OA, 1406
- iodide and albumin kinetics in normal wrists and knees, 73
- metalloproteases in experimental OA, 1466
- transitional microvascular pressure in joints, 80
- Carbaprostacyclin, in SSc, 1620
- Carbocysteine, sulfoxidation of penicillamine in RA and, 574
- Carbohydrates, IgG isotype, RF binding and, 790, 800
- Carbon monoxide diffusing capacity, nifedipine in SSc and, 1634
- Cardiac involvement
 - congenital complete heart block, 609
 - in SSc, 1256, 1634
- Cardiac myxoma, IL-6 in, 398
- Carpal tunnel syndrome, in polymyalgia rheumatica, 403
- Cartilage
 - articular. *See* Articular cartilage
 - collagen and, 1, 1512
 - deformation of, collagen-proteoglycan interactions and, 1512
 - degradation of, 388, 533, 1023
 - hyaline, 674, 1394
 - IL-1-induced IL-6 and proteoglycan synthesis in, 1695
 - inorganic pyrophosphate, glycosaminoglycan synthesis and, 235
 - loss of, 247, 578
 - matrix, 241, 388, 542, 728, 1384, 1466, 1512
 - metabolism of, inflammation and, in RA, 790
 - in mice, 1, 66, 253, 866, 1394
 - MRI of knee and, 441
 - neutrophil collagenase release and, 228
 - in OA, 219, 674, 728, 1466, 1626
 - proteoglycan, 674, 866, 1023, 1394
 - in RA, 325, 1493
 - staphylococcal arthritis and, 533, 1739
 - synovium junction with, in knee, 1170
- Casein
 - calpains, calpastatin and, in OA, 728
 - Staphylococcus aureus* in septic arthritis and, 533
 - stromelysin, cartilage degradation and, in inflammatory arthritis, 388
- Catabolism
 - effects of muramyl dipeptide on, in rabbit chondrocytes, 1801
 - fibronectin in chronic nephritis in rats and, 685
- Catecholamines, synovial membrane nerves in Sprague-Dawley rats and, 859
- Cathepsin G, serine proteinase inhibitors of articular cartilage and, 1384
- Cationic inhibitors, serine proteinase, of articular cartilage, 1384
- CD3+ cells
 - IgG, autoantibody synthesis and, in SLE, 1216
 - in RA, 485, 623
- CD4+ cells
 - depletion of, in SSc, 511
 - IgG, autoantibody synthesis and, in SLE, 1216
 - in RA, 623, 1064, 1864
 - in Sjögren's syndrome, 1674
 - in SLE, 1864

CD4- cells

- IgG, autoantibody synthesis and, in SLE, 1216
- on synovial lymphocytes in RA, 485
- CD4:CD8 ratio, depletion of T cells in SSc and, 511
- CD5
 - effect of TLI on Ly-1 B cells in (NZB × NZW)F₁ mice and, 553
 - in primary Sjögren's syndrome, 453
 - in RA, 339
- CD8 cells
 - depletion of, in SSc, 511
 - IgG, autoantibody synthesis and, in SLE, 1216
 - in RA, 485, 623, 733
 - in Sjögren's syndrome, 1674
- CD8+, CD28- T cells, in JRA, 205
- CD14, effect of gold sodium thiomalate and tenidap sodium (CP-66,248-2) on HL-60 cells and, 29
- CD16+ cells, IgG, autoantibody synthesis and, in SLE, 1216
- Cell-mediated immunity
 - effect of methotrexate on, 954
 - human articular chondrocytes and, 1477
 - IL in polymyositis and, 1007
- Cell surface
 - cytokines in inflammatory synovitis and, 1776
 - membranes, immune response toward articular chondrocytes and, 1477
- Cellular fatty acids, gamma-linolenic acid in RA and, 1526
- Cell wall, bacterial, catabolic effects of muramyl dipeptide on rabbit chondrocytes and, 1802
- Cement and cementless hip and knee replacements, 293
- Centers for Disease Control, L-tryptophan and eosinophilia-myalgia syndrome, 913, 918, 930
- Central nervous system in SLE
 - IL-6 in CSF and, 644
 - high-energy phosphates in, 827
- Cerebral infarction, in neuropsychiatric SLE, 827
- Cerebrospinal fluid, IL-6 in, in SLE, 644
- Cervical spine
 - pseudotumor of, during hemodialysis, 1567
 - radiography of, in atlantoaxial facet joint in RA, 325
- Cervico-occipital hinge, beta₂-microglobulin amyloid arthropathy of, in hemodialysis, 602
- Charcot arthropathy, joint trauma in diabetic neuropathy and, 412
- Chest radiographs
 - in classification of Wegener's granulomatosis, 1101
 - cyclosporine in pulmonary fibrosis in RA and, 1594
- Chicken studies
 - antihistone antibodies in ANA-positive juvenile arthritis and, 1836
 - anti-type II collagen in RA, 1493
- Childhood arthritis, chronic, renal disease in, 1560
- Childhood Behçet's syndrome, myositis in, 418
- Childhood Kawasaki syndrome, soluble IL-2 receptors in, 1371
- Chlorambucil, in JRA, 587
- Chloroquine
 - DNA autosensitivity in Japanese sisters and, 287
 - efficacy and toxicity of, in RA, 1449
- Cholecystotomy, biliary elimination of low-dose methotrexate and, 898

- Cholesterol**
blood, fibronectin in chronic nephritis in rats and, 685
subcutaneous crystals, in index finger, 1752
- Chondrocytes**
articular, 542, 1477, 1733
in canine OA, 1406, 1466
cartilage inorganic pyrophosphate, glycosaminoglycan synthesis and, 235
dietary omega-3 fatty acid in rat articular cartilage and, 1029
rabbit, catabolic effects of muramyl dipeptide on, 1801
Staphylococcus aureus in septic arthritis and, 533
stromelysin, cartilage degradation and, in inflammatory arthritis, 388
synovial, cytokines in RA and, 305
- Chondroitin sulfate**
cartilage proteoglycan-induced arthritis in BALB/c mice and, 1394
in early-onset primary OA and chondrodysplasia, 674
- Chondroitinase**, in proteoglycan-induced arthritis in BALB/c mice, 866
- Chromatography**, monoclonal antibody 6B6.6 idiotope on RF and, 187
- Chromosomes**
anti-HMG proteins in JRA and, 1378
lupus-inducing drugs, circular DNA and, 366
- Chronic active hepatitis**, lamin autoantibodies in RA and, 877
- Chronic arthritis**
childhood, renal disease in, 1560
metalloproteinase and cartilage proteoglycan depletion in, 241
- Chronic fatigue syndrome**, fibromyalgia and, 381
- Chronic hepatitis**, fibrosis, methotrexate and, in RA, 1037
- Chronic juvenile arthritis**, triamcinolone hexacetonide in, 821
- Chronic rheumatoid synovitis**, T cells in, 768
- Chronicity index**, renal biopsy, lupus nephritis and, 970
- Churg-Strauss syndrome**
histopathologic criteria for, 1074
myeloperoxidase autoantibodies in, 1264
1990 criteria for classification of, 1068, 1094
- Ciamexon**, in RA, 733
- Circular DNA**, lupus-inducing drugs and, 366
- Circulating hyaluronic acid**, cartilage metabolism in RA and, 790
- Circulating immune complexes**, intravenous immunoglobulin in thrombocytopenia in SLE and, 1233
- Circulating α -IFN**, acid lability to, in SLE and, 563
- Claudication**
extremity, in Takayasu arteritis, 1129
in giant cell arteritis, 1122
- Clinical status questionnaire**, formal education and, in SLE, 407
- Clinical trials**
guide to understanding methodology and interpreting results in, 131
in RA, 140
- C-myc proto-oncogene**, in primary Sjögren's syndrome, 49
- Coagulation**, recombinant tissue plasminogen activator therapy in SSc and, 274
- Coconut oil**, vitamin E, dietary fish oil and, in RA, 1416
- Cold-reactive IgM antilymphocyte autoantibodies**, in SLE, 1226
- Cold working conditions**, outcome measures in AS and, 1001
- Collagen**
anti-type II, in RA, 1493
arthritis induced by, 388, 451, 693, 1716
fibrillar, lysis of, by neutrophils in SF, 1333
minor cartilage, arthritogenicity of, in mice, 1
proteoglycan and, in cartilage, 1512
in rheumatoid vasculitis, 1646
in SSc, 842, 1829
Staphylococcus aureus in septic arthritis and, 533
type II, 1, 388, 1170
type IX, 1
type XI, 1, 1626
- Collagenase**
collagen lysis by neutrophils in SF and, 1333
effect of cytokines on, in synoviocytes, 1518
metalloprotease in canine OA and, 1466
neutrophil, release of, 228
IL-1 and, 1023, 1733, 1807
stromelysin, cartilage degradation and, in inflammatory arthritis, 388
substance P, IL-1, tumor necrosis factor and, 1023
- Comparative Systematic Studies in Rheumatic Diseases**, RF and methotrexate in RA, 1156
- Complement**
activation of, anti-lipid A in juvenile arthritis and, 520
allotypes of, ethnicity, MHC markers and, in SLE, 985
in proteoglycan-induced arthritis in BALB/c mice, 866, 1394
in SLE, IgM antilymphocyte autoantibodies and, 1226
- Complement C1q**, in rheumatoid vasculitis, 1646
- Complement C2**
effect of gold sodium thiomalate and tenidap sodium (CP-66,248-2) on HL-60 cells and, 29
ethnicity and, in SLE, 985
- Complement C3**
activation of, anti-lipid A and in pauciarticular JRA, 520
anti-dsDNA antibodies, disease exacerbations and, in SLE, 634
- Complement C3b**, receptors for, in DLE and SLE, 888
- Complement C4**, in SLE, 634, 985
- Complement CR1**, in DLE and SLE, 888
- Complementary DNA (cDNA)**
antigenicity of recombinant Ro (SS-A) fusion protein and, 102, 1829
collagen genes in systemic sclerosis and, 1829
- Complete heart block**, congenital, 609
- Compliance**, arthritis information service user behavior and, 212
- Complotype SC01**, ethnicity and, in SLE, 985
- Computed tomography**
MRI and, 1567, 1763
in phosphorus-31 nuclear magnetic resonance spectroscopy in neuropsychiatric SLE, 827
to study periarticular bone loss in RA, 615
- Concanavalin A**
dietary fatty acid supplements in RA and, 810

- Concanavalin A (*cont'd*)
in proteoglycan-induced arthritis in BALB/c mice, 866
T cells in JRA and, 205
- Condyle
femoral, bone and cartilage loss in adjuvant arthritis after cyclosporin A and, 247
substance P, IL-1, and tumor necrosis factor in, 1023
- Congenital complete heart block, human model of, 609
- Connective tissue
IL-1 and, 1733, 1807
platelet-derived growth factor in SSc and, 1534
rheumatoid nodules and, 761
- Connective tissue disease
antiperinuclear factor antigen and, 960
anti-Th in SSc and, 1822
anti-U1-70-kd autoantibody and HLA-DR4 in, 666
labial salivary gland histopathology in, 1682
subacute cutaneous LE during PUVA and, 302
- Contraceptives, oral, RA and, 173, 782, 947, 1462, 1770
- Cooperative Systematic Studies of Rheumatic Diseases Group, study of DMARD in JRA, 477
- Coping strategies, psychological factors in primary fibromyalgia syndrome and, 1279
- Core protein
in early-onset primary OA and chondrodysplasia, 674
retroviral antibodies in Sjögren's syndrome and, 774
- Cornea, in RA, 1442
- Coronary artery, aneurysms in, soluble IL-2R in childhood Kawasaki syndrome and, 1371
- Cortical bone, loss of, in RA, 615
- Cortical collapse, in hand OA in men, 1323
- Cortical thickness, in microfocal radiography of hand OA, 57
- Corticosteroid drugs
in cutaneous vasculitis and pheochromocytoma, 1852
intravenous gamma globulin in systemic JRA and, 1015
in RA, methotrexate and, 1149
Wegener's granulomatosis and, 1101
- Cost containment in arthritis, 746
- Cost-effectiveness, of treatment of RA, 1751
- CP-66,248-2 (tenidap sodium), effect of, on HL-60 cells, 29
- Craniocervical junction, pseudotumor of, during long-term hemodialysis, 1567
- C-reactive protein
NSAID and, in RA, 19, 623
in synovitis in lymphadenopathy with dysproteinemia, 578
- Creatine kinase, IL in PM and, 1007
- Creatinine
clearance of, 95, 277
glucocorticoid drugs, Gla-protein and, in rheumatic diseases, 1487
in polyarteritis nodosa, 1088
- Crescentic glomerulonephritis, myeloperoxidase autoantibodies in, 1264
- CREST syndrome
autoantibodies in scleroderma and, 1431
effect of diltiazem on calcinosis in, 1287
- Cricoarytenoid synovitis, in AS, 604
- Crithidia lucillae* assay, anti-dsDNA antibody, disease exacerbation and, in SLE, 634
- Cross-idiotypes, human RF, 1710
- Cross-reactive antigens, mycobacteria, RA and, 431
- Cross-reactive idiotypes, in human RF, 1347
- Cross-reactive kappa light chain idiotype, monoclonal antibody 6B6.6 idiotype on RF and, 187
- Cross-reactivity, arthritogenicity of minor collagens in mice and, 1
- Cruciate ligament, anterior
in canine OA, 1406, 1466
Charcot arthropathy in diabetic neuropathy and, 412
- Cryoglobulinemia, mixed, RF and, 800
- Crystals
AIDS-associated arthritis and, 268
CPPD, 235, 1442
subcutaneous cholesterol, in index finger, 1752
- C-terminal, in RA and SLE, 180, 993
- Cutaneous blood flow, in SSc, 1620
- Cutaneous LE, subacute, during PUVA, 302
- Cutaneous lesions, in bullous photosensitivity to naproxen, 903
- Cutaneous sclerosis, in SSc, 274, 1256
- Cutaneous vasculitis, pheochromocytoma and, 1852
- Cyanogen bromide-digested peptides, anti-type II collagen in RA and, 1493
- Cyclophosphamide
intravenous pulse, in myositis and Sjögren's syndrome, 1579
in JRA, 587
in multicentric reticulohistiocytosis in malignant melanoma, 1047
in RA, 113
in synovitis in lymphadenopathy with dysproteinemia, 578
T cell depletion in SSc and, 511
in Wegener's granulomatosis, 1101
- Cyclosporin A
bone and cartilage loss in adjuvant arthritis in rats after, 247
in JRA, 587
in RA, 1310, 1594
- Cysteine proteinase, calpains and calpastatin in OA, 728
- Cystic fibrosis, T cells in JRA and, 205
- Cysts, thyroglossal duct, tophaceous neck mass presenting as, 910
- Cytochrome P-450, estrogen metabolism in (NZB × NZW)F₁ model of SLE and, 107
- Cytokines
bone and cartilage loss in adjuvant arthritis in rats after cyclosporin A and, 247
effects of gold sodium thiomalate and tenidap sodium (CP-66,248-2) on HL-60 cells and, 29
IL and, 253, 1007, 1023
immune, collagen production by fibroblasts in scleroderma and, 842
in inflammatory synovitis, 1776
PGE₂ secretion by synoviocytes, NSAID and, 1162
in RA, 305, 615, 768
tumor necrosis factor and, 542, 1023
- Cytoplasmic antigens, antiperinuclear factor and, 960
- Cytoplasmic autoantibodies, antineutrophil
in polyarteritis nodosa, 1871
in vasculitis, 1264
- Cytoplasmic granularity, collagen production by fibroblasts in scleroderma and, 842

D

- DA rats, collagen arthritis in, 693
 Dapsone, in Wegener's granulomatosis, 1590
 DBA/1 mice, arthritogenicity of minor cartilage collagens in, 1
 Definite RA
 1987 revised criteria for, 1042
 oral contraceptives and, 173, 1462, 1770
 Deformity
 in OA, 853, 1601
 subluxing arthropathy, anti-Jo-1 antibody and, in PM/DM, 1640
 Deglutition, claudication and, in giant cell arteritis, 1122
 Delayed-type hypersensitivity, in collagen arthritis in rats, 693
 Demographic factors
 prognosis in SLE and, 37
 in self-report questionnaire in rheumatic disease assessment, 1317
 Dermal fibroblasts, in scleroderma, 650, 842, 1847
 Dermal mast cells, in SSc, 1702
 Dermal vessels, platelet-derived growth factor type B receptors in SSc and, 1534
 Dermatomyositis
 anti-signal recognition particle in, 1361
 penicillamine-induced, in RA, HLA-D genes and, 1445
 subluxing arthropathy and anti-Jo-1 antibody in, 1640
 Destructive arthritis, RF, HLA-DR4 and, in RA, 1600
 Destructive joint diseases, immune response toward human articular chondrocytes and, 1477
 Dexamethasone, effects of gold sodium thiomalate and tenidap sodium (CP-66,248-2) on HL-60 cells and, 29
 Diabetic neuropathy, Charcot arthropathy after joint trauma in, 412
 Dialysis, kidney, low-dose methotrexate and neutropenia in, 1060
 Diaphysis, inhibition of bone resorption in mouse fetus and, 66
 Diarrhea
 after auranofin in JRA, 466, 587
 in *Yersinia* reactive arthritis and HIV infection, 758
 Dietary fatty acids
 omega-3, articular cartilage in rats and, 1029
 in RA, 810
 Dietary fish oil, in RA, 810, 1416
 Dietary olive oil, in RA, 810
 Diethylcarbamazine, cartilage inorganic pyrophosphate, glycosaminoglycan synthesis and, 235
 Diffuse musculoskeletal pain, noninflammatory, self-report questionnaire in, 1317
 Diffuse scleroderma, 1431, 1829
 Digital ulceration, in SSc, recombinant tissue plasminogen activator therapy and, 274
 Dihydrofolate reductase, effect of methotrexate on peripheral blood mononuclear cells and, 954
 Diltiazem, effect of, on calcinosis, in CREST syndrome, 1287
 Diplococci, gram-negative, gonococcal pericarditis with tamponade in SLE and, 1438
 Disability, long-term, as outcome measure in AS, 1001
 Discoid LE, C3b receptors in, 888
 Discs, intervertebral
 in proteoglycan-induced arthritis in BALB/c mice, 866
 serine proteinase inhibitors of cartilage in, 1384
 Disease activity
 IL in polymyositis and, 1007
 Ly-1 B cells and, in (NZB \times NZW)F₁ mice, 553
 in RA
 methotrexate and, 9, 330, 1447
 NSAID and, 19, 623
 sulfoxidation status of penicillamine and, 574
 renal disease in chronic childhood arthritis and, 1560
 in SLE
 acid lability to α -IFN and, 563
 disease exacerbation, anti-dsDNA antibodies and, 634
 pregnancy and, 605
 soluble IL-2 receptors and, in rheumatic diseases, 375, 1145
 T cells in JRA and, 205
 Disease duration
 in RA, 325, 1611
 in SLE, clinical status questionnaires, formal education and, 407
 soluble IL-2 receptors in SSc and, 375, 1145
 Disease flares
 NSAID-enhanced PGE₂ secretion by synoviocytes and, 1162
 in SLE, 605, 634
 Disease onset
 anti-signal recognition particle in PM and, 1361
 in collagen arthritis in rats, 693
 in giant cell arteritis, 1122
 in Henoch-Schönlein purpura, 1114
 in hypersensitivity vasculitis, 1108
 in JRA, 466, 587, 1378
 outcome measures in AS and, 1001
 in polyarthritis and spondylitis in BALB/c mice, 866
 in RA, 173, 1462
 in Takayasu arteritis, 1129
 Disease outcome, renal biopsy, lupus nephritis and, 970
 Disease progression
 antineutrophil cytoplasmic antibodies in polyarteritis nodosa and, 1871
 in RA, oral contraceptives and, 1462
 soluble IL-2 receptors and, 375, 1145
 Disease severity
 IgA-RF in polyarticular JRA and, 199
 in RA, 325, 477, 810
 Disease-modifying antirheumatic drugs (DMARD), in RA, 113, 451, 477, 810
 Distal radial epiphysis, triamcinolone hexacetonide in juvenile arthritis and, 821
 Distal interphalangeal joints
 classification of OA of the hand and, 1601
 subluxing arthropathy, anti-Jo-1 antibody and, in PM/DM, 1640
 Distal radius, periarticular bone loss in RA and, 615
 DNA
 autosensitivity of, in Japanese sisters, 287

DNA (cont'd)

- binding of, anti-DNA antibodies, heparin, glomerulonephritis and, 1554
 - circular, lupus-inducing drugs and, 356
 - complementary, 102, 1829
 - double-stranded, 634
 - HLA antigens in juvenile arthritis and, 1787
 - human RF cross-idiotypes and, 1710
 - molecular characterization of topo I in scleroderma and, 1501
 - native, 356
 - penicillamine-induced LE and, 1582
 - in RA, 180, 939, 1655
 - recombinant, anti-RNP in rheumatic diseases and, 834
 - in SLE, 153, 180, 349
 - in Sjögren's syndrome, 49, 349
 - Z, 356, 366
- DNase, DNA autosensitivity in Japanese sisters and, 287
- Docosahexaenoic acid, in RA, 810
- Dopamine β -hydroxylase, synovial membrane nerves in Sprague-Dawley rats and, 859
- Doppler flow cytometry, in SSc, 1620
- Dorsal root ganglionectomy, Charcot arthropathy after joint trauma in diabetic neuropathy, 412
- Double-stranded DNA, in SLE, disease exacerbation and, 634
- DQ loci
- DQw1, in SLE, 1542
 - DQw4, DQw6:Dw18, in juvenile arthritis, 1787
 - DQw7 (DQw3.1), amino acids in RA and, 939
 - DQ β 1 alleles, in SLE, 1542 immunoglobulin idiotypes in SLE and, 978
 - immunoglobulin idiotypes in SLE and, 978
- DR
- DR1 (Dw1), amino acids and, in RA, 939
 - DR3 allele, ethnicity and, in SLE, 985
 - DR3/4, HLA, ANA and, in scleroderma, 657
 - DR4, in SLE, 1542
 - DR4 DRB1 genes, amino acids and, in RA, 939
 - DR5, DRw6, DRw8, DRw17, HLA-D, anti-Jo-1 and, in myositis, 1240
 - DR β 1, DR β 3, HLA-D, anti-Jo-1 and, in myositis, 1240
 - loci, immunoglobulin idiotypes in SLE and, 978
 - in Sjögren's syndrome, 1674
- Drug approval agencies, outcome measurement in RA and, 591
- Drug-induced SLE, 1857
- Drug interactions, in RA, 1611
- Drug sensitivity, in Churg-Strauss syndrome, 1094
- Drugs
- antibiotic, 1438
 - antilymphocyte globulin, 511
 - antimalarial, 113, 1449
 - anti-retroviral, 268
 - aspirin, 1611
 - auranofin, 330, 466, 587, 1449
 - azathioprine, 587, 605
 - azidothymidine (AZT), 268
 - carbocysteine, 574
 - chlorambucil, 587
 - chloroquine, 287, 1449
 - ciamexon, 733

Drugs (cont'd)

- corticosteroid, 1015, 1101, 1149, 1852
 - cyclophosphamide, 113, 511, 578, 587, 1047, 1101, 1579
 - cyclosporin A, 247, 587, 1310, 1594
 - dapsone, 1590
 - dexamethasone, 29
 - diltiazem, 1287
 - DMARDs, 113, 451, 477, 810
 - estrogen, 525
 - fluorouracil, topical, 303
 - flurbiprofen, 19, 623
 - gamma-IFN, 587
 - glucocorticoid, 1487
 - gold
 - intramuscular, in JRA, 587
 - in RA, 113, 1449
 - heparin, 1554
 - hydralazine, 366, 1665
 - hydroxychloroquine, 587, 1449, 1611
 - ibuprofen, 19, 623, 1061
 - immunosuppressive, 733
 - indomethacin, 893, 1162
 - L-canavanine, 366
 - L-tryptophan, 913, 918, 930
 - leucovorin, 1745
 - lupus-inducing, 366
 - methotrexate, 91, 303, 330, 450, 898, 954, 1037, 1060, 1149, 1156, 1449
 - methylprednisolone, 578
 - N-acetylprocainamide, 366
 - naproxen, 903
 - nifedipine, 1634
 - NSAID, 19, 29, 113, 451, 587, 623, 903, 1056, 1061, 1162, 1560
 - over-the-counter, 1056
 - penicillamine, 113, 574, 587, 1445, 1449
 - piroxicam, 1162
 - prednisone, 511, 587, 827, 1015, 1487
 - procainamide, 366, 1665
 - second-line, 1449
 - slow-acting antirheumatic, 1560
 - sodium salicylate, 1162
 - steroid, 1015, 1284, 1487, 1594
 - sulfasalazine, 113, 451, 1449
 - sulfonamide, 1590
 - tenidap sodium (CP-66,248-2), 29
 - triamcinolone hexacetonide, 821, 1284
- Dual-photon absorptiometry, periarticular bone loss in RA and, 615
- Dupuytren's contracture, 1442
- Dw4, amino acids and, in RA, 939
- Dysmotility, esophageal
- autoantibodies in scleroderma and, 1431
 - diltiazem in calcinosis in CREST syndrome and, 1287
- Dysplasia, epiphyseal, early-onset primary OA, chondrodysplasia and, 674
- Dysproteinemia, in synovitis in angioimmunoblastic lymphadenopathy, RA and, 578

E

- Ear, swelling of, in collagen arthritis in rats, 693

- Early-onset primary OA, chondrodysplasia and, 674
- Ecchymoses, DNA autosensitivity in Japanese sisters and, 287
- Echocardiography, in study of gonococcal pericarditis with tamponade in SLE, 1438
- Echography, of salivary glands, in Sjögren's syndrome, 505
- Economics
arthritis and, 746
in musculoskeletal conditions, 750
- Effusions
joint, in RA, cartilage metabolism and, 790
in synovitis in lymphadenopathy with dysproteinemia, 578
- Eicosanoids, gamma-linolenic acid in RA and, 1526
- Eicosapentaenoic acid, in RA, 810
- Elastase, leukocyte, serine proteinase inhibitors of cartilage and, 1384
- Elbow, in Panner's disease, 911
- Elderly
arthritis and health status in, 1205
pelvic insufficiency fractures in, 426
- Electrocautery, in anterior cruciate ligament transection-induced canine OA, 1406
- Electron microscopy
in AIDS-associated arthritis, 268
in characterization of antiperinuclear factor antigen, 960
lupus-type inclusions in umbilical cord blood mononuclear cells and, 1420
in study of human parvovirus B19 arthropathy, 1297
in study of omega-3 fatty acids in rat articular cartilage, 1029
- Electrophoresis, arthritogenicity of minor collagens in mice and, 1
- Encephalopathy, in neuropsychiatric SLE, 827
- Endogenous IL-2, IgG, autoantibody synthesis and, in SLE, 1216
- Endoplasmic reticulum, antiperinuclear factor antigen and, 960
- Endothelial cells, in AIDS-associated arthritis, 268
- Environmental agents, human lupus-type inclusions in umbilical cord blood mononuclear cells and, 1420
- Enzyme linked-immunosorbent assay (ELISA)
antihistone antibodies in ANA-positive juvenile arthritis and, 1836
anti-U1-70-kd autoantibody, HLA-DR4 and, in connective tissue diseases, 666
IgA in polyarticular JRA and, 199
immunoglobulin isotypes, anti-topo I, anticentromere autoantibodies and, 724
monoclonal antibody 6B6.6 idiotype on RF and, 187
in PM, 1007
in RA, 180, 1180, 1196, 1493, 1646, 1688
in SLE, 180, 356, 634
soluble IL-2 receptors and, 375, 1145, 1371
- Enzymes
collagen and, in cartilage, 1512, 1626
degradation of, in OA, 219, 1466
intravenous pulse cyclophosphamide in myositis and Sjögren's syndrome and, 1579
stromelysin and cartilage degradation in inflammatory arthritis, 388
- Enzymes (*cont'd*)
synovial membrane nerves in Sprague-Dawley rat and, 859
urinary tubular, subclinical renal dysfunction in RA and, 95
- Eosinophilia, in Churg-Strauss syndrome, 1094
- Eosinophilia-myalgia syndrome, L-tryptophan ingestion and, 913, 918, 930
- Eosinophils
extravascular, in Churg-Strauss syndrome, 1094
in hypersensitivity vasculitis, 1108
IL-1, methylated bovine serum albumin-induced arthritis in mice and, 253
- Epidemiologic studies
eosinophilia-myalgia syndrome after oral L-tryptophan, 913, 918, 930
prevalence survey of scleroderma in South Carolina, 1062
of SLE, 1857
- Epiphyseal dysplasia, early-onset primary OA, chondrodysplasia and, 674
- Epiphysis, triamcinolone hexacetonide in juvenile arthritis and, 821
- Epithelial cells, immune response toward articular chondrocytes and, 1477
- Epitopes
anti-RNP antibodies in rheumatic diseases and, 834
arthritogenicity of minor collagens in mice and, 1
cartilage proteoglycan-induced arthritis in BALB/c mice and, 1394
HLA-D, anti-Jo-1 and, in myositis, 1240
molecular characterization of topo I in scleroderma and, 1501
monoclonal antibody 6B6.6 idiotype on RF and, 187
in RA, 180, 993, 1493
in SLE, 180, 993, 1273, 1864
- Epstein-Barr nuclear antigen-1 (EBNA-1), in RA and SLE, 993
- Erosions
IL-1 and, in methylated bovine serum albumin-induced arthritis in mice, 253
in RA, 151, 325
synovitis in lymphadenopathy with dysproteinemia and, 578
- Erosive arthritis
human parvovirus B19 arthropathy and, 1297
nonarticular, induced in mice by IL-1 and methylated bovine serum albumin, 253
- Erosive disease, in RA, 1600
- Erosive polyarthritis, cartilage proteoglycan-induced, in BALB/c mice, 1394
- Erythema infectiosum, human parvovirus B19 arthropathy and, 1297
- Erythrocyte sedimentation rate
in giant cell arteritis, 1122
intravenous gamma globulin in systemic JRA and, 1015
in RA, 19, 477, 623, 790, 1449
in synovitis with lymphadenopathy and dysproteinemia, 578
- Erythrocytes
folic acid, methotrexate toxicity and, in RA, 9, 1447

Erythrocytes (*cont'd*)
 Ro (SS-A) antigen in guinea pig and, 1815
 in Wegener's granulomatosis, 1101
 Erythrocyturia, renal disease in chronic childhood arthritis and, 1560
 Esophageal dysmotility
 autoantibodies in scleroderma and, 1431
 diltiazem in calcinosis in CREST syndrome and, 1287
 Estrogen
 exogenous sex hormones in RA and, 947
 knee OA in women and, 525
 metabolism of, in (New Zealand black \times New Zealand white)F₁ murine model of SLE, 107
 Ethnic studies
 AS in Canary Islands aborigines (guanches), 1294
 major histocompatibility complex in SLE and, 985, 1542
 Etiopathogenesis, of early-onset primary OA and chondrodysplasia, 674
 Excisional biopsy, in foreign body synovitis, 1753
 Exercise
 eosinophilia-myalgia syndrome after L-tryptophan and, 930
 estrogen and, in knee OA in women, 525
 Exocrinopathy, autoimmune, retroviral antibodies in primary Sjögren's syndrome and, 774
 Exogenous collagen, in human OA cartilage, 1626
 Exogenous sex hormones, in RA, 947
 Experimental arthritis, substance P and, 87
 Experimental OA, metalloprotease in, 1466
 Experimental synovitis, cytokines in RA and, 305
 Extended sick leave, as outcome measure in AS, 1001
 Extraarticular features of systemic JRA, as outcome measures after intravenous gamma globulin, 1015
 Extramedullary plasmacytoma, in primary Sjögren's syndrome, 150
 Extravascular eosinophils, in Churg-Strauss syndrome, 1094
 Extremities
 claudication of, in Takayasu arteritis, 1129
 in polymyalgia rheumatica, 403
 Eye, in pediatric Behçet's syndrome with myositis, 418

F

Factor
 antiperinuclear, 759, 960
 B, activation of, in SLE, 1598
 fibroblast growth, 305, 493
 granulocyte-macrophage colony-stimulating, in Felty's syndrome, 1865
 granulocyte-monocyte colony-stimulating, cytokines in RA and, 305
 growth, 305, 493, 1180, 1534
 hepatocyte-stimulating, IL-6 in cardiac myxoma and, 398
 platelet-activating, methotrexate in RA and, 1149
 translation-related, HLA-D, anti-Jo-1 and, in myositis, 1240
 tumor necrosis, 305, 1023, 1518
 Farr assay, anti-dsDNA antibodies, disease exacerbations and, in SLE, 634
 Fasciitis, eosinophilic, eosinophilia-myalgia syndrome after L-tryptophan ingestion and, 913, 918, 930

Fat, aspiration of, from abdomen, in amyloidosis, 301
 Fatigue, chronic, in fibromyalgia, 381
 Fatty acids, cellular, gamma-linolenic acid in RA and, 1526
 Fc fragments
 IgG, 800, 1196
 RF, 800, 1340
 FDA Arthritis Advisory Committee, guidelines for approving NSAID for over-the-counter use, 1056
 Feet
 Charcot arthropathy after joint trauma in diabetic neuropathy and, 412
 interphalangeal joints of, in collagen arthritis in rats, 693
 Felty's syndrome, granulocyte-macrophage colony-stimulating factor in neutropenia in, 1865
 Femoral condyle, bone and cartilage loss in adjuvant arthritis in rats after cyclosporin A, 247
 Femoral epiphysis, proximal, triamcinolone hexacetonide in juvenile arthritis and, 821
 Femoral head
 dietary omega-3 fatty acids in rat articular cartilage and, 1029
 in early-onset primary OA and chondrodysplasia, 674
 Fetus
 cartilage proteoglycan-induced arthritis in BALB/c mice and, 1394
 congenital complete heart block and, 609
 loss of, in primary Raynaud's phenomenon, 1249
 mouse, inhibition of bone resorption by mechanical stimulation in, 66
 in proteoglycan-induced polyarthritis and spondylitis in BALB/c mice, 866
 Fibers, synovial membrane nerves in Sprague-Dawley rats and, 859
 Fibrillar collagen, lysis of, by neutrophils in SF, 1333
 Fibrillation, in anterior cruciate ligament transection-induced canine OA, 1406
 Fibrin, IL-1 and, in methylated bovine serum albumin-induced arthritis in mice, 253
 Fibrinoids, rheumatoid nodules and, 761
 Fibrinolysis, recombinant tissue plasminogen activator therapy in SSc and, 274
 Fibroblast growth factor
 cytokines in RA and, 305
 synoviocytes and, 493
 Fibroblasts
 collagen lysis by neutrophils in SF and, 1333
 immune response to human articular chondrocytes and, 1477
 in scleroderma, 650, 842, 1847
 stromal, platelet-derived growth factor in SSc and, 1534
 synovial, cytokines and, 305, 1518, 1776
 Fibromyalgia
 ACR 1990 criteria for classification of, 160, 1863
 chronic fatigue syndrome and, 381
 Fibronectin
 in chronic nephritis in rats, 685
 genes, in SSc, 1868
 Fibrosis
 bridging, hepatitis, methotrexate and, in RA, 1037
 pulmonary, 1361, 1594
 in SSc, 842, 1702

Fifth disease, human parvovirus B19 arthropathy and, 1297
Fingers

- anti-Th in SSc and, 1822
- cholesterol crystals in, 1752
- diltiazem in calcinosis in CREST syndrome and, 1287
- in RA, 151, 316

Fish oil

- articular cartilage in rats and, 1029
- in RA, 810, 1416

Flow cytometry

- collagen production by fibroblasts in scleroderma and, 842
- post-occlusive hyperemic response in SSc and, 1620
- in RA, 485, 623

Fluid balance, microvascular, hydrostatic and oncotic determinants of, in canine joints, 80

Fluorescent ANA, in synovitis in lymphadenopathy with dysproteinemia, 578

Fluorouracil, topical, toxic response to, methotrexate in RA and, 303

Flurbiprofen, in RA, 19, 623

Folate

- methotrexate and, 9, 954, 1447, 1745
- in Wegener's granulomatosis, 1590

Folic acid, low-dose methotrexate in RA and, 1447

Folinic acid, effect of methotrexate on peripheral blood mononuclear cells and, 954

Followup studies

- arthritis information service user behavior, 212
- of hand OA in men, 1323
- of RA, 173, 325, 1462

Food and Drug Administration (FDA), outcome measurement in RA and, 591

Foreign body synovitis, 1753

Formal education level, clinical status questionnaires and, in SLE, 407

Fragments

- anti-RNP antibodies in rheumatic diseases and, 834
- 11.3-kb *Pvu* II, in scleroderma, 569

Framingham Osteoarthritis Study, estrogen and knee OA in women, 525

Full-term infants, born to mothers with primary Raynaud's phenomenon, 1249

Functional ability

- health status and, in elderly persons with arthritis, 1205
- IgA-RF in polyarticular JRA and, 199
- impact of musculoskeletal conditions and, 750
- measurement of, in RA, 591
- outcome measures in AS and, 1001
- signal measurement strategies as outcome measures in OA and, 739

G

Galactose, IgG isotype, RF binding and, 800

Galactosyltransferase-associated protein kinase gene, in RA, 1655

γ gene, T cell antigen receptor, restriction fragment length polymorphism in scleroderma and, 569

Gamma globulin, intravenous, in systemic JRA, 1015

γ -IFN

bone and cartilage loss in adjuvant arthritis in rats after cyclosporin A and, 247

cytokines in RA and, 305

effect of, on synoviocytes, 1518

effects of gold sodium thiomalate and tenidap sodium (CP-66,248-2) on HL-60 cells and, 29

IL-1 release by rat synovial cells and, 261

in JRA, 587

Gamma-linolenic acid, in RA, 1526

Ganglionectomy, Charcot arthropathy after joint trauma in diabetic neuropathy and, 412

Gangrene, T cell depletion in SSc and, 511

Gastroenteritis, Reiter's syndrome after urethrectomy and, 885

Gastrointestinal bleeding, in Henoch-Schönlein purpura, 1114

Gel electrophoresis, to study tumor necrosis factor and cartilage degradation, 542

Gel filtration, in RA, 1180, 1688

Gel-separation studies, of congenital complete heart block, 609

Gelatin, *Staphylococcus aureus* in septic arthritis and, 533

Gelatinase, collagen degradation in human OA cartilage and, 1626

Gender

ACR 1990 criteria for classification of fibromyalgia and, 160

eosinophilia-myalgia syndrome after L-tryptophan ingestion and, 913, 918, 930

giant cell arteritis and, 1122

in OA, 525, 1323

outcome measures in AS and, 1001

in polyarteritis nodosa, 1088

in RA, 325, 810, 1042, 1611

in SLE, 407, 978, 1857

soluble IL-2 receptors in SSc and, 375, 1145

Genes

fibroblast growth factor, synoviocyte synthesis of, 493

fibronectin, in SSc, 1868

galactosyltransferase-associated protein kinase, in RA, 1655

in SSc, 569, 1829

HLA-D and, in myositis, 1240, 1445

human RF cross-idiotypes and, 1710

I-E, sequence of, from NZW mice, 583

immunoglobulin V, autoantibodies and, in New Zealand black mice, 711

in SLE, 978, 985, 1542

monoclonal antibody 6B6.6 idiotope on RF and, 187

Ro (SS-A) antigen in guinea pig and, 1815

Genetics

collagen arthritis in rats, 693

congenital complete heart block, 609

early-onset primary OA and chondrodysplasia, 674

OA-related changes in human articular cartilage and, 219

in RA, 339, 1188, 1770

in SLE, 985, 1542, 1857

Giant cell (temporal) arteritis

histopathologic criteria for, 1074

1990 criteria for classification of, 1068, 1122

Giant cells, IL-1 and, in methylated bovine serum albumin-induced arthritis in mice, 253

Gla-protein, glucocorticoid drugs and, in rheumatic diseases, 1487

Glands

- labial salivary, in connective tissue diseases, 1682
- retroviral antibodies in Sjögren's syndrome and, 774

GLO, ethnicity in SLE and, 985

Global assessment

- physician, 466, 587, 1560, 1723
- in RA, 19, 330, 623

Glomerular basement membrane, fibronectin in chronic nephritis in rats and, 685

Glomerular filtration rate

- creatinine clearance and, in SLE, 277
- subclinical renal dysfunction in RA and, 95

Glomerulonephritis

- anti-DNA antibodies, heparin and, in MRL-*lpr/lpr* mice, 1554
- idiopathic crescentic, myeloperoxidase autoantibodies in, 1264

Glucocorticoid drugs, Gla-protein in rheumatic diseases and, 1487

Glucosaminidase, *N*-acetyl- β , renal disease in chronic childhood arthritis and, 1560

Glycine

- in RA, 939, 993
- in SLE, 993

Glycoprotein, IgM antilymphocyte autoantibodies and, in SLE, 1226

Glycosaminoglycans

- bone and cartilage loss in adjuvant arthritis in rats after cyclosporin A and, 247
- catabolic effects of muramyl dipeptide on rabbit chondrocytes and, 1801
- substance P, IL-1, tumor necrosis factor and, 1023
- synthesis of, 235, 1406, 1807

Glycosylation, IgG isotype, RF binding and, 800

Gm allotypes, HLA, ANA and, in scleroderma, 657

Gold

- intramuscular, in JRA, 587
- in RA, 113, 1449

Gold sodium thiomalate, effect of, on HL-60 cells, 29

Gonococcal pericarditis, tamponade in, in SLE, 1438

gp46, gp~200, IgM antilymphocyte autoantibodies in SLE and, 1226

Gram-negative diplococci, in gonococcal pericarditis with tamponade in SLE, 1438

Granules, perinuclear, characterization of antiperinuclear factor antibodies and, 960

Granulocyte-macrophage colony-stimulating factor

- cytokines in RA and, 305
- in Felty's syndrome, 1865

Granulocytes

- cytokines in inflammatory synovitis and, 1776
- in Henoch-Schönlein purpura, 1114
- in hypersensitivity vasculitis, 1108
- inflammation, NSAID and, in RA, 19
- in polyarteritis nodosa, 1088

Granulomatosis

- allergic, criteria for classification of, in Churg-Strauss syndrome, 1094
- Wegener's, 1990 criteria for, 1068, 1074, 1101

Granulomatous processes, in giant cell arteritis, 1122

Grip strength, in RA, second-line drugs and, 1449

Growth factors

- fibroblast, 305, 493
- platelet-derived, 305, 1534
- polypeptide, synovocyte synthesis of, in RA, 493
- transforming, β , 305, 650, 1180

Growth plate cartilage, cartilage proteoglycan-induced arthritis in BALB/c mice and, 1394

Guinea pig studies

- human IgM-RF and, 1340
- Ro (SS-A) antigen, 1815

Gut, mycobacteria, RA and, 431

Gynecologic studies, pregnancy in primary Raynaud's phenomenon, 1249

H

H1 histone

- autoantibodies, in SLE, 1273
- penicillamine-induced LE and, 1582

H₁ mice, spontaneous arthritis in, 1716

H2B, penicillamine-induced LE and, 1582

HAF10 hybridoma, rheumatoid synovial cell-derived monoclonal RF and, 1188

Hand

- in acromegalic arthropathy, 455
- in bullous photosensitivity to naproxen, 903
- diltiazem in calcinosis in CREST syndrome and, 1287
- multicentric reticulohistiocytosis, melanoma, cyclophosphamide and, 1047
- in OA, 57, 455, 1323, 1601
- radiography of, in RA, 316
- subluxing arthropathy, anti-Jo-1 antibody and, in PM/DM, 1640

Haplotypes, major histocompatibility complex, ethnicity and, in SLE, 985

Head, tilt of, atlantoaxial facet joint in RA and, 325

Headache, localized, in giant cell arteritis, 1122

Health status

- in elderly with arthritis, 1205
- in signal measurement strategies as outcome measures in OA, 739
- psychological factors in primary fibromyalgia syndrome and, 1279

Heart, congenital complete block of, 609

Heavy chains, human V_H4 gene RF and, 1347

Helper/inducer cells, CD4+, T cell depletion in SSc and, 511

Hemodialysis

- beta₂-microglobulin amyloid arthropathy of cervico-occipital hinge in, 602
- long-term, pseudotumor of craniocervical junction during, 1567

Hemoglobin, intravenous gamma globulin in systemic JRA and, 1015

Hemoglobinuria, in chronic childhood arthritis, 1569

Hemoptysis, in Wegener's granulomatosis, 1101

- Hemorrhage**
in anterior cruciate ligament transection-induced canine OA, 1406
gastrointestinal, in Henoch-Schönlein purpura, 1114
- Hemostasis**, effect of, on anterior cruciate ligament transection-induced canine OA, 1406
- Henoch-Schönlein purpura**
histopathologic criteria for, 1074
1990 criteria for classification of, 1068, 1114
- Heparin**, anti-DNA antibodies, glomerulonephritis and, in MRL-*lpr/lpr* mice, 1554
- Heparin-agarose**, synovocyte synthesis of fibroblast growth factor and, 493
- Hepatic enzyme abnormalities**, methotrexate in RA and, 1611
- Hepatic insufficiency**, hepatitis, bridging fibrosis, methotrexate and, in RA, 1037
- Hepatitis**
B, 1088, 1871
in RA, 877, 1037
- Hepatocyte-stimulating factor**, IL-6 in cardiac myxoma and, 398
- Hepatotoxicity**, ciamexon in RA and, 733
- Herpesvirus-6**, human, in Sjögren's syndrome, 1749
- Hexosamine**, in articular cartilage in rats after omega-3 fatty acids, 1029
- High performance liquid chromatography**, to study histone H1 autoantibodies in SLE, 1273
- High-energy phosphates**, in neuropsychiatric SLE, 827
- Hip joint**
MRI of, 441
radiographic analysis in RA and, 316
replacement of, with and without cement, 293
total arthroplasty of, in primary OA and chondrodysplasia, 674
triamcinolone hexacetonide in juvenile arthritis and, 821
- Histamine**, T cells in JRA and, 205
- Histidyl-transfer RNA synthetase**, HLA-D, anti-Jo-1 and, in myositis, 1240
- Histology**
arthritogenicity of minor collagens in mice and, 1
in characterization of antiperinuclear factor antigen, 960
renal biopsy, lupus nephritis and, 970
- Histones**
anti-HMG proteins in JRA and, 1378
H1 autoantibodies, in SLE, 1273
human RF cross-idiotypes and, 1710
in juvenile arthritis, 1836
- Histopathology**
criteria, for vasculitis, 1074
of labial salivary gland, in connective tissue diseases, 1682
of spontaneous staphylococcal arthritis and osteitis in mice, 1739
- HL-60 cells**, effects of gold sodium thiomalate and tenidap sodium (CP-66,248-2) on, 29
- HLA**
alleles, in SLE, 1542
anti-Jo-1 and, in myositis, 1240
antigens, 666, 1170, 1574, 1776, 1787
immunoglobulins in SLE and, 978
- HLA (cont'd)**
molecules, infectious agents, immunity, rheumatic diseases and, 457
typing of, immunoglobulin idiotypes in SLE and, 978
- HLA-A**
antigen, in HIV-associated psoriasis, 1574
ethnicity and, in SLE, 987
- HLA-B**
antigen, in HIV-associated psoriasis, 1574
ethnicity in SLE and, 985
- HLA-B8, HLA-D, anti-Jo-1 and**, in myositis, 1240
- HLA-B27**
antigen, Reiter's syndrome after urethrectomy and, 885
in HIV-associated psoriasis, 1574
- HLA-C**
antigen, in HIV-associated psoriasis, 1574
ethnicity and, in SLE, 985
- HLA-D genes**, 1240, 1445
- HLA-DQ**
anti-Jo-1 and, in myositis, 1240
antigen, 666, 1574
- HLA-DR**
alleles, in RA, amino acids and, 939
antigen, 657, 1574, 1787
in SLE, 985, 1216
in SSc, 511, 1534
- HLA-DR1, ANA in scleroderma and**, 657
- HLA-DR2, in SLE**, 985, 1542
- HLA-DR3**
ANA in scleroderma and, 657
anti-Jo-1 in myositis and, 1240
- HLA-DR4**
ANA in scleroderma and, 657
anti-U1-70-kd autoantibody and, in connective tissue disease, 666
in juvenile arthritis, 1787
in RA, 173, 939, 1599, 1600, 1770
- HLA-DR5, ANA in scleroderma and**, 657
- HLA-DR8 ANA in scleroderma and**, 657
- HLA-DRw8, anti-Jo-1 and**, in myositis, 1240
- HLA-DRw52 haplotype, anti-Jo-1 and**, in myositis, 1240
- HLA-DRw53, anti-U1-70-kd autoantibody, HLA-DR4 and**, in connective tissue disease, 666
- HLA-DRβ**
anti-Jo-1 and, in myositis, 1240
1, antibody to, in RA, 1867
- HMG-1, HMG-2, in JRA**, 1378
- Homocysteine**, effect of methotrexate on peripheral blood mononuclear cells and, 954
- Hormones**
estrogen metabolism in (NZB × NZW)_{F1} model of SLE, 107
parathyroid, periarticular bone loss in RA and, 615
sex, exogenous, in RA, 947
- Hospitalization**
in arthritis, economics and, 746
cost-effectiveness of, in RA, 1751
- Human immunodeficiency virus (HIV)**
acute myositis in AIDS and, 298
in psoriasis, psoriatic arthritis, and Reiter's syndrome, 1574

- Human immunodeficiency virus (*cont'd*)**
infection, 758, 1064
rheumatic disease and, 1295
- Human immunodeficiency virus-1 (HIV-1), retroviral antibodies in Sjögren's syndrome and, 774**
- Human immunodeficiency virus-2 (HIV-2), retroviral antibodies in Sjögren's syndrome and, 774**
- Human studies**
antigenicity of recombinant Ro (SS-A) fusion protein, 102
anti-U1-70-kd autoantibody and HLA-DR4 in connective tissue diseases, 666
of articular cartilage, 219, 1029, 1384
cartilage proteoglycan-induced arthritis in BALB/c mice and, 1394
cellular immune response to articular chondrocytes, 1477
collagen arthritis in rats and, 693
collagen degradation in OA cartilage, 1626
collagen lysis by neutrophils in SF and, 1333
congenital complete heart block, 609
effect of cytokines on synoviocytes, 1518
gamma-linolenic acid in RA, 1526
heparin in glomerulonephritis in MRL-*lpr/lpr* mice and, 1554
herpesvirus-6 in Sjögren's syndrome, 1749
IFN- γ , collagenase, IL-1 and, in articular chondrocytes, 1733
IgG isotype and RF binding, 800
IgM-RF, 1340
IL-1, 253, 1807
immunoglobulin idiotypes in SLE, 978
lupus-type inclusions in umbilical cord blood mononuclear cells, 1420
molecular characterization of topo I in scleroderma, 1501
neutrophil collagenase release, 228
NSAID-enhanced PGE₂ secretion by synoviocytes, 1162
proteoglycan-induced arthritis in BALB/c mice, 866
of RF, 187, 1188, 1347, 1710
rheumatologic manifestations of parvovirus B19 infection, 1297
substance P, IL-1, and tumor necrosis factor in rabbits and, 1023
synovium-cartilage junction of normal knee, 1170
tumor necrosis factor and cartilage degradation, 542
- Human T lymphotropic virus-I (HTLV-I)**
acute myositis in AIDS and, 298
retroviral protein in Sjögren's syndrome and, 774
- Humoral response, arthritogenicity of minor collagens in mice and, 1**
- Hyaline cartilage**
articular, in primary OA and chondrodysplasia, 674
cartilage proteoglycan-induced arthritis in BALB/c mice and, 1394
- Hyaluronic acid**
cartilage metabolism in RA and, 790
cartilage proteoglycan and, 241, 1394
in chondrodysplasia, 674
effect of cytokines on, in synoviocytes, 1518
IL-1, glycosaminoglycan synthesis and, 1807
in OA, 219, 674
viscosity of, after myeloperoxidase-derived oxidant exposure, 453
- Hybridomas**
autoantibodies in NZB mice and, 711
cartilage proteoglycan-induced arthritis in BALB/c mice and, 1394
RF and, 800, 1188
- Hydralazine**
circular DNA and, 366
T cells and, in SLE and RA, 1665
- Hydrostatic determinants of microvascular fluid balance, in canine joints, 80**
- Hydroxychloroquine**
in JRA, 587
in RA, 1449, 1611
- Hydroxylase**
estrogen metabolism in (NZB \times NZW)F₁ model of SLE and, 107
synovial membrane nerves in Sprague-Dawley rats and, 859
- Hydroxyproline**
dietary omega-3 fatty acids, rat articular cartilage and, 1029
substance P, IL-1, tumor necrosis factor and, 1023
- Hyperactivity**
B cell, cellular requirements for, in SLE, 1216
monocyte, IL-1, tumor necrosis factor α and, in scleroderma, 893
- Hypercalciuria, in psoriatic arthritis after 1,25-dihydroxyvitamin D₃, 1723**
- Hypereosinophilic syndrome, eosinophilia-myalgia syndrome after L-tryptophan ingestion and, 913, 918, 930**
- Hypergammaglobulinemia**
retroviral antibodies in Sjögren's syndrome and, 774
subclinical renal dysfunction in RA and, 95
- Hyperplasia, synovial, cartilage proteoglycan-induced arthritis in BALB/c mice and, 1394**
- Hypersensitivity vasculitis**
histopathologic criteria for, 1074
1990 criteria for classification of, 1068, 1108
- Hypertension, in cutaneous vasculitis and pheochromocytoma, 1852**
- Hypertrophy**
cartilage, in anterior cruciate ligament transection-induced canine OA, 1406
spontaneous arthritis in mice and, 1716, 1739
- Hypoproliferative peripheral blood mononuclear cells, cyclosporin A in RA and, 1310**
- Hypothyroidism, anti-Th in SSc and, 1822**

I

- Ia antigen, IL-1 release by rat synovial cells and, 261**
- Ibuprofen**
lupus anticoagulant and, in SLE, 1061
in RA, 19, 623
- IdGN2 immunoglobulin idotype, in SLE, 978**
- Idiopathic crescentic glomerulonephritis, myeloperoxidase autoantibodies in, 1264**
- Idiopathic OA, 674, 1601**
- Idiopathic thrombocytopenic purpura, intravenous gamma globulin in systemic JRA and, 1015**
- Idiotypes, monoclonal antibody 6B6.6, on RF, 187, 1347**

Idiotypes

IgG, in RA, 1196
immunoglobulin, in SLE, 978

IdX immunoglobulin idiotype, in SLE, 978

I-E genes, sequence of, from autoimmune NZW mice, 583

IgA

antibodies, collagen, C1q and, in rheumatoid vasculitis, 1646

autoantibodies, anti-topo I, anticentromere autoantibodies and, 724

κ , extramedullary plasmacytoma in Sjögren's syndrome and, 150

RF

methotrexate and, in RA, 1156

monoclonal antibody 6B6.6 idiotope and, 187

in polyarticular JRA, 199

IgD B cells, TLI and, in New Zealand mice, 702

IgE, in eosinophilia-myalgia syndrome after L-tryptophan ingestion, 913, 918, 930

IgG

antibodies, 520, 993, 1196, 1378, 1646, 1836

anticardiolipin antibodies, pregnancy and, in Raynaud's phenomenon, 1249

antiphospholipid antibody, in SLE, fetal death and, 501

autoantibodies, anti-topo I, anticentromere autoantibodies and, 724

effect of methotrexate on peripheral blood mononuclear cells and, 954

effect of TLI on LY-1 B cells in (NZB \times NZW) F_1 mice and, 553

fibronectin in chronic nephritis in rats and, 685

heat-aggregated, collagen lysis by neutrophils in SF and, 1333

human, 1188, 1340

idiotypes of, 187, 978, 1196

intravenous gamma globulin in systemic JRA and, 1015

isotype, 501, 724, 800

monomeric, collagen lysis by neutrophils in SF and, 1333

mycobacteria, RA and, 431

neutrophil collagenase release and, 228

in penicillamine-induced LE, 1582

polyclonal, autoantibody synthesis in SLE and, 1216

RF, binding of, 800

in SLE, 1216, 1233

IgG1, cartilage proteoglycan-induced arthritis in BALB/c mice and, 1394

IgM

antibodies, 520, 1297, 1836

anticardiolipin antibodies, pregnancy and, in Raynaud's phenomenon, 1249

antilymphocyte autoantibodies, in SLE, 1226

anti-topo I, anticentromere autoantibodies and, 724

B cells, TLI and, in New Zealand mice, 702

cartilage proteoglycan-induced arthritis in BALB/c mice and, 1394

effect of methotrexate on peripheral blood mononuclear cells and, 954

monoclonal, protein, cross-reactive idiotypes of human RF and, 1347

penicillamine-induced LE and, 1582

IgM (cont'd)

RF

monoclonal antibody 6B6.6 idiotope on, 187

in RA, 19, 339, 623, 1156, 1188

synthesis of, effect of methotrexate on peripheral blood mononuclear cells and, 954

Immune complexes

IgG and IgA antibodies, collagen, C1q and, in rheumatoid vasculitis, 1646

circulating, intravenous immunoglobulin in thrombocytopenia in SLE and, 1233

effect of fibronectin on chronic nephritis in rats and, 685

Immune cytokines, collagen production by fibroblasts in scleroderma and, 842

Immune response

anti-topoisomerase I, anticentromere autoantibodies and, 724

bone and cartilage loss in adjuvant arthritis in rats after cyclosporin A and, 247

cell-mediated, effect of methotrexate on, 954

cellular, human articular chondrocytes and, 1477

congenital complete heart block and, 609

human IgM-RF and, 1340

molecular characterization of topo I in scleroderma and, 1501

in RA, 810, 993, 1310, 1493

in Sjögren's syndrome, 349, 774

soluble IL-2 receptors in rheumatic disease and, 375, 1145

in SLE, 349, 644, 993

T cells in JRA and, 205

Immunity

depletion of T cells in SSc and, 511

infectious agents, rheumatic diseases and, 457

Immunization, in collagen arthritis in rats, 693

Immunoabsorption, nRNP core protein and, in RA and SLE, 180

Immunoblotting

amyloid from κ light chain subgroup III and, 880

congenital complete heart block and, 609

human V_H4 gene RF and, 1347

immunoglobulin isotype, anti-topo-I, anticentromere autoantibodies and, 724

of Ro (SS-A) antigen in guinea pig, 1815

in Sjögren's syndrome, 349, 774

in SLE, 180, 349, 1273

in study of anti-HMG proteins in JRA, 1378

to study calpains and calpastatin in OA, 728

Immunochemistry, tumor necrosis factor, human cartilage degradation and, 542

Immunodiffusion, SS-A (Ro) polypeptides in SLE and Sjögren's syndrome and, 349

Immunomodulation therapy, ciamexon in RA, 733

Immunofluorescence

cartilage proteoglycan-induced arthritis in BALB/c mice and, 1394

in histologic characterization of antiperinuclear factor, 960

IgM antilymphocyte autoantibodies in SLE studied by, 1226

immunoglobulin isotypes, anti-topo I, anticentromere autoantibodies and, 724

in study of autoantibodies in SSc, 1431, 1822

in *Yersinia*-induced arthritis, 1795

- Immunogenes, SLE sera binding to Z-DNA polynucleotides and, 356
- Immunogenesis, arthritogenicity of minor collagens in mice and, 1
- Immunogenetics
of congenital complete heart block, 609
in juvenile arthritis, 1787
in scleroderma-related ANA, 657
- Immunogenic DNA, in pathogenesis of SLE, 153
- Immunoglobulin V gene expression, autoantibodies and, in New Zealand black mice, 711
- Immunoglobulins
amyloid from κ light chain subgroup III and, 880
cartilage proteoglycan-induced arthritis in BALB/c mice and, 1394
CD5-expressing B cells in RA and, 339
idiotypes of, in SLE, 978
intravenous, in thrombocytopenia in SLE, 1233
maternal, congenital complete heart block and, 609
retroviral antibodies in Sjögren's syndrome and, 774
surface-bound, collagen lysis by neutrophils in SF and, 1333
- Immunohistochemistry
to study platelet-derived growth factor in SSc, 1534
to study metalloproteinase in canine OA, 1466
to study TLI and B cell infiltration in New Zealand mice, 702
synovial membrane nerves in Sprague-Dawley rat and, 859
- Immunohistology, of synovium-cartilage junction of human knee, 1170
- Immunology, OA-related changes in articular cartilage and, 219
- Immunomodulation, of T cell depletion in SSc, 511
- Immunopathology
in amyloid from κ light chain subgroup III, 880
rheumatoid synovial cell-derived monoclonal RF and, 1188
in SLE, 1857
- Immunoperoxidase staining
of synovium-cartilage junction in human knee, 1170
stromelysin, cartilage degradation and, in inflammatory arthritis, 388
- Immunoprecipitation
to study anti-signal recognition particle in PM, 1361
to study anti-Th in SSc, 1822
- Immunoreactivity
stromelysin, cartilage degradation and, in inflammatory arthritis, 388
synovial membrane nerves in Sprague-Dawley rats and, 859
- Immunoregulation, T cells in JRA and, 205
- Immunosuppressive drugs, ciamexon in RA, 733
- Indomethacin
IL-1, tumor necrosis factor α and, in scleroderma, 893
PGE₂ secretion by synoviocytes and, 1162
- Infarction, cerebral, in neuropsychiatric SLE, 827
- Infection
bacterial, in Felty's syndrome, 1865
HIV, *Yersinia* reactive arthritis and, 758
- Infection (cont'd)
human parvovirus B19, rheumatologic manifestations of, 1297
immunity, rheumatic diseases and, 457
intraarticular, *Staphylococcus aureus* in septic arthritis and, 533
nontropical pyomyositis, myalgia and, in AIDS, 1728
prognosis in SLE and, 37
in Reiter's syndrome after urethrectomy, 885
soluble IL-2 receptors and, 375, 1145
Streptococcus pneumoniae, in suprapatellar bursa of knee, 1063
- Inflammation
collagen lysis by neutrophils in SF and, 1333
congenital complete heart block and, 609
foreign body synovitis and, 1753
granulomatous, in Wegener's granulomatosis, 1101
in hypersensitivity vasculitis, 1108
IL-1 and, in methylated bovine serum albumin-induced arthritis in mice and, 253
joint, 693, 1763
metalloproteinase, cartilage proteoglycan depletion and, in chronic arthritis, 241
platelet-derived growth factor in SSc and, 1534
in RA, 19, 623, 733, 761, 768, 790, 1526
soluble IL-2 receptors and, 375, 1145
stromelysin, cartilage degradation and, 388
substance P, arthritis and, 87
in synovitis in lymphadenopathy with dysproteinemia, 578
synovial, rheumatoid nodules and, 761
synovium-cartilage junction of human knee and, 1170
T cells in JRA and, 205
- Inflammatory arthritis
cartilage degradation in, 388, 542
collagen induced, 1716
SF and T cells in, 1596
Yersinia reactive arthritis, HIV infection and, 758
- Inflammatory joint disease, synovial membrane nerves in Sprague-Dawley rats and, 859
- Inflammatory myositis, HLA-D and anti-Jo-1 in, 1240
- Inflammatory synovitis, cytokines in, 1776
- Inhibitors, cytokine, in RA, 305
- Injectable gold, efficacy and toxicity of, in RA, 1449
- Inorganic phosphate, in neuropsychiatric SLE, 827
- Inorganic pyrophosphate, cartilage, glycosaminoglycan synthesis and, 235
- Insulin, synoviocyte synthesis of fibroblast growth factor and, 493
- Insulin-dependent diabetes mellitus, Charcot arthropathy after joint trauma in, 412
- Intercellular adhesion molecule-1, in scleroderma, 1847
- Interferon (IFN)
alpha, acid lability to, in SLE, 563
gamma, 29, 247, 587, 1733, 1776
lupus-type inclusions in umbilical cord blood mononuclear cells and, 1420
- Interleukin-1 (IL-1)
bone and cartilage loss in adjuvant arthritis in rats after cyclosporin A and, 247
glycosaminoglycan synthesis and, 1807
IFN- γ , collagenase and, in articular chondrocytes, 1733

Interleukin-1 (cont'd)

- IL-6 induced by, proteoglycan synthesis in articular cartilage and, 1695
- to induce acute erosive monarticular arthritis in mice, 253
- leucovorin, methotrexate and, in mice, 1745
- in RA, 305, 810
- release of, by rat synovial cells, 261
- in scleroderma, 893
- stromelysin, cartilage degradation and, in inflammatory arthritis, 388
- tumor necrosis factor, 542, 1023
- Interleukin-1 α (IL-1 α)
 - catabolic effects of muramyl dipeptide on rabbit chondrocytes and, 1801
 - in polymyositis, 1007
 - effect of, on synoviocytes, 1518
- Interleukin-1 β (IL-1 β), cytokines in inflammatory synovitis and, 1776
- Interleukin-2 (IL-2)
 - IgG, autoantibody synthesis and, in SLE, 1216
 - in polymyositis, 1007
 - in proteoglycan-induced arthritis in BALB/c mice, 866
 - receptors for, 375, 485, 511, 1007, 1145, 1310, 1371, 1688
 - soluble, 375, 1145, 1371, 1688
- Interleukin-4 (IL-4), in rheumatoid synovitis, 1180
- Interleukin-6 (IL-6)
 - cytokines and, 305, 1776
 - in cardiac myxomas, 398
 - IL-1 and, 1695, 1807
 - in SLE, 644, 1216
- Intermittent compressive force, inhibition of osteoclastic bone resorption by, in mouse fetus, 66
- International Conference on SLE, Second, highlights of, 1857
- Interphalangeal joints
 - in collagen arthritis in rats, 693
 - in hand OA, 57, 1601
 - subluxing arthropathy, anti-Jo-1 antibody and, in PM/DM, 1640
- Interstitial nephritis, bone sclerosis simulating osteonecrosis after renal transplantation and, 1444
- Intervertebral discs
 - in proteoglycan-induced arthritis in BALB/c mice, 866
 - serine proteinase inhibitors of articular cartilage in, 1384
- Intraarticular blood, in anterior cruciate ligament transection-induced canine OA, 1406
- Intraarticular infection, *Staphylococcus aureus* in septic arthritis and, 533
- Intraarticular triamcinolone hexacetonide
 - in childhood arthritis, 821
 - "steroid flare" from injection of, 1284
- Intramuscular gold, in JRA, 587
- Intramuscular methotrexate, pharmacokinetics of, in RA, 91
- Intravenous gamma globulin, in systemic JRA, 1015
- Intravenous immunoglobulin, in thrombocytopenia in SLE, 1233
- Intravenous pulse cyclophosphamide, in myositis and Sjögren's syndrome, 1579
- Iodide kinetics, in normal canine wrists and knees, 73
- Iron, in anterior cruciate ligament transection-induced canine OA, 1406

- Irradiation, cartilage proteoglycan-induced arthritis in BALB/c mice and, 1394
- Isoelectric focusing, to study IgG idiotypes in RA, 1196

J

- Jaw, claudication of, in giant cell arteritis, 1122
- Jo-1, HLA-D, anti-Jo-1 and, in myositis, 1240
- Joint
 - in anterior cruciate ligament transection-induced canine OA, 1406
 - canine, transitional microvascular pressure in, 80
 - in collagen arthritis, 693, 1716
 - collagen lysis by neutrophils in SF and, 1333
 - collagen-proteoglycan interactions in cartilage in, 1512
 - counts of, in psoriatic arthritis after 1,25-dihydroxyvitamin D₃, 1723
 - degeneration of, Charcot arthropathy in diabetic neuropathy and, 412
 - destruction of, synovium-cartilage junction of knee and, 1170
 - diseases of, 199, 412, 493, 693, 859, 1477
 - in foreign body synovitis, 1753
 - hand, in acromegalic arthropathy and OA, 455
 - hip, 441, 821
 - inflammation, 1763
 - interphalangeal, 693, 1601
 - irrigation, in anterior cruciate ligament transection-induced canine OA, 1406
- knee
 - albumin kinetics in, in normal canine, 73
 - in collagen arthritis in rats, 693
 - MRI of, 441
 - T cells and, 485
- lavage of, substance P, IL-1, tumor necrosis factor and, 1023
- metacarpophalangeal, in OA, 57, 674, 1601
- neutrophil collagenase release and, 228
- in OA, 57, 455, 674, 1323, 1626
- peripheral, 674, 1001
- proximal interphalangeal, 57
- in RA
 - atlantoaxial facet, 325
 - cartilage metabolism and, 790
 - counts of, 9, 1447, 1449
 - dietary fatty acid supplements and, 810
 - DMARD and, 477
 - erosions of, 151
 - indices of, folic acid and methotrexate toxicity in, 9, 1447
 - metacarpal, radiographic analysis and, 316
 - methotrexate, auranofin and, 330
 - painful, 330, 477
 - sacroiliac, 1763
 - scores of, NSAID and, 623
 - swelling of, 330, 477
 - T cells and, 299, 485, 768
 - tenderness of, 477
- sacroiliac, lumbosacral pain in brucellosis and, 1052
- space of, 57, 253, 1323

Joint (cont'd)

- stromelysin, cartilage degradation and, in inflammatory arthritis, 388
- substance P, IL-1, and tumor necrosis factor in, 1023
- swelling of, 241, 330, 477, 810
- in synovitis with lymphadenopathy with dysproteinemia, 578
- in synovium-cartilage junction of human knee, 1170
- tenderness of, 19, 477, 790, 810, 1449
- trapeziometacarpal, in classification of OA of the hand, 1601
- trauma to, Charcot arthropathy in diabetic neuropathy and, 412
- triamcinolone hexacetonide in childhood arthritis and, 821
- wrist, 73, 615
- in *Yersinia*-induced arthritis, 1795
- Juvenile arthritis
 - ANA-positive, antihistone antibodies in, 1836
 - HLA antigens in, 1787
 - pauciarticular, C3 activation and anti-lipid A in, 520
 - triamcinolone hexacetonide in, 821
- Juvenile chronic arthritis, MRI of knee and hip in, 441
- Juvenile rheumatoid arthritis
 - anti-HMG proteins in, 1378
 - auranofin in, 466, 587
 - foreign body synovitis and, 1753
 - MRI of articular destruction in, 1426
 - polyarticular, renal disease in, 1560
 - soluble IL-2 receptors in, 375, 1145
 - suppressor cells in, 205
 - systemic, intravenous gamma globulin in, 1015
- Juxtaarticular radiolucencies, in microfocal radiography of hand OA, 57

K

- κ chains
 - human RF cross-idiotypes and, 1710
 - light, 187, 880, 993, 1340, 1347
- Kawasaki disease
 - intravenous gamma globulin in systemic JRA and, 1015
 - childhood, soluble IL-2 receptors in, 1371
- Kellgren/Lawrence scale, in study of hand OA in men, 1323
- Keratan sulfate
 - cartilage and, 790, 1394
 - in early-onset primary OA and chondrodysplasia, 674
 - synovium-cartilage junction of human knee and, 1170
- Keratin, nRNP core protein and, in RA and SLE, 180
- Keratoconjunctivitis sicca, labial salivary gland in connective tissue diseases and, 1682
- Kidney dialysis, low-dose methotrexate and neutropenia in, 1060
- Kinetics, arthritogenicity of minor collagens in mice and, 1
- Km allotypes, HLA, ANA and, in scleroderma, 657
- Knee
 - bone sclerosis in, after renal transplantation, 1444
 - canine, 73, 80, 1406, 1466
 - cartilage, staphylococcal septic arthritis and, 533
 - Charcot arthropathy after joint trauma in diabetic neuropathy and, 412
 - in cutaneous vasculitis with pheochromocytoma, 1852

Knee (cont'd)

- human, synovium-cartilage junction of, 1170
- IL-1 and, in methylated bovine serum albumin-induced arthritis in mice, 253
- injury, estrogen and, in OA in women, 525
- joint, in collagen arthritis in rats, 485, 693
- MRI of, 441, 1426
- OA, 525, 853
- replacement of, with and without cement, 293
- Streptococcus pneumoniae* infection of suprapatellar bursa, 1063
- subluxing arthropathy, anti-Jo-1 antibody and, in PM/DM, 1640
- substance P, IL-1, and tumor necrosis factor in, 1023
- triamcinolone hexacetonide in juvenile arthritis and, 821
- Kupffer cells, fibronectin in chronic nephritis in rats and, 685

L

- L-canavanine, circular DNA and, 366
- L-tryptophan, eosinophilia-myalgia syndrome and ingestion of, 913, 918, 930
- La (SS-B)
 - congenital complete heart block and, 609
 - retroviral antibodies in Sjögren's syndrome and, 774
- Labial salivary gland
 - B cells expressing CD5 in, in Sjögren's syndrome, 453
 - histopathology of, in connective tissue diseases, 1682
- Lacrimal gland, retroviral antibodies in Sjögren's syndrome and, 774
- Lactoferrin, neutrophil collagenase release and, 228
- λ light chains
 - EBNA-1 and, in RA and SLE, 993
 - human IgM-RF and, 1340
- Laminin, soluble IL-2 receptors in SSc and, 375, 1145
- Lamins, autoantibodies to, in RA, 877
- Laparotomy, biliary elimination of low-dose methotrexate and, 898
- Lateral deformity, in hand OA in men, 1323
- LC1 antibody, V_H4 gene RF and, 1347
- Learned helplessness, Rheumatology Attitudes Index in SLE and, 281
- Leg
 - in pediatric Behçet's syndrome with myositis, 418
 - pain, in polymyalgia rheumatica, 403
 - in proteoglycan-induced arthritis in BALB/c mice, 866
 - Yersinia* reactive arthritis, HIV infection and, 758
- Lesion
 - cutaneous, in bullous photosensitivity to naproxen, 903
 - diltiazem in calcinosis in CREST syndrome and, 1287
 - glomerular, anti-DNA antibodies, heparin, glomerulonephritis and, 1554
 - renal biopsy, lupus nephritis and, 970
 - skin, 1074, 1534
 - synoviocyte synthesis of fibroblast growth factor in RA and, 493
 - in Wegener's granulomatosis, histopathologic classification of, 1074
- Leu-4+ cells, platelet-derived growth factor in SSc and, 1534
- Leu-7+ natural killer cells, cyclosporin A in RA and, 1310

- Leu-M3, effects of gold sodium thiomalate and tenidap sodium (CP-66,248-2) on HL-60 cells and, 29
- Leucovorin, IL-1, methotrexate and, in mice, 1745
- Leukocytes
cartilage and, 241, 1384
DNA autosensitivity in Japanese sisters and, 287
lupus-type inclusions in umbilical cord blood mononuclear cells and, 1420
in polyarteritis nodosa, 1088
polymorphonuclear, 578, 1394
- Leukocyturia, renal disease in chronic childhood arthritis and, 1560
- Leukotriene
LTA₄ epoxide hydrolase, leukotriene B₄, methotrexate and, in RA, 1149
LTB₄ in RA
dietary fatty acid supplements and, 810
gamma-linolenic acid and, 1526
methotrexate and, 1149
LTC₄, gamma-linolenic acid in RA and, 1526
- Lewis rats, collagen arthritis in, 693
- Life stress, psychological factors in primary fibromyalgia syndrome and, 1279
- Life-table analysis, skin score in SSc and, 1256
- Ligaments, anterior cruciate
in canine OA, 1406, 1466
Charcot arthropathy in diabetic neuropathy and, 412
- Ligands
cytokines in inflammatory synovitis and, 1776
neutrophil collagenase release and, 228
- Light chains
 κ , 187, 1340, 1347
 λ , human IgM-RF and, 1340
- Link protein, OA-related changes in human articular cartilage and, 219
- Linoleic acid, dietary omega-3 fatty acids, articular cartilage in rats and, 1029
- Linolenic acid, gamma, in RA, 1526
- Lipopolysaccharides
catabolic effects of muramyl dipeptide on rabbit chondrocytes and, 1801
dietary fatty acid supplements in RA and, 810
IL-1 and, 261, 893
- Livedo reticularis, in polyarteritis nodosa, 1088
- Liver
biopsy, hepatitis, fibrosis, methotrexate and, in RA, 1037
enzymes, antirheumatic drugs in RA and, 1611
estrogen metabolism in, in (NZB \times NZW)F₁ model of SLE, 107
Ro (SS-A) antigen in guinea pigs, 1815
- Localized headache, in giant cell arteritis, 1122
- Long-term disability, as outcome measure in AS, 1001
- Longitudinal Study on Aging, health status in elderly with arthritis and, 1205
- Low-affinity IL-2 receptors, soluble, in rheumatoid synovial fluid, 1688
- Low back pain, in brucellosis, 1052
- Low-dose cyclophosphamide, in RA, 113
- Low-dose methotrexate
biliary elimination of, 898
effect of, on peripheral blood mononuclear cells, 954
- Low-dose methotrexate (*cont'd*)
in JRA, 587
neutropenia and, in renal dialysis, 1060
in RA, 9, 91, 113, 330, 1447
- Low molecular weight serine proteinase inhibitors of human articular cartilage, 1384
- Lumbar spine, periarticular bone loss in RA and, 615
- Lumbosacral pain, in brucellosis, 1052
- Lung
biopsy, in pulmonary fibrosis in RA, cyclosporine in, 1594
in Churg-Strauss syndrome, 1094
nifedipine and, in SSc, 1634
subluxing arthropathy, anti-Jo-1 antibody and, in PM/DM, 1640
in Wegener's granulomatosis, histopathologic classification of, 1074
- Lupus. *See also* Systemic lupus erythematosus
ethnicity and major histocompatibility complex markers in, 985
immunoglobulin idiotypes in, 978
murine, I-E genes and, 583
- Lupus erythematosus
penicillamine induced, 1582
subacute cutaneous, during PUVA, 302
- Lupus-inducing drugs, circular DNA and, 366
- Lupus-like disorder, adrenal insufficiency with anticardiolipin antibodies and, 1842
- Lupus nephritis
heparin in, 1554
immunoglobulin idiotypes in, 978
major histocompatibility complex genes in, 1542
renal biopsy in, 970
- Lupus-type inclusions, human, in umbilical cord blood mononuclear cells, 1420
- Ly-1 cells, TLI and, in New Zealand mice, 553, 702, 711
- Lyme disease
MRI of knee in, 441
prevalence of, 299
- Lymph nodes, biopsy of, in synovitis with lymphadenopathy, 578
- Lymphadenopathy, angioimmunoblastic, synovitis in, simulating RA, 578
- Lymphatic drainage, iodide and albumin kinetics in canine wrists and knees and, 73
- Lymphocytes
B. *See* B cells
CD8+, IgG, autoantibody synthesis and, in SLE, 1216
cytokines in inflammatory arthritis and, 1776
effect of methotrexate on peripheral blood mononuclear cells and, 954
IL and, 1007
IL-2 receptors and, 375, 1145, 1688
mononuclear, in spontaneous arthritis, 1716
in proteoglycan-induced arthritis in BALB/c mice, 866
in RA
ciamexon and, 1007
galactosyltransferase-associated protein kinase gene and, 1655
NSAID and, 19, 623
peripheral blood, 1180
proliferation of, cyclosporin A and, 1310

Lymphocytes (cont'd)

- T. See T cells
- tumor necrosis factor, human cartilage degradation and, 542
- Lymphoid infiltration, retroviral antibodies in Sjögren's syndrome and, 774
- Lymphokines
 - bone and cartilage loss in adjuvant arthritis in rats after cyclosporin A and, 247
 - intracellular adhesion molecule on fibroblasts in scleroderma and, 1847
 - soluble IL-2 receptors and, 1145
 - in synovitis, 1180, 1776
- Lymphoma, B cell, *c-myc* proto-oncogene in primary Sjögren's syndrome and, 49
- Lysates
 - IgM antilymphocyte autoantibodies in SLE and, 1226
 - leukocyte, DNA autosensitivity in Japanese sisters and, 287
- Lysis
 - fibrillar collagen, by neutrophils in SF, 1373
 - lysophil collagenase release and, 228
- Lysozymes, serine proteinase inhibitors of articular cartilage and, 1384

M

Macrophages

- dietary fatty acid supplements in RA and, 810
- cytokines in inflammatory synovitis and, 1776
- effects of and tenidap sodium (CP-66,248-2) on HL-60 cells and, 29
- in Felty's syndrome, 1865
- metalloproteinase in canine OA and, 1466
- peritoneal, fibronectin in chronic nephritis in rats and, 685
- RFD7+, platelet-derived growth factor in SSc and, 1534
- synovium-cartilage junction of human knee and, 1170
- Maculopapular rash, in hypersensitivity vasculitis, 1108
- Magnetic resonance imaging (MRI)
 - of articular destruction, in JRA, 1426
 - of knee and hip, 441
 - in neuropsychiatric SLE, 827
 - pseudotumor of craniocervical junction during hemodialysis and, 1567
 - of sacroiliac joint inflammation, 1763
- Major histocompatibility complex
 - cytokines in inflammatory synovitis and, 1776
 - I-E genes from autoimmune NZW mice and, 583
 - in scleroderma, 657, 1847
 - in SLE, 985, 1542
- Malignancy, synovocyte synthesis of fibroblast growth factor in RA and, 493
- Malignant melanoma, multicentric reticulohistiocytosis and cyclophosphamide in, 1047
- Mannose, IgG isotype, RF binding and, 800
- Marketing
 - of ACR, 436, 439
 - of methotrexate in U.S. and Canada, 450
- Mast cells, dermal, in SSc, 1702
- Matrix
 - cartilage
 - calpains, calpastatin and, in OA, 728

Matrix (cont'd)

- catabolism of, serine proteinase inhibitors and, 1384
- collagen-proteoglycan interactions and, 1512
- degradation of, 388, 542
- metalloproteinase, cartilage depletion and, in chronic arthritis, 241
- metalloproteinase and, 241, 1466
- proteoglycan, cartilage inorganic pyrophosphate, glycosaminoglycan synthesis and, 235
- synovium-cartilage junction of human knee and, 1170
- Measles, soluble IL-2 receptors in childhood Kawasaki syndrome and, 1371
- Medical care usage, impact of musculoskeletal diseases and, 750
- Melanoma, malignant, multicentric reticulohistiocytosis, cyclophosphamide and, 1047
- Menhaden fish oil, dietary omega-3 fatty acids in rat articular cartilage and, 1029
- Meniscus, MRI of, 441
- Menopause
 - estrogen and, in knee OA in women, 525
 - exogenous sex hormones in RA and, 947
- Mental status, phosphates in neuropsychiatric SLE and, 827
- Mesangial basement membrane, fibronectin in chronic nephritis in rats and, 685
- Messenger RNA
 - collagen genes in progressive systemic sclerosis and, 1829
 - C-myc* proto-oncogene in primary Sjögren's syndrome and, 49
 - IL-1 release by synovial cells and, 261
 - stromelysin, cartilage degradation and, in inflammatory arthritis, 388
- Metaanalyses, of efficacy and toxicity of second-line drugs in RA, 1449
- Metabolism, in eosinophilia-myalgia syndrome after oral L-tryptophan ingestion, 913, 918, 930
- Metacarpal joints, radiographic analysis in RA and, 316
- Metacarpophalangeal joints, in OA, 57, 674, 1601
- Metalloproteinase, in experimental canine OA, 1466
- Metalloproteinase
 - cartilage proteoglycan depletion and, in chronic arthritis, 241
 - IFN- γ , IL-1 and, in human articular chondrocytes, 1733
- Methionine, effect of methotrexate on peripheral blood mononuclear cells and, 954
- Methotrexate
 - effect of, on peripheral blood mononuclear cells, 954
 - IL-1, leucovorin and, in mice, 1745
 - low-dose, 330, 898, 1060, 1447
 - oral, in JRA, 587
 - pricing of, in U.S. and Canada, 450
 - in RA
 - in combination with other drugs, 113, 1611
 - efficacy and toxicity of, 1449
 - folic acid and, 1447
 - hepatitis, fibrosis and hepatic insufficiency in, 1037
 - leukotriene B₄ and, 1149
 - low dose, 330, 1447
 - pharmacokinetics of intramuscular and subcutaneous injection of, 91

- Methotrexate (cont'd)**
 RF and, 1156
 toxic response to topical fluorouracil in, 303
- Methylated bovine serum albumin**, to induce acute erosive monarticular arthritis in mice, 253
- Methylation**
 c-myc proto-oncogene in primary Sjögren's syndrome and, 49
 T cell DNA, in SLE and RA, 1665
- Methylprednisolone**, in synovitis with lymphadenopathy and dysproteinemia, 578
- Microcytotoxicity assays**, to study IgM antilymphocyte autoantibodies in SLE, 1226
- Microfocal radiography**, in assessment of hand OA, 57
- Micromechanical studies**, of collagen-proteoglycan interactions in cartilage, 1512
- Microproteinuria**, subclinical renal dysfunction in RA and, 95
- Microvascular bed**
 albumin kinetics in canine wrists and knees and, 73
 hydrostatic and oncotic determinants of, in canine joints, 80
- Microvascular blood flow**, hyperemic response in SSc and, 1620
- Minerals**, inhibition of bone resorption in mouse fetus and, 66
- Miscarriage**, in primary Raynaud's phenomenon, 1249
- Mitogens**
 in RA, 810, 1180, 1688
 synovocyte synthesis of fibroblast growth factor and, 493
- Mixed cryoglobulinemia**, RF and, 800, 1188
- Mixed leukocyte infiltrate**, in polyarteritis nodosa, 1088
- Mobility**, effect of osteophytes on varus-valgus instability in OA knee and, 853
- Modified Health Assessment Questionnaire Activities of Daily Living**, learned helplessness in SLE and, 281
- Molecular biology**, of SLE, 1857
- Molecular characterization of topo I**, in scleroderma, 1501
- Molecular mimicry**, infectious agents, immunity, rheumatic diseases and, 457
- Monarticular arthritis**
 erosive, IL-1 and methylated bovine serum albumin-induced arthritis in mice, 253
 metalloproteinase and cartilage proteoglycan depletion in, 241
- Monarticular JRA**, foreign body synovitis and, 1753
- Monensin**, cartilage inorganic pyrophosphate, glycosaminoglycan synthesis and, 235
- Monoclonal antibodies**
 anti-HLA-DR, IgG, autoantibody synthesis and, in SLE, 1216
 autoantibodies in NZB mice and, 711
 cartilage proteoglycan-induced arthritis in BALB/c mice and, 1394
 murine, human V_H4 gene RF and, 1347
 OA-related changes in articular cartilage and, 219
 platelet-derived growth factor in SSc and, 1534
 in RA, 187, 485
 synovium-cartilage junction of human knee and, 1170
 T cells and, 205, 485
- Monoclonal RF**
 binding of, IgG isotype and, 800
 human RF cross-idiotypes and, 1710
 IgM, 1340
 monoclonal antibody 6B6.6 idiotope on, 187
- Monocytes**
 activation of, in PM, 1007
 effects of gold sodium thiomalate and tenidap sodium (CP-66,248-2) on, 29
 immune response toward articular chondrocytes and, 1477
 metalloproteinase in canine OA and, 1466
 in RA, 305, 1526
 tumor necrosis factor and, 542, 893
- Monomeric IgG**
 collagen lysis by neutrophils in SF and, 1333
 human IgM-RF and, 1340
- Mononeuropathy**
 in Churg-Strauss syndrome, 1094
 in polyarteritis nodosa, 1088
- Mononuclear cells**
 blood, human IgM-RF and, 1340
 cartilage proteoglycan-induced arthritis in BALB/c mice and, 1394
 collagen production by fibroblasts in scleroderma and, 842
 gamma-linolenic acid in RA and, 1526
 IL-1 and, in methylated bovine serum albumin-induced arthritis in mice and, 253
 immune response to chondrocytes and, 1477
 infiltrates of, in giant cell arteritis, 1122
 peripheral blood
 cyclosporin A in RA and, 1310
 effect of methotrexate on, 954
 IgG, autoantibody synthesis and, in SLE, 1216
 in RA, 810, 1310
 in SSc, 375, 893, 1145
 in proteoglycan-induced arthritis and spondylitis in BALB/c mice, 866
 in spontaneous arthritis, 1716
 in synovitis in lymphadenopathy with dysproteinemia, 578
 umbilical cord blood, human lupus-type inclusions in, 1420
- Monophosphoryl-lipid A**, antibodies, in juvenile arthritis, 520
- Morbidity**
 learned helplessness in SLE and, 281
 toxicity index for drugs and, 121
- Morning stiffness**
 intravenous gamma globulin in systemic JRA and, 1015
 in RA, 19, 477, 623, 790
- Mortality**
 drug toxicity index and, 121
 eosinophilia-myalgia syndrome, L-tryptophan ingestion and, 913, 918, 930
 health status in elderly with arthritis and, 1205
 in SLE, 37, 281
 soluble IL-2 receptors in SSc and, 375, 1145
- Mouse studies**. *See also* Autoimmune New Zealand white mice; B10.PL(H-2^m) mice; BALB/c mice; DBA mice; H₁ mice; MRL-lpr/lpr mice; Naive BALB/c mice; (New Zealand black × New Zealand white)F₁ mice; Syngeneic mice

Mouse studies (cont'd)

- cartilage proteoglycan-induced arthritis, 1394
- fetal, inhibition of bone resorption in, by mechanical stimulation, 66
- human RF cross-idiotypes and, 1710
- IL-1 in, 253, 1745
- monoclonal antibody 6B6.6 idiotope on RF, 187
- spontaneous arthritis in, 1716, 1739
- MRL-*lpr/lpr* mice, anti-DNA antibodies, glomerulonephritis and heparin in, 1554
- Mucosa, buccal, antiperinuclear factor antigen and, 960
- Multicentric reticulohistiocytosis
 - cyclophosphamide in malignant melanoma and, 1047
 - Sjögren's syndrome and, 1870
- Multifocal myalgia, subacute, nontropical pyomyositis as cause of, in AIDS, 1728
- Multinucleated giant cells, in giant cell arteritis, 1122
- Muramyl dipeptide, catabolic effects of, on rabbit chondrocytes, 1801
- Murine hybridoma MH60.BSF2, IL-6 in CSF in, in SLE, 644
- Murine lupus, I-E genes and, 583
- Murine monoclonal antibodies, human V_H4 gene RF and, 1347
- Muscle
 - biopsy, 418, 579, 913, 918, 930
 - intravenous pulse cyclophosphamide in myositis and Sjögren's syndrome, 1579
 - lesions, in nontropical pyomyositis, subacute multifocal myalgia and AIDS, 1728
 - in pediatric Behçet's syndrome with myositis, 418
 - weakness of, in PM, 1007
- Musculoskeletal disease, impact of, 750
- Musculoskeletal involvement, HIV and, 1295
- Musculoskeletal pain
 - in fibromyalgia and chronic fatigue syndrome, 381
 - noninflammatory diffuse, self-report questionnaire in, 1317
- Myalgia
 - eosinophilia-myalgia syndrome, L-tryptophan ingestion, 913, 918, 930
 - in polyarteritis nodosa, 1088
- Myasthenia gravis, intravenous gamma globulin in systemic JRA and, 1015
- Mycobacteria, RA and, 431
- Mycobacterium avium* complex-induced septic arthritis, osteomyelitis and, in AIDS, 757
- Myeloma, amyloid from κ light chain subgroup III and, 880
- Myelomonocytic cell lines, effects of gold sodium thiomalate and tenidap sodium (CP-66,248-2) on HL-60 cells and, 29
- Myelopathy, atlantoaxial facet joint in RA and, 325
- Myeloperoxidase autoantibodies, in vasculitis, 1264
- Myeloperoxidase-derived oxidants, viscosity of hyaluronic acid after exposure to, 453
- Myositis
 - in AIDS, 298
 - HLA-D and anti-Jo-1 in, 1240
 - intravenous pulse cyclophosphamide in, 1579
 - in pediatric Behçet's syndrome, 418
 - penicillamine-induced, HLA-D genes and, 1445
 - subluxing arthropathy, anti-Jo-1 antibody and, in PM/DM, 1640

Myxoma

- atrial, 1442
- cardiac, IL-6 in, 398

N

- N-acetylprocainamide, circular DNA and, 366
- N-acetyl- β -glucosaminidase, renal disease in chronic childhood arthritis and, 1560
- Naive BALB/c mouse studies, proteoglycan-induced polyarthritis and spondylitis, 866
- Naproxen, bullous sensitivity to, 903
- National Institutes of Health scoring system, for renal biopsy in lupus nephritis, 970
- Native DNA, SLE sera binding to Z-DNA polynucleotides and, 356
- Native type II collagen, arthritogenicity of, in mice, 1
- Natural killer cells, Leu-7+, cyclosporin A in RA and, 1310
- Neck
 - atlantoaxial facet joint in RA and, 325
 - tophaceous mass in, presenting as thyroglossal duct cyst, 910
- Necrosis in RA, 761, 1037
- Necrotizing arteritis, in giant cell arteritis, 1122
- Necrotizing vasculitis, systemic, myeloperoxidase autoantibodies in, 1264
- Neisseria gonorrhoeae*, gonococcal pericarditis with tamponade in SLE and, 1438
- Neoplasia
 - azathioprine-induced, 605
 - c-myc proto-oncogene in primary Sjögren's syndrome and, 49
 - in cutaneous vasculitis with pheochromocytoma, 1852
- Nephritis
 - chronic, effect of fibronectin on, in rats, 685
 - estrogen metabolism in (NZB \times NZW)F₁ model of SLE and, 107
 - interstitial, bone sclerosis after renal transplantation and, 1444
 - lupus, 970, 978, 1542, 1554
- Nephritogenic antibodies, immunoglobulin idiotypes in SLE and, 978
- Nerve
 - substance P, arthritis and, 87
 - in synovial membrane in Sprague-Dawley rat, 859
- Neurologic diseases, in SLE, 644
- Neurologic involvement
 - Charcot arthropathy after joint trauma in diabetic neuropathy, 412
 - in neuropsychiatric SLE, 827
- Neuromuscular involvement, in eosinophilia-myalgia syndrome after oral L-tryptophan, 913, 918, 930
- Neuropathy
 - diabetic, Charcot arthropathy after joint trauma in, 412
 - in polyarteritis nodosa, 1088
- Neuropeptides, synovial membrane nerves in Sprague-Dawley rat and, 859
- Neurosensory deficits, Charcot arthropathy after joint trauma in diabetic neuropathy and, 412

- Neurotransmitters, substance P, IL-1, tumor necrosis factor and, 1023
- Neutral metalloproteinase, cartilage proteoglycan depletion and, in chronic arthritis, 241
- Neutropenia
granulocyte-macrophage colony-stimulating factor treatment of, in Felty's syndrome, 1865
low-dose methotrexate in renal dialysis and, 1060
- Neutrophils
collagenase release and, 228
IL-1 and, in methylated bovine serum albumin-induced arthritis in mice, 253
lysis of fibrillar collagen by, in SF, 1333
in RA, 810, 1149
sulfonamides in Wegener's granulomatosis and, 1590
- New Zealand mice
I-E genes from autoimmune NZW mice and, 583
TLI in, 553, 702
- Newborn infants
human IgM-RF in, 1340
lupus-type inclusions in umbilical cord blood mononuclear cells and, 1420
- Nifedipine, lung and, in SSc, 1634
- Nociception, synovial membrane nerves in Sprague-Dawley rat and, 859
- Nociceptors, polymodal, substance P, arthritis and, 87
- Nodular RA, autoantibodies to lamins in, 877
- Nodules
chest, in Wegener's granulomatosis, 1101
human parvovirus B19 arthropathy and, 1297
in RA, 325, 1442
rheumatoid, 761
- Nonadrenergic nerves, in synovial membrane in Sprague-Dawley rat, 859
- Nongonococcal bacterial arthritis, spontaneous, osteitis and, in mice, 1739
- Noninflammatory diffuse musculoskeletal pain, self-report questionnaire in, 1317
- Nonsteroidal antiinflammatory drugs (NSAID)
bullous photosensitivity to, 903
effects of gold sodium thiomalate and tenidap sodium (CP-66,248-2) on HL-60 cells and, 29
guidelines for approving for over-the-counter use of, 1056
in JRA, 587
lupus anticoagulant and, 1061
multicentric reticulohistiocytosis, melanoma, cyclophosphamide and, 1047
PGE₂ secretion by synoviocytes and, 1162
in RA, 19, 113, 452, 623
renal disease in chronic childhood arthritis and, 1560
- Nontropical pyomyositis, as cause of subacute, multifocal myalgia in AIDS, 1728
- Noradrenaline, synovial membrane nerves in Sprague-Dawley rat and, 859
- Northern blotting
stromelysin, cartilage degradation and, in inflammatory arthritis, 388
in synoviocyte synthesis of fibroblast growth factor in RA, 493
- Nuclear antigens
autoantibodies in scleroderma and, 1431
- Nuclear antigens (*cont'd*)
Epstein-Barr nuclear antigen-1, in RA and SLE, 993
- Nuclear magnetic resonance spectroscopy, in neuropsychiatric SLE, 827
- Nuclear RNP (nRNP), core protein, antibodies and, in RA and SLE, 180
- Nucleolar antigens, autoantibodies in scleroderma and, 1431
- Nucleolar 701 RNA protein particle, anti-Th in SSc and, 1822
- Nucleoprotein, antiperinuclear factor antigen and, 960
- Nucleosomes, lupus-inducing drugs, circular DNA and, 366
- Nucleotides
I-E genes in NZW autoimmune mice and, 583
major histocompatibility genes in SLE and, 1542
oligo-, 939, 1188, 1787
rheumatoid synovial cell-derived monoclonal RF and, 1188
- Nulliparity, oral contraceptives, pregnancy and, in RA, 782
- Nurses' Health Study, exogenous sex hormones in RA and, 947
- Nursing homes, health status in elderly with arthritis and, 1205
- O
- Obituaries
Munthe, Eimar, 1278
Short, Charles L., 756
- Odontoid process, craniocervical pseudotumor during hemodialysis and, 1567
- Oleic acid, in RA, 810
- Oligoadenylate synthetase, human lupus-type inclusions in umbilical cord blood mononuclear cells and, 1420
- Oligonucleotides
HLA antigens in juvenile arthritis and, 1787
HLA-DR alleles, amino acids and, in RA, 939
rheumatoid synovial cell-derived monoclonal RF and, 1188
- Olive oil supplements, in RA, 810
- Omega-3 fatty acids, dietary
in RA, 810
in rats, 1029
- Oncotic determinants of microvascular fluid balance, in canine joints, 80
- 1,25-dihydroxyvitamin D₃
periarticular bone loss in RA and, 615
in psoriatic arthritis, 1723
- Oral contraceptives in RA
exogenous sex hormones and, 947
pregnancy and, 782, 1770
risk factors associated with, 173, 1462, 1770
- Oral L-tryptophan, eosinophilia-myalgia syndrome and, 913, 918, 930
- Oral methotrexate
in JRA, 587
leukotriene B₄ and, in RA, 1149
- Oral ulcers, in Wegener's granulomatosis, 1101
- Orosomucoid, cartilage metabolism in RA and, 790
- Osteitis, in spontaneous staphylococcal arthritis in mice, 1739

Osteoarthritis (OA)

- calpains and calpastatin in, 728
- canine, after anterior cruciate ligament transection, 1406
- cartilage in, 219, 1029, 1626
- Charcot arthropathy after joint trauma in diabetic neuropathy and, 412
- early-onset primary, chondrodysplasia and, 674
- experimental, metalloproteinase in, 1466
- hand, 57, 1323, 1601
- hip, 441
- IL-1-induced IL-6 and proteoglycan synthesis in, 1695
- immune response toward articular chondrocytes and, 1477
- knee, 441, 525, 853
- MRI in, 441
- RA in oral contraceptive users and, 173, 1770
- radiographic abnormalities in, 455
- signal measurement strategies as outcome measure in, 739
- substance P and, 87
- synovocyte synthesis of fibroblast growth factor and, 493
- Osteoarticular involvement, lumbosacral pain in brucellosis and, 1042
- Osteochondritis dissecans, triamcinolone hexacetonide in juvenile arthritis and, 821
- Osteoclastic bone resorption, inhibition of, by mechanical stimulation, 66
- Osteomyelitis
 - foreign body synovitis and, 1753
 - Mycobacterium avium* septic arthritis and, in AIDS, 757
- Osteonecrosis
 - bone sclerosis after renal transplantation and, 1444
 - collagen degradation in human OA cartilage and, 1626
 - MRI of hip in, 441
- Osteophytes
 - in OA, 57, 853, 1323
 - synovium-cartilage junction of human knee and, 1170
- Osteoporosis, pelvic insufficiency fractures in, 426
- Outcome measures
 - in clinical trials, 140
 - intravenous gamma globulin in systemic JRA and, 1015
 - signal measurement strategies in OA, 739
- Outcome studies, pregnancy in primary Raynaud's phenomenon, 1249
- Outpatient treatment of RA, cost-effectiveness of, 1751
- Ovalbumin
 - effect of fibronectin on chronic nephritis in rats and, 685
 - metalloproteinase, cartilage proteoglycan depletion and, in chronic arthritis, 241
- Over-the-counter drugs, FDA guidelines for approval of NSAID for, 1056
- Overlap syndromes
 - anti-signal recognition particle in PM and, 1361
 - polyangiitis, myeloperoxidase autoantibodies in, 1264
 - scleroderma and, 1431, 1822
- Oxidants, myeloperoxidase-derived, viscosity of hyaluronic acid and, 453
- Oxygenation, arachidonic acid, gamma-linolenic acid in RA and, 1526

P

- p17 gag, p24 gag, retroviral antibodies in Sjögren's syndrome and, 774

Pain

- abdominal, 403, 758, 1114
- in brucellosis, 1052
- in fibromyalgia, 160, 1279
- leg, 403, 418
- musculoskeletal, 381, 1317
- in polymyalgia rheumatica, 403
- psychological factors in primary fibromyalgia syndrome and, 1279
- in RA, 19, 325, 330, 477
- signal measurement strategies as outcome measures in OA and, 739
- testicular, in polyarteritis nodosa, 1088
- Palpable purpura
 - in Henoch-Schönlein purpura, 1114
 - in hypersensitivity vasculitis, 1108
- Pancreas, anti-signal recognition particle in PM and, 1361
- Panner's disease, 911
- Pannus
 - craniocervical pseudotumor during hemodialysis and, 1567
 - IL-1 and, in methylated bovine serum albumin-induced arthritis in mice, 253
 - in spontaneous rheumatoid-like arthritis in mice, 1716
 - synovium-cartilage junction of human knee and, 1170
- Papanicolaou staining, histologic characterization of antiperinuclear factor and, 960
- Paranasal sinus abnormality, in Churg-Strauss syndrome, 1094
- Paraprotein, monoclonal antibody 6B6.6 idiotope on RF and, 187
- Parathyroid hormone, periarticular bone loss in RA and, 615
- Parotid gland, salivary gland echography in Sjögren's syndrome and, 505
- Parvovirus B19 infection, human, rheumatologic manifestations of, 1297
- Pathogenesis
 - in AIDS-associated arthritis, 268, 1728
 - anti-type II collagen in RA and, 1493
 - cytokines in inflammatory synovitis and, 1776
 - depletion of T cells in SSc and, 511
 - of IL-1, 253, 1807
 - in SLE, immunogenic DNA in, 153
 - substance P, IL-1, tumor necrosis factor and, 1023
 - synovium-cartilage junction in human knee and, 1170
- Pathogenetics, immune response toward articular chondrocytes and, 1477
- Pathology, articular, arthritogenicity of minor collagens in mice and, 1
- Pathophysiology
 - cytokines in RA and, 305
 - in eosinophilia-myalgia syndrome after oral L-tryptophan ingestion, 913, 918, 930
- Patient assessment
 - ACR 1990 criteria for classification of fibromyalgia and, 160
 - global, 330, 477
- Pauciarticular JRA
 - anti-HMG proteins in, 1378
 - IgA-RF in polyarticular JRA and, 199

- Pauciarticular juvenile arthritis**
 antihistone antibodies in ANA-positive juvenile arthritis and, 1836
 C3 activation and anti-lipid A in, 520
 HLA antigens in, 1787
- Pediatric Behçet's syndrome, myositis in, 418**
- Pediatric Rheumatology Collaborative Study Group, auranofin in JRA, 466, 587**
- Pelvic insufficiency fractures, 426**
- Pelvis**
 in early-onset primary OA and chondrodysplasia, 674
 insufficiency fractures of, 426
- Penicillamine**
 in JRA, 587
 LE induced by, 1582
 myositis induced by, HLA-D genes and, 1445
 in RA, gold and, 113, 574, 1449
- Penis, cutaneous vasculitis in pheochromocytoma and, 1852**
- Pepsin**
 agglutinators, IgG idiotype in RA and, 1196
 arthritogenicity of minor cartilage collagens in mice and, 1
- Peptidergic nerve, in synovial membrane in Sprague-Dawley rats, 859**
- Peptides**
 in RA, 993, 1493
 in SLE, 993
 synovial membrane nerves in Sprague-Dawley rat and, 859
 synoviocyte synthesis of fibroblast growth factor and, 493
- Peptidoglycan, catabolic effects of muramyl dipeptides on rabbit chondrocytes and, 1801**
- Periarticular bone**
 loss of, in RA, 615
 marrow, MRI in sacroiliac joint inflammation and, 1763
- Periarticular calcifications, triamcinolone hexacetonide in juvenile arthritis and, 821**
- Periarticular tissue, in foreign body synovitis, 1753**
- Pericarditis, gonococcal, with tamponade, in SLE, 1438**
- Perinuclear granules, characterization of antiperinuclear factor antigen and, 960**
- Periodontoid soft tissue, craniocervical pseudotumors during hemodialysis and, 1567**
- Periosteal tissue, synovium-cartilage junction of human knee and, 1170**
- Periosteum**
 inhibition of bone resorption in mouse fetus and, 66
 synovium-cartilage junction of human knee and, 1170
- Peripheral arthritis, HIV-associated psoriasis and, 1574**
- Peripheral blood**
 cartilage metabolism in RA and, 790
 collagen lysis by neutrophils in SF and, 1333
 lymphocytes, 485, 1180, 1596
 monocytes, IL-1, tumor necrosis factor α and, in scleroderma, 893
 mononuclear cells
 c-myc proto-oncogene in, in Sjögren's syndrome, 49
 effect of methotrexate on, 954
 IgG, autoantibody synthesis and, in SLE, 1216
 immune response to chondrocytes and, 1477
 in RA, 810, 1310
 in SSc, 375, 893, 1145
- Peripheral blood (cont'd)**
 in RA, 733, 790, 810, 1180, 1310, 1596
 T cells and, 205, 1477
- Peripheral eosinophilia, in eosinophilia-myalgia syndrome after oral L-tryptophan, 913, 918, 930**
- Peripheral joints**
 in early-onset primary OA and chondrodysplasia, 674
 outcome measures in AS and, 1001
- Peripheral lymphocytes, soluble IL-2 receptors in SSc and, 375, 1145**
- Peripheral nerves, substance P, arthritis and, 87**
- Peripheral polyarthritis, in synovitis in lymphadenopathy with dysproteinemia, 578**
- Peripheral synovitis, in polymyalgia rheumatica, 403**
- Peripheral T cells, depletion of, in SSc, 511**
- Peritoneal macrophages, fibronectin in chronic nephritis in rats and, 685**
- Perivascular infiltrates, platelet-derived growth factor in SSc and, 1534**
- Pharmacokinetics, of methotrexate in RA, 91, 898**
- Phenotypes**
 platelet-derived growth factor in SSc and, 1534
 in RA, 485, 939, 1310
 TLI, B cell infiltration and, in New Zealand mice, 702
- Phorbol ester, IL-1 release by rat synovial cells and, 261**
- Phorbol myristate acetate**
 collagen lysis by neutrophils in SF and, 1333
 IL-4, transforming growth factor β and, in RA synovitis, 1180
- Phosphatase, inhibition of bone resorption in mouse fetus and, 66**
- Phospholipase A₂, leukotriene B₄, methotrexate and, in RA, 1149**
- Phospholipid, IgG, fetal death in SLE and, 501**
- Photosensitivity, bullous, to naproxen, 903**
- Physical cartilage, in early-onset primary OA and chondrodysplasia, 674**
- Physician assessment**
 global, 330, 466, 477, 587, 1560, 1723
 in RA, 9, 19, 623, 1447
- Phytohemagglutinin**
 IL-4, transforming growth factor β and, in RA synovitis, 1180
 soluble IL-2 receptors in SSc and, 375, 1145
 T cells in JRA and, 205
- Pigmented villonodular synovitis, MRI of knee and hip in, 441**
- Piroxicam, PGE₂ secretion by synoviocytes and, 1162**
- Placenta, congenital complete heart block and, 609**
- Plasma**
 cells, in AIDS-associated arthritis, 268
 clearance of fibronectin in chronic nephritis in rats and, 685
 substance P, arthritis and, 87
 transitional microvascular pressure in canine joints and, 80
- Plasmacytoma, extramedullary, in primary Sjögren's syndrome, 150**
- Plasmacytosis, proliferative polyclonal, IL-6 in cardiac myxoma and, 398**
- Plasmids, lupus-inducing drugs, circular DNA and, 366**

- Plasmin, metalloprotease in canine OA and, 1466
- Plasminogen activator
in canine OA, 1466
therapy in Raynaud's phenomenon and scleroderma, 274
tumor necrosis factor, human cartilage degradation and, 542
- Platelet-derived growth factor
cytokines in RA and, 305
type B receptors for, in skin in SSc, 1534
- Platelets
intravenous gamma globulin in systemic JRA and, 1015
intravenous immunoglobulin in thrombocytopenia in SLE and, 1233
leukotriene B₄, methotrexate and, in RA, 1149
neutrophil collagenase release and, 228
- Pleurisy, penicillamine-induced LE and, 1582
- Pokeweed mitogen
dietary fatty acid supplements in RA and, 810
effect of methotrexate on peripheral blood mononuclear cells and, 954
- Polarized microscopy
to detect amyloidosis in Behçet's syndrome, 1586
in study of "steroid flare" after intraarticular triamcinolone hexacetonide injection, 1284
- Poly(dA-dC)-poly(dG-dT), poly(dG-m^sdC)-poly(dG-m^sdC), SLE serum binding to Z-DNA polynucleotide and, 356
- Polyamines
effect of methotrexate on peripheral blood mononuclear cells and, 954
Z-DNA polynucleotides, SLE serum binding to, 356
- Polyarteritis nodosa
antineutrophil cytoplasmic antibodies in, 1870
histopathologic criteria for, 1074
myeloperoxidase autoantibodies in, 1264
1990 criteria for classification of, 1088
- Polyarthralgia, human parvovirus B19 infection and, 1297
- Polyarthritis
arthritogenicity of minor collagens in mice and, 1
in BALB/c mice, 866, 1394
chronic, symmetric, AIDS-associated, 268
exogenous sex hormones in RA and, 947
in HIV-associated psoriasis, 1574
human parvovirus B19 infection and, 1297
penicillamine-induced LE and, 1582
peripheral, angioimmunoblastic lymphadenopathy, synovitis and, 578
- Polyarticular JRA
anti-HMG proteins in, 1378
auranofin in, 466, 587
HLA antigens in, 1787
IgA-RF in, 199
renal disease in, 1560
- Polycation-induced arthritis, metalloproteinase and cartilage proteoglycan depletion in, 241
- Polychondritis, relapsing, anti-type II collagen in RA and, 1493
- Polyclonal B cells, activation of, immunoglobulin idiotypes in SLE and, 978
- Polyclonal IgG, autoantibody synthesis in SLE and, 1216
- Polyclonal plasmacytosis, proliferative, IL-6 in cardiac myxoma and, 398
- Polyclonal RF
binding of, IgG isotype and, 800
IgM and, 1340
monoclonal antibody 6B6.6 idiotype on, 187
- Polyclonal topo I, molecular characterization of, in scleroderma, 1501
- Polyclonality, rheumatoid synovial cell-derived monoclonal RF and, 1188
- Poly-D-lysine, metalloproteinase, cartilage proteoglycan depletion and, in chronic arthritis, 241
- Polymodal nociceptors, substance P, arthritis and, 87
- Polymorphisms
galactosyltransferase-associated protein kinase gene in RA and, 1655
restriction fragment length, HLA-D, anti-Jo-1 and, in myositis, 1240
- Polymorphonuclear leukocytes
cartilage proteoglycan-induced arthritis in BALB/c mice and, 1394
in synovitis in lymphadenopathy with dysproteinemia, 578
- Polymorphonuclear lymphocytes, in spontaneous rheumatoid-like arthritis in mice, 1716
- Polymyalgia rheumatica, atypical presentation of, 403
- Polymyositis
anti-signal recognition particle in, 1361
HLA-D and anti-Jo-1 in, 1240
IL-1 α , IL-2, and soluble IL-2 receptors in, 1007
low-dose methotrexate and neutropenia in, in dialysis, 1060
penicillamine-induced, in RA, HLA-D genes and, 1445
soluble IL-2 receptors in, 375, 1145
- Polyneuropathy
in Churg-Strauss syndrome, 1094
in polyarteritis nodosa, 1088
- Polynucleotides, Z-DNA, SLE binding to, 356
- Polypeptides
70-kd, autoantibodies, HLA-DR4 and, in connective tissue disease, 666
SS-A (Ro), immune response of, in SLE and Sjögren's syndrome, 349
synovial membrane nerves in Sprague-Dawley rat and, 859
synoviocyte synthesis of fibroblast growth factor and, 493
- Porphyria, bullous photosensitivity to naproxen and, 903
- Postmenopausal women, exogenous sex hormones in RA and, 947
- Post-occlusive hyperemic response, in SSc, 1620
- Postpartum studies, amyloid from κ light chain subgroup III, 880
- Prednisone
Gla-protein and, in rheumatic diseases, 1487
in JRA, 587, 1015
in neuropsychiatric SLE, 827
T cell depletion in SSc and, 511
- Pregnancy
amyloid from κ light chain subgroup III in, 880
congenital complete heart block in infants and, 609
oral contraceptives and, in RA, 782, 1770

- Pregnancy (cont'd)**
in primary Raynaud's phenomenon, 1249
in SLE, 501, 605
- Premature infants, in mothers with primary Raynaud's phenomenon, 1249**
- Primary care settings, fibromyalgia and chronic fatigue syndrome in, 381**
- Primary fibromyalgia**
ACR 1990 criteria for classification of fibromyalgia and, 160
psychological factors in, 1279
- Primary OA, 674, 1601**
- Primary Raynaud's phenomenon**
autoantibodies in SSc and, 1431, 1822
post-occlusive hyperemic response in SSc and, 1620
pregnancy in, 1249
- Primary Sjögren's syndrome**
B cells expressing CD5 in labial salivary glands in, 453
C-myc proto-oncogene in, 49
extramedullary plasmacytoma in, 150
retroviral antibodies in, 774
SS-A (Ro) polypeptides in, 349
- Probable RA**
1987 revised criteria for, 1042
oral contraceptives and, 1462
- Procainamide**
circular DNA and, 366
T cells in SLE and RA and, 1665
- Procollagen, fibroblasts in scleroderma and, 842, 1847**
- Prognosis, factors affecting, in SLE, 37**
- Proliferative polyclonal plasmacytosis, IL-6 in cardiac myxoma and, 398**
- Prostacyclin analog vasodilator, post-occlusive hyperemic response in SSc and, 1620**
- Prostaglandin E, effect of cytokines on, in synoviocytes, 1518**
- Prostaglandin E₁, IL-1, glycosaminoglycan synthesis and, 1807**
- Prostaglandin E₂**
gamma-linolenic acid in RA and, 1526
IL-1 and, 1023
metalloproteinase, cartilage proteoglycan depletion and, in chronic arthritis, 241
secretion of, by synoviocytes, NSAID and, 1162
- Protease**
chondrocyte, staphylococcal septic arthritis and, 533
collagen lysis by neutrophils in SF and, 1333
29-kd serine, myeloperoxidase autoantibodies in vasculitis and, 1264
- Protein**
A, 180, 834
amyloid JUN, 880
C4A, major histocompatibility complex genes in SLE and, 1542
cartilage and, 219, 388, 1384, 1394
chromosomal, anti-HMG proteins in JRA and, 1378
core, in early-onset primary OA and chondrodysplasia, 674
effect of fibronectin on chronic nephritis in rats and, 685
fibroblasts in scleroderma and, 842, 1847
Gla, glucocorticoid drugs and, in rheumatic diseases, 1487
- Protein (cont'd)**
human monoclonal IgM, cross-reactive idiotypes, RF and, 1347
lupus-inducing drugs, circular DNA and, 366
molecular characterization of topo I in scleroderma and, 1501
para-, monoclonal antibody 6B6.6 idiotope of RF and, 187
POM, 880
in RA, 180, 431, 1655
recombinant Ro (SS-A) fusion, antigenicity of, 102
serine proteinase inhibitors of articular cartilage and, 1384
in Sjögren's syndrome, 349, 774
in SLE, 180, 349, 1273, 1542
stromelysin, cartilage degradation and, in inflammatory arthritis, 388
synthesis of, staphylococcal septic arthritis and, 533
U1-70-kd, autoantibodies, HLA-DR4 and, in connective tissue disease, 666
- Proteinase**
cartilage and, 542, 1384
cysteine, calpains, calpastatin and, in OA, 728
- Proteinuria**
effect of fibronectin on chronic nephritis in rats and, 685
renal function and, in rheumatic diseases, 95, 1560
- Proteoglycan-induced polyarthritis and spondylitis, in naive BALB/c mice, 866**
- Proteoglycans**
cartilage, 219, 241, 398, 674, 1023, 1029, 1394, 1512, 1695
catabolic effects of muramyl dipeptide on rabbit chondrocytes and, 1801
in OA, 219, 674, 728
in staphylococcal septic arthritis, 533
stromelysin, cartilage degradation and, in inflammatory arthritis, 388
- Proto-oncogenes, C-myc, in primary Sjögren's syndrome, 49**
- Proton magnetic resonance imaging, in neuropsychiatric SLE, 827**
- Proximal femoral epiphysis, triamcinolone hexacetonide in juvenile arthritis and, 821**
- Proximal interphalangeal joint, in OA of the hand, 57, 1601**
- Pseudogout, staphylococcal septic arthritis and, 1442**
- Pseudopodagra, 607**
- "Pseudoporphyria," bullous sensitivity to naproxen and, 903**
- Pseudotumor, in craniocervical junction, during hemodialysis, 1567**
- Psoriasis and psoriatic arthritis, HIV in, 1574**
- Psoriatic arthritis, 1,25-dihydroxyvitamin D₃ in, 1723**
- Psychological factors, in primary fibromyalgia syndrome, 1279**
- Psychosis, in neuropsychiatric SLE, 827**
- Psychosocial Adjustment to Illness Scale, learned helplessness in SLE and, 281**
- Pulmonary fibrosis**
anti-signal recognition particle in PM and, 1361
cyclosporine for, in RA, 1594
- Pulmonary infiltrates, in Churg-Strauss syndrome, 1094**
- Pulmonary involvement, in SSc, 511, 1634, 1822**
- Pulse cyclophosphamide, intravenous, in myositis and Sjögren's syndrome, 1579**

- Purpura**
cutaneous vasculitis in pheochromocytoma and, 1852
Henoch-Schönlein, 1990 criteria for, 1068, 1074, 1114
Purulent pericarditis, gonococcal pericarditis with tamponade in SLE and, 1438
Putrescine, SLE sera binding to Z-DNA polynucleotides and, 356
Pyomyositis, nontropical, as cause of subacute multifocal myalgia in AIDS, 1728
Pyrimidine
effect of methotrexate of peripheral blood mononuclear cells and, 954
SLE sera binding to Z-DNA polynucleotides and, 356
Pyrophosphate, inorganic, cartilage, glycosaminoglycan synthesis and, 235

Q

- Q albumin**, IL-6 in CSF in SLE and, 644
Quality of life, measurement of, in RA, 591
Questionnaires
clinical status, formal education and, in SLE, 407
in fibromyalgia and chronic fatigue syndrome, 381
Modified Health Assessment, Activities of Daily Living, 281
as outcome measures in RA, 591
Psychological Adjustment to Illness Scale, 281
Rheumatology Attitudes Index, 281
self-report, in RA and diffuse musculoskeletal pain, 1317
Stanford Health Assessment, 1001
visual analog pain scale, 281

R

- Rabbit studies**
catabolic effects of muramyl dipeptide on chondrocytes, 1801
human IgM-RF and, 1340
IgG idiotypes in RA, 1196
metalloproteinase and cartilage proteoglycan depletion in chronic arthritis, 241
septic arthritis, 533
substance P, IL-1, and tumor necrosis factor, 1023
Yersinia-induced arthritis, 1795
Racial factors
arthritis information service user benefits and, 212
HLA-D, anti-Jo-1 and, in myositis, 1240
in SLE, 37, 407
Radiography
in acromegalic arthropathy, 455
ACR 1990 criteria for classification of fibromyalgia and, 160
cervical spine, of atlantoaxial facet joint in RA, 325
chest, 1101, 1594
in chondrodysplasia, 674
in classification of Churg-Strauss syndrome, 1094
diltiazem in calcinosis in CREST syndrome and, 1287
of labial salivary gland in connective tissue diseases, 1682
MRI of sacroiliac joint inflammation compared to, 1763
in OA, 57, 455, 525, 674, 1323, 1601
of pelvic insufficiency fractures, 426

- Radiography (cont'd)**
in RA, 316
in synovitis in lymphadenopathy and dysproteinemia, 578
after triamcinolone hexacetonide in childhood arthritis, 821
Radioimmunoassay
cartilage metabolism in RA and, 790
substance P, arthritis and, 87
Radioimmunoprecipitation assay, in analysis of antinuclear and antinucleolar autoantibodies in scleroderma, 1431
Rash
maculopapular, in hypersensitivity vasculitis, 1108
penicillamine-induced LE and, 1582
in RA, 623, 733
Rat studies. *See also* DA rats; Lewis rats; Sprague-Dawley rats
articular cartilage and dietary omega-3 fatty acids, 1029
bone and cartilage loss in adjuvant arthritis in, after cyclosporin A, 247
collagen (type II) arthritis, 451, 693
effect of fibronectin on chronic nephritis, 685
histone H1 autoantibodies in SLE, 1273
IL-1 release by synovial cells, 261
mycobacteria, RA and, 431
stromelysin and cartilage degradation in inflammatory arthritis, 388
Raynaud's phenomenon
anti-signal recognition particle in PM and, 1361
autoantibodies in scleroderma and, 1431
diltiazem in calcinosis in CREST syndrome and, 1287
primary, 1249, 1620
recombinant tissue plasminogen activator therapy in, 274
Reactive arthritis, *Yersinia*, HIV infection and, 758
Reactive hyperemia, in SSc, 1620
Recall antigens, soluble, cyclosporin A in RA and, 1310
Recombinant DNA, anti-RNP antibodies in rheumatic diseases and, 834
Recombinant human cytokines, effects of, on synoviocytes, 1518
Recombinant human IFN
gamma, collagenase, IL-1 and, in articular chondrocytes, 1733
human lupus-type inclusions in umbilical cord blood mononuclear cells and, 1420
Recombinant IL-1
collagenase, IFN-gamma and, in articular chondrocytes, 1733
human, β , 253, 1023, 1162, 1518
Recombinant IL-6, IL-2-induced, proteoglycan synthesis and, in articular cartilage, 1695
Recombinant plasmids, lupus-inducing drugs, circular DNA and, 366
Recombinant Ro (SS-A) fusion protein, antigenicity of, 102
Recombinant tissue plasminogen activator therapy, in scleroderma and Raynaud's phenomenon, 274
Recombinant tumor necrosis factor
human, 542, 1023, 1518
NSAID-enhanced PGE₂ secretion by synoviocytes and, 1162
Rectal biopsy, in amyloidosis in Behçet's syndrome, 1586
Rehabilitation, vocational, outcome measures in AS and, 1001

- Reiter's syndrome
HIV in, 1574
substance P and, 87
after urethrectomy, 885
- Relapsing polychondritis, anti-type-II collagen in RA and, 1493
- Renal biopsy, in lupus nephritis, 970
- Renal damage, heparin for glomerulonephritis in MRL-*lpr/lpr* mice and, 1554
- Renal disease
in chronic childhood arthritis, 1560
creatinine clearance, glomerular filtration rate and, in SLE, 277
- Renal dysfunction, subclinical, in RA, 95
- Renal involvement
anti-DNA antibodies, glomerulonephritis, heparin and, in MRL-*lpr/lpr* mice, 1554
fibronectin in chronic nephritis in rats, 685
myeloperoxidase autoantibodies in vasculitis and, 1264
skin score and, in SSc, 1256
- Renal transplantation, bone-end sclerosis simulating osteonecrosis after, 1444
- Renal tubular function, in chronic childhood arthritis, 1560
- Renal vascular lesions, in histopathologic classification of vasculitis, 1074
- Restriction fragment length polymorphism
HLA-D, anti-Jo-1 and, in myositis, 1240
T cell antigen receptor γ gene, in scleroderma, 569
- Reticulohistiocytosis, multicentric
cyclophosphamide in malignant melanoma and, 1047
Sjögren's syndrome and, 1870
- Reticulum, endoplasmic, antiperinuclear factor antigen and, 960
- Retroviral proteins, in primary Sjögren's syndrome, 774
- RFD7+ macrophages, platelet-derived growth factor in SSc and, 1534
- Rheumatic diseases
ACR 1990 criteria for classification of fibromyalgia and, 160
ACR slide competition and collection, 1442
anti-RNP antibodies in, 834
economics of, 746
formal education and, 407
glucocorticoid drugs and Gla-protein in, 1487
HIV in, 1295
human parvovirus B19 infection and, 1297
infectious agents, immunity and, 457
inflammatory, synovium-cartilage junction of human knee and, 1170
soluble IL-2 receptors in, 375, 1145
- Rheumatoid arthritis (RA)
amino acids and HLA-DR alleles in, 939
antibodies and nRNP core protein in, 180
anti-HLA-DR β 1 in, 1867
anti-human herpesvirus-6 in Sjögren's syndrome and, 1749
antiperinuclear factor in, 759
antiperinuclear factor antigen in, 960
anti-type II collagen in, 1493
aspirin in, 1611
autoantibodies to lamins in, 877
B cells in, 339
- Rheumatoid arthritis (*cont'd*)
bone loss in, 615
cartilage metabolism and inflammation in, 790
CD5-expressing B cells in, 339
chronic synovitis in, 768
ciamexon in, 733
classification of OA of the hand and, 1601
clinical trials in, 140
collagen lysis by neutrophils in SF and, 1333
corneal furrow in, 1442
cost-effectiveness of treatment of, 1751
craniocervical pseudotumor during hemodialysis and, 1567
cyclosporin A in, 1310, 1594
cytokines in, 305, 1776
dietary fatty acid in, 810, 1029
DMARD in, 113, 451, 477, 810
EBNA-1 in, 993
economics of, 736
exogenous sex hormones in, 947
fibroblast growth factor and synovocyte synthesis in, 493
fibrosis and hepatitis in, 1037
fish oil supplements in, 810, 1416
fluorouracil in, toxic response to, 303
folic acid and methotrexate in, 9, 1447
galactosyltransferase-associated protein kinase gene in, 1655
gamma-linolenic acid in, 1526
glycine in, 993
hepatic enzymes in, 1611
hepatitis and hepatic insufficiency in, 1037
HIV in, 1064
HLA and ANA in scleroderma and, 657
HLA-DR alleles and amino acids in, 939
HLA-DR4 in, 1599, 1600
human parvovirus B19 arthropathy and, 1297
hydroxychloroquine in, 1611
IgG in, 800, 1196
IgM-RF in, 1340
IL-2 receptors in, 1688
IL-4 and transforming growth factor β in synovitis in, 1180
IL-6 in, 305, 398, 1695
immune response in, 993, 1477
inflammation in, 19, 623, 790
joints in, 151, 299
lamin autoantibodies in, 877
leukotriene B $_4$ in, 1149
lymphocytes in, 339
methotrexate in, 9, 91, 303, 898, 954, 1037, 1149, 1156, 1447, 1611, 1745
monoclonal antibody 6B6.6 idiotope on RF in, 187
MRI of knee and hip in, 441
mycobacteria and, 431
neutrophils in, 228, 1149
1987 revised criteria for, 1042
nodular, 877
nodules in, 761, 1442
nRNP core protein and antibodies in, 180
NSAID in, 19, 623
olive oil supplements in, 810
oral contraceptives and, 173, 782, 1462

Rheumatoid arthritis (*cont'd*)

- penicillamine and sulfoxidation status in, 574
 - penicillamine-induced PM/DM in, HLA-D genes and, 1445
 - periarticular bone loss in, 615
 - pregnancy in, 1770
 - psychological factors in, 1279
 - pulmonary fibrosis treated with cyclosporine in, 1594
 - radiographic analysis in, 316
 - renal dysfunction in, 95
 - RF in, 187, 1156, 1599, 1600
 - rheumatoid synovial cell-derived monoclonal RF in, 1188
 - rheumatoid synovial inflammatory reaction in, 761
 - second-line drugs in, 1449
 - self-report questionnaire in, 1317
 - seronegative, 960
 - seropositive, 187, 1064
 - sex hormones in, 947
 - soluble IL-2 receptors in, 375, 1145
 - substance P and, 87
 - sulfoxidation and penicillamine in, 574
 - synoviocyte synthesis of fibroblast growth factor in, 493
 - synovitis in, 578, 768
 - synovium-cartilage junction in, 1170
 - T cells in, 299, 485, 1665
 - toxic response to topical fluorouracil in, methotrexate and, 303
 - vasculitis in, 1646
 - vitamin E and dietary fish oil in, 1416
- ## Rheumatoid factor (RF)
- amyloid from κ light chain subgroup III and, 880
 - binding of, IgG isotype and, 800
 - in human parvovirus B19 arthropathy, 1297
 - human, 1347, 1710
 - IgA, in polyarticular JRA, 199
 - IgM, 339, 954, 1340
 - monoclonal antibody 6B6.6 idiotope on, 187
 - monoclonal, 1188, 1340
 - in RA, 623, 1156, 1599, 1600
 - rheumatoid synovial cell-derived monoclonal, 1188
 - in spontaneous rheumatoid-like arthritis in mice, 1716
 - in synovitis in lymphadenopathy with dysproteinemia, 578
 - Yersinia*-induced arthritis and, 1795
- ## Rheumatoid-like arthritis, spontaneous, in mice, 1716
- ## Rheumatoid nodules, in RA, 761
- ## Rheumatoid synovial cells, monoclonal RF derived from, 1188
- ## Rheumatoid synovial fibroblasts, cytokines in inflammatory synovitis and, 1776
- ## Rheumatoid synovitis
- chronic, T cells in, 768, 1437 (correction)
 - cytokines in, 305
 - IL-4 and transforming growth factor β in, 1180
- ## Rheumatoid vasculitis, IgG and IgA antibodies, collagen, and C1q in, 1646
- ## Rheumatology and rheumatologists
- in management of congenital complete heart block, 609
 - marketing the ACR, 436, 439
 - 1990 criteria for classification of vasculitis, 1065, 1068, 1074, 1088, 1094, 1101, 1108, 1114, 1122, 1129, 1135
- ## Ribonucleic acid (RNA)
- anti-Th in SSC and, 1822

Ribonucleic acid (*cont'd*)

- autoantibodies in NZB mice and, 711
 - galactosyltransferase-associated protein kinase gene in RA and, 1655
 - HLA-D, anti-Jo-1 and, in myositis, 1240
 - messenger, 49, 261, 388, 1829
 - Ro (SS-A) antigen in guinea pig and, 1815
 - SS-A (Ro) polypeptides and, in SLE and Sjögren's syndrome, 349
 - synthesis of, staphylococcal septic arthritis and, 533
 - transfer, anti-signal recognition particle in PM and, 1361
- ## Ribonucleoprotein (RNP)
- antiperinuclear factor antigen and, 960
 - anti-Th in SSC and, 1431, 1822
 - anti-U1-70kd autoantibody, HLA-DR4 and, in connective tissue disease, 666
 - nuclear, core protein, antibodies and, in RA and SLE, 180
- ## Risk factors, of RA in women on oral contraceptives, 173
- ## Ro antibody, in labial salivary gland in connective tissue diseases, 1682
- ## Ro (SS-A)
- antigen, 609, 1815
 - fusion protein, recombinant, antigenicity of, 102
 - retroviral antibodies in Sjögren's syndrome and, 774
- ## Rotational tilt of head, atlantoaxial facet joint in RA and, 325

S

- ## S-adenosylmethionine, effect of methotrexate on peripheral blood mononuclear cells and, 954
- ## Sacroiliac joint inflammation, MRI in, 1763
- ## Safranin O, dietary omega-3 fatty acids in rat articular cartilage and, 1029
- ## Salicylates, methotrexate and, in RA, 1611
- ## Salivary gland
- labial, in connective tissue diseases, 1682
 - in Sjögren's syndrome, 150, 453, 505, 774
- ## *Salmonella*-induced arthritis, *Yersinia*-induced arthritis and, 1795
- ## Scalp tenderness, in giant cell arteritis, 1122
- ## Scintigraphy, in evaluation of lumbosacral pain in brucellosis, 1052
- ## Scl-70, molecular characterization of, in scleroderma, 1501
- ## Sclerodactyly
- autoantibodies in scleroderma and, 1431
 - diltiazem in calcinosis in CREST syndrome and, 1287
- ## Scleroderma
- adhesion molecule-1 on fibroblasts in, 1847
 - antinuclear and antinucleolar autoantibodies in, 1431
 - collagen genes in, 1829
 - dermal mast cells in, 1702
 - diffuse, autoantibodies in, 1431
 - epidemiology of, 1062
 - fibroblasts in, 650, 842
 - immunoglobulin isotypes, anti-topo I, and anticentromere autoantibodies in, 724
 - IL-1 and tumor necrosis factor α in, 893
 - immunogenetics of ANA related to, 657
 - low-dose methotrexate and neutropenia in, dialysis in, 1060
 - molecular characterization of topo I in, 1501

Scleroderma (cont'd)

platelet-derived growth factor type B receptors in, 1534
recombinant tissue plasminogen activator therapy in, 274
subluxing arthropathy and anti-Jo-1 antibody in PM/DM and, 1640

T cells and restriction fragment length polymorphism in, 569

Sclerosis

of atlantoaxial facet joint in RA, 325
bone, osteonecrosis and, after renal transplantation, 1444
cutaneous, skin score in SSc and, 1256
recombinant tissue plasminogen activator therapy in, in SSc, 274

in SSc, 1256, 1829

subchondral, in hand OA, 57, 1323

Second International Conference on SLE, 1857

Second-line drugs, efficacy and toxicity of, in RA, 1449

Sedentary work, outcome measures in AS and, 1001

Seizures, in neuropsychiatric SLE, 827

Self-assessment, inflammation, NSAID and, in RA, 19

Self-evaluation, folic acid, methotrexate toxicity and, in RA, 9, 1447

Self-report questionnaires, in RA and noninflammatory diffuse musculoskeletal pain, 1317

Septic arthritis

foreign body synovitis and, 1753

Mycobacterium avium, osteomyelitis and, in AIDS, 757

Staphylococcus aureus, 533, 1442

Serine

protease, 29-kd, myeloperoxidase autoantibodies in vasculitis and, 1264

proteinase inhibitor, of cartilage, 1384

Seronegative RA, antiperinuclear factor antigen in, 960

Seropositive RA

AIDS and, 1064

atlantoaxial facet joint in, 325

cyclosporin A in, 1310

methotrexate, hepatitis, fibrosis, and hepatic insufficiency in, 1037

monoclonal antibody 6B6.6 idiotope on RF in, 187

subclinical renal dysfunction in, 95

Serum albumin, IL-6 in CSF in SLE and, 644

Serum antibodies, retroviral proteins and, in Sjögren's syndrome, 774

Serum glutamic oxaloacetic transaminase, serum glutamic pyruvic transaminase values, methotrexate and, in RA, 1611

7-hydroxy metabolite of methotrexate, biliary elimination of, 89

70-kd polypeptide, autoantibodies, HLA-DR4 and, in connective tissue disease, 666

Sex hormones, exogenous, in RA, 947

Shoulder

atlantoaxial facet joint in RA and, 325

canine, transitional microvascular pressure in, 80

pain in, in polymyalgia rheumatica, 403

in subluxing arthropathy with anti-Jo-1 antibody in PM/DM, 1640

Sialadenitis, labial salivary gland in connective tissue diseases and, 1682

Sick leave, extended, as outcome measure in AS, 1001

Signal measurement strategies, as outcome measurements in OA, 739

Signal recognition particle, antibody to, in PM, 1361

Single-dose methotrexate, leukotriene B₄ and, in RA, 1149

Sinuses, in Churg-Strauss syndrome, 1094

6B6.6 cross-reactive idiotypes, human VH4 gene RF and, 1347

Sjögren's syndrome

anti-human herpesvirus-6 in, 1749

extramedullary plasmacytoma in, 150

immune response to SS-A (Ro) polypeptides in, 349

intravenous pulse cyclophosphamide in, 1579

multicentric reticulohistiocytosis and, 1870

primary, 49, 150, 774

retroviral antibodies in, 774

salivary gland in, 505, 1682

Skin

biopsy, 418, 578, 1534

bullous photosensitivity to naproxen and, 903

in eosinophilia-myalgia syndrome after oral L-tryptophan ingestion, 913, 918, 930

lesions, 1074, 1534

multicentric reticulohistiocytosis, melanoma, cyclophosphamide and, 1047

in SSc, 511, 650, 842, 1256, 1534, 1620, 1702, 1829

in spontaneous staphylococcal arthritis and osteitis in mice, 1739

Sleep, disturbance of, in primary fibromyalgia syndrome, 1279

Slow-acting antirheumatic drugs (SAARD), renal disease in chronic childhood arthritis and, 1560

Small arterioles, in Henoch-Schönlein purpura, 1114

Small bowel, anti-Th in SSc and, 1822

Small full-term infants, in primary Raynaud's phenomenon, 1249

Small nuclear RNP (snRNP), anti-RNP antibodies in rheumatic diseases and, 834

Smoking

estrogen and, in knee OA in women, 525

lung, nifedipine and, in SSc, 1634

Socioeconomic factors, impact of musculoskeletal conditions and, 750

Sodium azide, collagen lysis by neutrophils in SF and, 1333

Sodium chloride, synoviocyte synthesis of fibroblast growth factor and, 493

Sodium salicylate, PGE₂ secretion by synoviocytes and, 1162

Soft tissue

diltiazem in calcinosis in CREST syndrome and, 1287

periodontoid, craniocervical pseudotumor during hemodialysis and, 1567

rheumatism, risk of RA in oral contraceptive users and, 173, 1770

swelling of, in synovitis with lymphadenopathy, 578

tophaceous neck mass presenting as thyroglossal duct cyst, 910

Solid-phase wheat germ agglutinin, to study IgM antilymphocyte autoantibodies in SLE, 1226

Soluble IL-2 receptors

in childhood Kawasaki syndrome, 1371

in polymyositis, 1007

- Soluble IL-2 receptors (cont'd)**
in rheumatoid synovial fluid, 1688
in SSc, 375, 1145
- Soluble recall antigens, cyclosporin A in RA and, 1310**
- Southern blotting**
effect of TLI on Ly-1 B cells in (NZB \times NZW) F_1 mice and, 553
to study HLA-D and anti-Jo-1 in myositis, 1240
- Special Treatment Center for Juvenile Arthritis, Cincinnati, 587**
- Spectroscopy, phosphorus-31 nuclear magnetic resonance, in neuropsychiatric SLE, 827**
- Spermidine**
effect of methotrexate on peripheral blood mononuclear cells and, 954
SLE sera binding to Z-DNA polynucleotides and, 356
- Spermine, SLE sera binding to Z-DNA polynucleotides and, 356**
- Spine**
in acromegalic arthropathy, 455
cervical, 325, 1567
in chondrodysplasia, 674
in OA, 455, 674
lumbar, periarticular bone loss in RA and, 615
- Spleen**
cells, effect of TLI on Ly-1 B cells in (NZB \times NZW) F_1 mice and, 553
in Churg-Strauss syndrome, histopathologic classification of, 1074
- Spondylarthropathy**
classification of OA of the hand and, 1601
HIV-associated psoriasis and, 1574
- Spondylitis, proteoglycan-induced, in BALB/c mice, 866, 1394**
- Spontaneous staphylococcal arthritis, osteitis and, in mice, 1739**
- Sprague-Dawley rats, dietary omega-3 fatty acids in, 1029**
- SS-A antibody, subacute cutaneous LE during PUVA and, 302**
- SS-A (Ro) polypeptides, immune responses of, in SLE and Sjögren's syndrome, 349**
- Staphylococcus aureus**
Cowan I, human IgM-RF and, 1340
septic arthritis, 533, 1442
in spontaneous nongonococcal bacterial arthritis, 1739
- Starling forces, albumin kinetics and, in normal canine wrists and knees, 73**
- Statistics**
in clinical trials, 140
in cost-effectiveness study of treatment of RA, 1751
in developing classification criteria for rheumatic disease, 1137
drug toxicity index and, 121
outcome measures in AS and, 1001
- Stearic acid, gamma-linolenic acid in RA and, 1526**
- Steroid drugs**
cyclosporine and, in pulmonary fibrosis in RA, 1594
Gla-protein and, in rheumatic diseases, 1487
intravenous gamma globulin in systemic JRA and, 1015
"Steroid flare," from intraarticular triamcinolone hexacetonide injection, 1284
- Stiffness**
collagen-proteoglycan interactions in cartilage and, 1512
in OA, 739, 1601
- Stillborn infants, in primary Raynaud's phenomenon, 1249**
- Stromal fibroblasts, platelet-derived growth factor type B receptors in SSc and, 1534**
- Stromelysin, cartilage degradation in inflammatory arthritis and, 388**
- Subacute cutaneous LE, during PUVA therapy, 302**
- Subacute multifocal myalgia, caused by nontropical pyomyositis in AIDS, 1728**
- Subaxial subluxation, atlantoaxial facet joint in RA and, 325**
- Subchondral bone**
IL-1 and, in methylated bovine serum albumin-induced arthritis in mice, 253
in MRI of sacroiliac joint inflammation, 1763
- Subchondral sclerosis, in hand OA, 57, 1323**
- Subclavian arteries, in Takayasu arteritis, 1129**
- Subcutaneous calcinosis, in subluxing arthropathy with anti-Jo-1 antibody in PM/DM, 1640**
- Subcutaneous cholesterol crystal deposition, in index finger, 1752**
- Subcutaneous methotrexate injections, pharmacokinetics of, in RA, 91**
- Subcutaneous tissue, abdominal fat aspiration in diagnosis of amyloidosis and, 301**
- Subluxation, atlantoaxial, 325, 1567**
- Subluxing arthropathy, anti-Jo-1 antibody and, in PM/DM, 1640**
- Submandibular gland, salivary gland and, 150, 505**
- Substance P**
arthritis and, 87
IL-1, tumor necrosis factor and, 1023
synovial membrane nerves in Sprague-Dawley rat and, 859
- Sugar phosphates, in neuropsychiatric SLE, 827**
- Sulfasalazine**
in type II collagen-induced arthritis in rats, 451
in RA, 113, 1449
- Sulfate**
cartilage inorganic pyrophosphate, glycosaminoglycan synthesis and, 235
catabolic effects of muramyl dipeptide on rabbit chondrocytes and, 1801
chondroitin, in early-onset primary OA and chondrodysplasia, 674
keratan, 674, 790, 1394
- Sulfonamide, in Wegener's granulomatosis, 1590**
- Sulfoxidation, penicillamine in RA and, 574**
- Superoxides, neutrophil collagenase release and, 228**
- Suppressor cells, in JRA, 205**
- Suprapatellar bursa, knee, Streptococcus pneumoniae infection in, 1063**
- Surface-bound immunoglobulins, collagen lysis by neutrophils in SF and, 1333**
- Surgery**
in canine OA, 1406, 1466
IL-6 in cardiac myxoma and, 398
multicentric reticulohistiocytosis, melanoma, cyclophosphamide and, 1047
Reiter's syndrome after urethrectomy, 885

Surgery (cont'd)

in subluxing arthropathy with anti-Jo-1 antibody in PM/DM, 1640

Surgical biopsy, in synovitis in lymphadenopathy with dysproteinemia, 578

Survival

prognosis in SLE and, 37

renal biopsy, lupus nephritis and, 970

in SSc, 1256, 1822

Swelling

bone and cartilage loss in adjuvant arthritis in rats after cyclosporin A and, 247

in collagen arthritis in rats, 693

finger, anti-Th in SSc and, 1822

joint, in RA, 330, 477, 810

in OA of the hand, 1601

in pediatric Behçet's syndrome with myositis, 418

soft tissue, in synovitis in lymphadenopathy, 578

in spontaneous staphylococcus arthritis, 1739

Symmetric polyarthritis, AIDS-associated, 268

Synergism

effects of cytokines on synoviocytes and, 1518

tumor necrosis factor, human cartilage degradation and, 542

Syngeneic mice, proteoglycan-induced polyarthritis and spondylitis in, 866

Synovectomy, MRI in JRA and, 1426

Synovial biopsy

in AIDS-associated arthritis, 268

in anterior cruciate ligament transection-induced canine OA, 1406

in synovitis with lymphadenopathy with dysproteinemia, 578

in *Yersinia*-induced arthritis, 1795

Synovial cells

IL-1 and, 261, 1023, 1807

rheumatoid, monoclonal RF derived from, 1188

in spontaneous rheumatoid-like arthritis in mice, 1716

Synovial fibroblasts, cytokines and, 305, 1518, 1776

Synovial fluid

antiperinuclear factor in, 960

in foreign body synovitis, 1753

IL-1-induced IL-6, proteoglycan synthesis and, in articular cartilage, 1695

immune response toward articular chondrocytes and, 1477

in inflammatory arthritis, 1596

lysis of fibrillar collagen by neutrophils in, 1333

monoclonal antibody 6B6.6 idiotope of RF and, 187

OA, calpains and calpastatin in, 728

RA, IL-4 and transforming growth factor β in synovitis in, 1180

soluble IL-2 receptors and, 375, 1145, 1688

substance P, arthritis and, 87

in synovitis in lymphadenopathy with dysproteinemia, 578

transitional microvascular pressure in canine joints and, 80

Synovial hyperplasia, cartilage proteoglycan-induced arthritis in BALB/c mice and, 1394

Synovial inflammation, rheumatoid, rheumatoid nodules and, 761

Synovial iron deposition, effect of hemostasis on anterior cruciate ligament transection-induced canine OA and, 1406

Synovial lining

in AIDS-associated arthritis, 268

metalloprotease in canine OA and, 1466

metalloproteinase, cartilage proteoglycan depletion and, in chronic arthritis, 241

Synovial lymphocytes, T cell receptors in RA and, 485

Synovial membrane

IL-4, transforming growth factor β and, in RA synovitis, 1180

metalloprotease in canine OA and, 1466

nonadrenergic and peptidergic nerves in, in Sprague-Dawley rats, 859

Yersinia-induced arthritis in, 1795

Synovial plasma, iodide and albumin kinetics in, in canine wrists and knees, 73

Synovial tissue

immune response toward articular chondrocytes and, 1477

in RA, 493, 1196

in spontaneous staphylococcal arthritis and osteitis in mice, 1739

Synoviocytes

AIDS-associated arthritis and, 268

fibroblast growth factor and, 493

human, NSAID-enhanced PGE₂ secretion by, 1162

Synovitis

in AIDS-associated arthritis, 268

in canine OA after anterior cruciate ligament transection, 1406

cartilage proteoglycan-induced arthritis in BALB/c mice and, 1394

chronic rheumatoid, T cells in, 768

cricoarytenoid, in AS, 604

inflammatory, cytokines in, 1776

after intraarticular triamcinolone hexacetonide injection, 1284

peripheral, in polymyalgia rheumatica, 403

pigmented villonodular, MRI of knee in, 441

in RA, 305, 578, 768, 1180

Synovium

in canine OA, 1406, 1466

cytokines in inflammatory synovitis and, 1776

in foreign body synovitis, 1753

MRI of knee and, 441

in RA, 768, 1196

in spontaneous rheumatoid-like arthritis in mice, 1716

stromelysin, cartilage degradation and, in inflammatory arthritis, 388

T cells in chronic rheumatoid synovitis and, 768

Synovium-cartilage junction, in human knee, 1170

Systemic amyloidosis, in Behçet's syndrome, 1586

Systemic arteritis, Henoch-Schönlein purpura and, 1114

Systemic inflammation, cartilage metabolism in RA and, 790

Systemic JRA

IgA-RF in polyarticular JRA and, 199

intravenous gamma globulin in, 1015

Systemic lupus erythematosus (SLE)

α -IFN in, 563

antibodies and nRNP core protein in, 180

Systemic lupus erythematosus (*cont'd*)

- antiperinuclear factor antigen in, 960
 - antiphospholipid antibody and fetal death in, 501
 - anti-RNP antibodies in, 834
 - anti-U1-70-kd autoantibody and HLA-DR4 in, 666
 - autoantibodies in, 1273, 1857
 - C3 and anti-lipid A in pauciarticular juvenile arthritis and, 520
 - C3b receptors in, 888
 - CNS in, 827
 - creatinine clearance and glomerular filtration rate in, 277
 - CSF in, IL-6 in, 644
 - disease exacerbation and anti-dsDNA antibodies in, 634
 - DNA in, 153
 - drug-induced, 1857
 - EBNA-1 in, 993
 - estrogen metabolism in (NZB \times NZW) F_1 model of, 107
 - ethnicity and major histocompatibility complex markers in, 985
 - factor B activation in, 1598
 - fetal death and IgG antiphospholipid antibody in, 501
 - formal education and clinical status questionnaire in, 407
 - glomerular filtration rate and creatinine clearance in, 277
 - glomerulonephritis in, 1554
 - glycine in, 993
 - gonococcal pericarditis with tamponade in, 1438
 - heparin for glomerulonephritis in, 1554
 - high-energy phosphates in CNS in, 827
 - histone H1 autoantibodies in, 1273
 - HLA-DR4 and anti-U1-60-kd autoantibody in, 666
 - IgG in, 501, 800, 1216
 - IgM antilymphocyte autoantibodies in, 1226
 - immune response in, 349, 993
 - immunogenic DNA in, 153
 - immunoglobulins in, 978, 1233
 - lupus anticoagulant and ibuprofen in, 1061
 - major histocompatibility complex in, 985, 1542
 - nRNP core protein and antibodies in, 180
 - phosphorus-31 nuclear magnetic resonance spectroscopy in, 827
 - pregnancy in, 605, 1857
 - prognosis in, 37
 - renal biopsy and nephritis in, 970
 - rheumatoid vasculitis and, 1646
 - Rheumatology Attitudes Index and learned helplessness in, 281
 - Second International Conference on, 1857
 - sera binding to Z-DNA polynucleotides, 356
 - soluble IL-2 receptors in, 375, 1145
 - T cells in, 1665
 - tamponade in gonococcal pericarditis in, 1438
 - thrombocytopenia in, 1233
- Systemic necrotizing vasculitis, myeloperoxidase autoantibodies in, 1264
- Systemic sclerosis (SSc)
- antiperinuclear factor antigen in, 960
 - collagen genes in, 1829
 - dermal mast cells in, 1702
 - epidemiology of, 1062
 - fibronectin genes in, 1868
 - lung and nifedipine in, 1634

Systemic sclerosis (*cont'd*)

- platelet-derived growth factor type B receptors in, 1534
 - post-occlusive hyperemic response in, 1620
 - recombinant tissue plasminogen activator therapy in, 274
 - skin score in, 1256
 - soluble IL-2 receptors in, 375, 1145
 - T cell depletion in, 511
- Systemic vasculitis, Churg-Strauss syndrome and, 1094
- Systemic vasospasm, pregnancy in primary Raynaud's phenomenon and, 1249
- Systolic blood pressure, in Takayasu arteritis, 1129

T

T cells

- bone and cartilage loss in adjuvant arthritis in rats after cyclosporin A and, 247
 - collagen arthritis in rats and, 693
 - cytokines in inflammatory synovitis and, 1776
 - depletion of, in SSc, 511
 - immune response toward human articular chondrocytes and, 1477
 - in JRA, 205
 - peripheral blood, in inflammatory arthritis, 1596
 - in RA, 299, 623, 768, 1180, 1665, 1688, 1864
 - receptors for, 457, 485, 569, 1542
 - in SLE, 1226, 1665, 1864
 - soluble IL-2 receptors in rheumatic diseases and, 375, 1145
 - in spontaneous rheumatoid-like arthritis in mice, 1716
 - in SSc, 1534, 1847
- Takayasu arteritis
- aorta in, 1074
 - histopathologic criteria for, 1074
 - 1990 criteria for classification of, 1068, 1129
- Tamponade, gonococcal pericarditis with, in SLE, 1438
- Tartrate, inhibition of bone resorption in mouse fetus and, 66
- ^{99m}Tc Technetium, creatinine clearance, glomerular filtration rate and, in SLE, 277
- Telangiectasias
- autoantibodies in scleroderma and, 1431
 - diltiazem in calcinosis in CREST syndrome and, 1287
- Temporal arteritis
- histopathologic criteria for, 1074
 - 1990 criteria for classification of, 1068, 1122
- Temporal artery, in giant cell arteritis, 1122
- Tender points
- ACR 1990 criteria for classification of fibromyalgia and, 160
 - in fibromyalgia and chronic fatigue syndrome, 381
- Tenderness
- ACR 1990 criteria for classification of fibromyalgia and, 160
 - in giant cell arteritis, 1122
 - joint, 477, 790, 810, 1449
 - testicular, in polyarteritis nodosa, 1088
- Tendons
- in foreign body synovitis, 1753
 - in spontaneous rheumatoid-like arthritis in mice, 1716

- Tenidap sodium (CP-66,248-2), effect of, on HL-60 cells, 29
- Testicular pain or tenderness, in polyarteritis nodosa, 1088
- Thigh, cutaneous vasculitis in pheochromocytoma and, 1852
- Thoracic spine, in early-onset primary OA and chondrodysplasia, 674
- Thrombocytopenia, in SLE, 37, 1233
- Thrombocytopenia purpura, idiopathic, intravenous gamma globulin in systemic JRA and, 1015
- Thrombocytosis
eosinophilia-myalgia syndrome after L-tryptophan ingestion and, 913, 918, 930
intravenous gamma globulin in systemic JRA and, 1015
- Thumb
OA of the hand and, 1601
in subluxing arthropathy with anti-Jo-1 antibody in PM/DM, 1640
- Thymic medulla, B cell infiltration of, TLI and, in New Zealand mice, 702
- Thymus
antihistone antibodies in ANA-positive juvenile arthritis and, 1836
B cell infiltration of, TLI and, in New Zealand mice, 702
- Thyroglossal duct cysts, tophaceous neck mass presenting as, 910
- Tibia
bony spur of, triamcinolone hexacetonide in juvenile arthritis and, 821
in proteoglycan-induced arthritis in mice, 866
- Toe, in pseudopodagra, 607
- Toluidine blue staining
in cartilage proteoglycan-induced arthritis in BALB/c mice, 1394
dietary omega-3 fatty acids in rat articular cartilage and, 1029
- Tongue, claudication of, in giant cell arteritis, 1122
- Tophaceous neck mass, presenting as thyroglossal duct cyst, 910
- Topical fluorouracil, toxic response to, in RA, methotrexate and, 303
- Topoisomerase I (Scl-70), molecular characterization of, in scleroderma, 1501
- Total hip arthroplasty, in early-onset primary OA and chondrodysplasia, 674
- Total knee arthroplasty, with and without cement, 293
- Total knee replacement, effect of osteophytes on varus-valgus instability in, in OA, 853
- Total lymphoid irradiation (TLI)
B cell infiltration and, in New Zealand mice, 702
effect of, on Ly-1 B cells in (NZB \times NZW)_F1 mice, 553
- Toxic oil syndrome, eosinophilia-myalgia syndrome after L-tryptophan ingestion and, 913, 918, 930
- Toxicity
index for, side effects and, 121
in RA, 9, 303, 330, 574, 733, 1447, 1449
- Trabecular bone
in adjuvant arthritis in rats after cyclosporin A, 247
periarticular bone loss in RA and, 615
- Transaminase, hepatitis, fibrosis, methotrexate and, in RA, 1037
- Transfer RNA (tRNA), anti-signal recognition particle in PM and, 1361
- Transforming growth factor β
in RA, 305, 1180
in scleroderma dermal fibroblasts, 650
- Translation-related factors, HLA-D, anti-Jo-1 and, in myositis, 1240
- Trapeziometacarpal joint, in OA of the hand, 1601
- Trauma, joint, Charcot arthropathy in diabetic neuropathy and, 412
- Traumatic arthritis, substance P and, 87
- Traumatic joint diseases, synovocyte synthesis of fibroblast growth factor and, 493
- Triamcinolone hexacetonide
in childhood arthritis, 821
intraarticular injection of, "steroid flare" from, 1284
- Tubular enzymes, urinary, subclinical renal dysfunction in RA and, 95
- Tumor necrosis factor
human cartilage degradation and, 542
substance P, IL-1 and, 1023
- Tumor necrosis factor α
cytokines and, 305, 1776
effect of, on synoviocytes, 1518
in scleroderma, 893
- Tumors
bone, foreign body synovitis and, 1753
IL-6 in cardiac myxoma and, 398
soluble IL-2 receptors and, 375, 1145
tophaceous neck mass presenting as thyroglossal duct cyst, 910
- Tyrosine hydroxylase, synovial membrane nerves in Sprague-Dawley rat and, 859

U

- U1 snRNP, anti-U1-70-kd autoantibody, HLA-DR4 and, in connective tissue disease, 666
- U1 snRNP-associated A protein, in rheumatic diseases, 834
- Ulcers
digital, in SSc, recombinant tissue plasminogen activator therapy in, 274
oral, in Wegener's granulomatosis, 1101
skin, T cell depletion in SSc and, 511
- Ultrasound
in management of congenital complete heart block, 609
of salivary gland in Sjögren's syndrome, 505
- Umbilical cord blood cells, 1340, 1420
- Uncadecapeptide, substance P, arthritis and, 87
- UPI protein, nRNP protein and, in RA and SLE, 180
- Urethrectomy, Reiter's syndrome after, 885
- Urethritis, in Reiter's syndrome after urethrectomy, 885
- Urinalysis, in amyloidosis in Behçet's syndrome, 1586
- Urinary excretion, renal disease in chronic childhood arthritis and, 1560
- Urinary protein, effect of fibronectin on chronic nephritis in rats and, 685
- Urinary sediment, in Wegener's granulomatosis, 1101
- Urinary tubular enzymes, subclinical renal dysfunction in RA and, 95

Urine

- biliary elimination of low-dose methotrexate and, 898
- subclinical renal dysfunction in RA and, 95

Urokinase

- metalloprotease in canine OA and, 1466
- tumor necrosis factor, human cartilage degradation and, 542

Uronic acid, in anterior cruciate ligament transection-induced canine OA, 1406

USA Pediatric Rheumatology Collaborative Study Group, auranofin in JRA, 466, 587

USSR Cooperative Children's Study Group, auranofin in JRA, 466, 587

Utility, measurement of, in RA, 591

Uveitis

- antihistone antibodies in ANA-positive juvenile arthritis and, 1836
- anti-HMG proteins in JRA and, 1378

V

V gene, expression of, in NZB mice, 711

Valine, HLA-DR alleles, amino acids and, in RA, 939

Varicose nerve terminals, synovial membrane nerves in Sprague-Dawley rat and, 859

Varus-valgus instability, reduction of, effect of osteophytes on, in OA knee, 853

Vasculitis

- criteria for classification of, 1065, 1068, 1074, 1088, 1094, 1101, 1108, 1114, 1122, 1120, 1135
- cutaneous, in pheochromocytoma, 1852
- histopathologic criteria for, 1074
- myeloperoxidase autoantibodies in, 1264
- in RA, 95, 1646
- systemic, 1094, 1264

Vasculitis Study Registry, ACR, in histopathologic classification of vasculitis, 1074

Vasoactive intestinal polypeptide, synovial membrane nerves in Sprague-Dawley rat and, 859

Vasospasm

- in SSc, 1634
- systemic, pregnancy in Raynaud's phenomenon and, 1249

Venules

- in Henoch-Schönlein purpura, 1114
- in hypersensitivity vasculitis, 1108

Vertebrae, bone and cartilage loss in adjuvant arthritis in rats after cyclosporin A and, 247

VH1 heavy chain, rheumatoid synovial cell-derived monoclonal RF and, 1188

V_H4 gene family, cross-reactive idiotypes of human RF and, 1347

Virions, in AIDS-associated arthritis, 268

Viruses

- AIDS-associated arthritis and, 268
- hepatitis B, antineutrophil cytoplasmic antibodies in polyarteritis nodosa and, 1871
- HIV, 298, 1294, 1574
- HTLV-I, acute myositis in AIDS and, 298

Visceral involvement, soluble IL-2 receptors in SSc and, 375, 1145

Viscosity, of hyaluronic acid, myeloperoxidase-derived oxidants and, 453

Visual analog pain scale

- learned helplessness in SLE and, 281
- in rheumatic disease assessment, 1317

Vitamin

- D₃, 29, 615, 1723
- E, during dietary fish oil in RA, 1416

V α light chain, rheumatoid synovial cell-derived monoclonal RF and, 1188

Vocational rehabilitation, outcome measures in AS and, 1001

W

Wa RF cross-idiotypic specificity, monoclonal antibody 6B6.6 idiotope on, 187

Walking time, NSAID in RA and, 19, 623

Water

- content, in anterior cruciate ligament transection-induced canine OA, 1406
- transitional microvascular pressure in canine joints and, 80

Wegener's granulomatosis

- histopathologic criteria for, 1074
- myeloperoxidase autoantibodies in, 1264
- 1990 criteria for classification of, 1068, 1101
- sulfonamides in, 1590

Weight loss, in polyarteritis nodosa, 1088

Weight-bearing condyles, substance P, IL-1, and tumor necrosis factor in, 1023

Western blotting

- autoantibodies and, 711, 877
- monoclonal antibody 6B6.6 idiotope on RF and, 187
- of Ro (SS-A), 102, 1815
- SS-A (Ro) polypeptides in SLE and Sjögren's syndrome and, 349
- stromelysin, cartilage degradation and, in inflammatory arthritis, 388
- in study of recombinant human IFN-gamma, collagenase and IL-1 in articular chondrocytes, 1733
- synoviocyte synthesis of fibroblast growth factor and, 493

White blood cells

- in Churg-Strauss syndrome, 1094
- in synovitis in lymphadenopathy with dysproteinemia, 578
- Wi-L₂ extracts, Ro (SS-A) antigen in guinea pig and, 1815
- Wistar rats, effect of fibronectin on chronic nephritis in, 685

Work, outcome measures in AS and, 1001

World Health Organization, classification system, for renal biopsy in lupus nephritis, 970

Wrist

- in AIDS with septic arthritis and osteomyelitis, 757
- in canine studies, 73, 80
- in microfocal radiographic assessment of hand OA, 57
- in RA, 57, 316
- in subluxing arthropathy with anti-Jo-1 antibody in PM/DM, 1640
- in synovitis in lymphadenopathy with dysproteinemia, 578

X

Xyloside, cartilage inorganic pyrophosphate, glycosaminoglycan synthesis and, 235

Y

Yersinia-induced arthritis, 1795

Yersinia reactive arthritis, HIV infection and, 758

Z

Z-DNA lupus-inducing drugs, circular DNA and, 366
polynucleotides, SLE sera binding to, 356

Zymography, tumor necrosis factor, human cartilage degradation and, 542

Zymosan, neutrophil collagenase release and, 228

